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General introduction
The function of the heart was first described in 1628 by the British physician 
William Harvey.1 Since then, our knowledge of the heart has grown tremen-
dously, with great advances having been made in the development of diagnos-
tic tools and therapeutic options for cardiac diseases. However, despite these 
improvements, ischemic heart disease remains the number one cause of death, 
accounting for 1 in 3 deaths globally.2 There are several reasons for this high 
prevalence. 
 Firstly, a substantial number of patients that presents with a fatal acute 
myocardial infarction does not experience any prior symptoms from the 
presence of (premature) coronary atherosclerosis (Part I). Secondly, in the 
current treatment of patients with an acute myocardial infarction and multi- 
vessel coronary artery disease (CAD) on the initial angiogram, there are still 
areas that are not yet fully elucidated (Part II). And finally, in ST-elevation 
myocardial infarction (STEMI) patients it is difficult to determine which 
patients are at increased risk of (fatal) ventricular arrhythmias after the acute 
phase since it are not only patients with a decreased left ventricular ejection 
fraction (LVEF) that experience arrhythmias (Part III).3 
 The aim of the studies presented in this thesis then was to determine the 
clinical value of different imaging techniques and invasive treatments to improve 
the prevention, management as well as the prognosis of ischemic heart disease.
PArT I · DETECTIoN oF ATHEroSCLEroSIS AND 
VArIATIoN IN CoroNAry ANAToMy
To reduce the incidence of fatal myocardial infarction it is important to 
identify which patients are at increased cardiovascular (CV) risk and might 
need preventive treatment with statins and/or aspirin. Coronary computed 
tomography angiography (CTA) is a validated and non-invasive imaging 
method to screen the coronary arteries for (premature) atherosclerosis as 
indicated by the presence of coronary plaques and stenosis.4 The great value 
of this non-invasive imaging technique lies in ruling out the presence of CAD 
in patients with a low to intermediate priori CV risk. Hence, coronary CTA 
avoids the need of direct screening with invasive angiography of patients with 
atypical chest pain or asymptomatic patients with an elevated CV risk profile.
One of the largest groups known to be at increased risk of the development of 
CAD is patients with diabetes mellitus (DM). Previous data even suggest that 
chaPter 1
11
this patient group has as high a risk of myocardial infarction as non-diabetic 
patients with a previous myocardial infarction.5 Therefore, the European 
Society of Cardiology (ESC) guidelines recommends to consider aspirin 
use for the primary prevention of CAD in patients at high-risk and DM.6 
However, the definition of patients at high-risk of CAD is not entirely clear, 
while the efficacy and safety of aspirin as preventive therapy also needs more 
research.7-9 To tailor aspirin treatment in patients with DM, the assessment 
of CAD using coronary CTA could be of superior value over established 
traditional CV risk factors to identify patients without CAD who do not need 
aspirin.10, 11 Therefore, Chapter 2 of this thesis investigates the prevalence 
of CAD on coronary CTA in high-risk patients with DM without chest-pain 
syndrome and evaluates associations between the presence and number of 
traditional CV risk factors and the presence of CAD on coronary CTA.
Screening patients for the presence of CAD by means of coronary CTA not 
only provides information about the presence of coronary atherosclerosis, 
it also frequently discovers variations in coronary anatomy and extracardiac 
abnormalities. One of the most common variations in coronary anatomy is 
an intramural course of the epicardial artery, which is defined as a coronary 
artery covered by ≥ 1 mm of superficial muscle fibers throughout its course. 
The literature reports widely varying prevalence rates of 6% up to 58% as 
based on findings from coronary CTA.12 The difference in reported prev-
alence of an intramural course of a coronary artery on coronary CTA can 
partly be explained by variations in the definition of intramural course (depth, 
length) and the minimal lumen area of the vessel taken into account. Not 
much is known about the influence of an intramural course of a coronary 
artery (on coronary CTA) on prognosis and outcome. Therefore, it is uncer-
tain whether this finding on coronary CTA should have consequences for 
management and therapy. Chapter 3 therefore evaluates whether an intramu-
ral course of a coronary artery as indicated by coronary CTA in patients with 
a low to intermediate CV risk profile without obstructive CAD is associated 
with poorer outcomes than are seen in patients without an intramural course.
PArT II ·  MANAGEMENT oF ACuTE 
MyoCArDIAL INFArCTIoN
For patients with acute STEMI, immediate invasive coronary angiography 
with the intention to proceed to instant revascularization is recommended.13 In 
more than half of these patients, interventional cardiologists detect multi-vessel 
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CAD on the initial coronary angiography.14, 15 However, the best strategy in 
STEMI patients with multi-vessel CAD regarding completeness of revascular-
ization of the non-culprit lesion(s) is still unclear. 16, 17 Advocates of complete 
revascularization state that in this way multiple plaque ruptures are stabilized 
with faster recovery of the left ventricular (LV) function, which may avoid the 
development of hibernation due to myocardial ischemia of the non-culprit 
lesion(s).18 However, revascularization of the non-culprit lesions is not without 
risk. It increases the risk of procedural complications, while in the acute phase 
the degree of stenosis in the non-culprit lesions is often overestimated, poten-
tially resulting in overtreatment. In addition, it has been suggested that in the 
acute phase patients are in a heightened pro-inflammatory and pro-thrombotic 
state, where a conservative approach (i.e. fewer interventions) is to be pre-
ferred.19 To overcome current issues about the optimal revascularization 
strategy in patients with STEMI and multi-vessel CAD, not only short-term 
results should be taken into account. Chapter 4 concerns an analysis whether 
complete revascularization is associated with superior long-term outcomes in 
these patients compared to peers having received incomplete revascularization. 
In addition, subgroups are analysed to determine which group has the most 
benefit from complete revascularization as compared to incomplete revascu-
larization. Specifically, gender differences may exist regarding outcome after 
complete or incomplete revascularization. Chapter 5 investigates whether in 
patients with a first STEMI and multi- vessel CAD, there are gender-related 
benefits on all-cause mortality between both revascularisation strategies. 
PArT II I  ·  ProGNoSIS oF ISCHEMIC HEArT DISEASE
The location and extent of acute myocardial infarction and the presence of 
myocardial ischemia both play an important role in the prognosis of and need 
for additional treatment in patients having suffered a STEMI.20-22 It is crucial 
that patients with a large myocardial infarction are monitored closely to prevent 
re-infarction and progression to heart failure. Additionally, patients with a 
reduced LVEF often require primary prevention with an implantable cardio-
verter defibrillator (ICD) to reduce the risk of sudden cardiac death.23 A wide 
range of non-invasive imaging tools is available to assess the post-STEMI 
residual LV systolic function. In contrast to single-photon emission computed 
tomography (SPECT), myocardial perfusion imaging (MPI), and magnetic 
resonance imaging (MRI), echocardiography is a safe, inexpensive, quick and 
non-invasive imaging technique suitable for bedside use. Although the most 
13
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widely used echocardiographic parameter for the assessment of residual LV 
systolic function is LVEF,24 left ventricular global longitudinal strain (LV 
GLS) as visualized by means of speckle-tracking echocardiography might 
be a better index of the extent of the infarction and the residual LV systolic 
function. However, not all factors that influence the correlation between LV 
GLS and infarct size have been clarified. Perhaps, the presence of myocardial 
ischemia may further impair LV GLS due to repetitive stunning. Chapter 6 
thus explores the influence of myocardial ischemia on the correlation between 
LV GLS and myocardial infarction size in patients after STEMI. 
To determine the prognosis of post-STEMI patients not only the residual 
LV systolic function but also cardiac denervation should be considered, 
particularly since cardiac sympathetic denervation is a powerful predictor 
of ventricular arrhythmias and sudden cardiac death.25, 26 123Iodine-meta- 
iodobenzylguanidine (123I-MIBG) scintigraphy is a non-invasive imaging 
technique providing (semi-)quantitative information about myocardial 
sympathetic activity.27 Different parameters can be obtained from planar 
123I-MIBG images. First, from the early and late planar 123I-MIBG images the 
heart-to-mediastinum (H/M) ratio can be derived, which parameter reflects 
the relative distribution of cardiac sympathetic nerve terminals and offers 
information about the neuronal function. In addition, the washout rate of the 
tracer between the early and late planar images provides information about 
the sympathetic drive. In patients with heart failure, the myocardial sympathetic 
neuronal uptake is decreased, which is reflected by a low H/M ratio and an 
increased washout rate.26 Furthermore, focal innervation defects can be ana-
lysed with 123I-MIBG SPECT. Chapter 7 gives an overview of recent trends 
and the latest results obtained with 123I-MIBG SPECT imaging.
 Besides the clinical indication to assess prognosis in patients with heart 
failure with 123I-MIBG imaging there is a growing number of other indications 
in the cardiology, for instance to evaluate the effects of cardiac medication.28, 
29 Chapter 8 provides a summary of these potential indications. 
 With the growing use of 123I-MIBG imaging there is a need for standardiza-
tion of the data-acquisition procedure.30 In addition, shortening of the waiting 
period between the early and late acquisition (which is now over 4 hours) 
is preferred. Chapter 9 of this thesis evaluates whether performing the late 
cardiac 123I-MIBG scan earlier than 4 hours post-injection (pi) has a relevant 
impact on the late H/M ratio in patients with heart failure. Moreover, a model 
to compare acquisitions derived from different late acquisition times would be 
of value to ease comparison of study results. Accordingly, Chapter 10 evaluates 
14
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whether a developed direct comparison model enables comparison of data 
from different acquisition times. 
Objectives and Outline of the Thesis
The aim of the studies presented in this dissertation is to evaluate the clinical 
relevance of different imaging techniques and invasive strategies to improve 
the early detection, management and prognosis of ischemic heart disease.
 Part I of this thesis evaluates the diagnostic value of coronary CTA in the 
early detection of CAD. More specifically, Chapter 2 provides an estimate 
how many patients with DM and one or more CV risk factors have CAD on 
coronary CTA. In addition, associations between the presence and number 
of traditional CV risk factors and the presence of CAD on coronary CTA is 
determined in high-risk DM patients without chest-pain syndrome. Chapter 
3 describes the influence of an intramural course of a coronary artery on the 
long-term outcome of patients screened for CAD using coronary CTA. 
 Part II of this thesis addresses the influence of different revascularization 
strategies on survival in patients with STEMI and multi-vessel CAD. In more 
detail, Chapter 4 evaluates the short- and long-term prognosis of such patients 
following complete versus incomplete revascularization during first admission. 
In addition, Chapter 5 investigates gender-related disparities in the outcomes 
of the two strategies in these patients. 
 Part III considers the respective values of 2-dimensional strain echocardi-
ography and 123I-MIBG scintigraphy in patients with ischemic heart disease. 
These techniques provide information on systolic LV function and cardiac 
innervation/denervation, which indices are both important for the prognosis 
of patients with ischemic heart disease. Chapter 6 describes the influence of 
myocardial ischemia extent on LV GLS in patients with previous STEMI
Chapters 7 and 8 focus on the current role of 123I-MIBG scintigraphy.
Chapter 7 provides a review on the respective relevance of planar and SPECT 
123I-MIBG imaging. An overview of the increasing number of potential 
clinical indications for 123I-MIBG imaging in cardiology beyond heart failure 
is provided in Chapter 8. 
 Chapters 9 and 10 address the optimization of planar 123I-MIBG imaging 
protocols, with a special focus on shortened scan-time intervals and easier 
comparison of data from different acquisition times. 
 Finally, in Chapter 11 the results obtained in the various studies are 
 summarized and conclusions drawn.
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Chapter 2
Value of Coronary Computed  
Tomography Angiography  
in Tailoring Aspirin Therapy for  
Primary Prevention of 
Atheros clerotic Events in Patients 
at High-risk with  Diabetes Mellitus




Aspirin use for primary prevention in patients at high-risk with diabetes mel-
litus (DM) is often recommended under the assumption that most patients 
with DM have coronary artery disease (CAD). However, not all patients may 
have CAD. The present study evaluated, in 425 patients at high-risk with DM 
(without chest pain syndrome or a history of cardiac disease), the prevalence 
of CAD on coronary computed tomography angiography (CTA). Moreover, 
the association between the presence and number of traditional cardiovascular 
(CV) risk factors and CAD (on coronary CTA) was evaluated. The median 
coronary artery calcium score was 29 (interquartile range 0 to 298). On coro-
nary CTA, 116 patients (27%) had no CAD (defined as <30% stenosis). Of 
the 309 patients (73%) with any CAD (≥30% stenosis), 35% had obstructive 
CAD (≥50% stenosis). The number of traditional CV risk factors was not 
associated with the presence of any CAD (≥30% stenosis; P=0.18) or obstruc-
tive CAD (≥50% stenosis; P=0.13). Hypertension was the only traditional 
CV risk factor associated with a higher frequency of any CAD (≥30% steno-
sis; odds ratio = 2.21, 95% CI 1.43 to3.41, P<0.001) and obstructive CAD 
(≥50% stenosis; odds ratio = 2.03, 95% CI 1.33 to 3.11, P=0.001). In conclu-
sion, in patients at high-risk with DM without chest pain syndrome, any CAD 
was ruled out by coronary CTA in 27%, whereas 65% of the patients did not 
have obstructive CAD. The number of CV risk factors was not associated with 
the presence of CAD. Hypertension was the only traditional CV risk factor 
that was associated with a higher frequency of CAD. These observations 
support potential use of coronary CTA to tailor aspirin therapy in patients at 
high-risk with DM.
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Introduction
The European Society of Cardiology (ESC) guidelines recommend to con-
sider aspirin use for primary prevention in patients at high-risk with diabetes 
mellitus (DM).1 However, the definition of patients at high-risk with DM is 
not entirely clear. The 2012 ESC guidelines on cardiovascular (CV) disease 
prevention suggested that patients with DM, and at least one other CV risk 
factor or target organ damage, should be considered to be at very high-risk 
and all other patients with DM to be at high-risk.2 Traditional risk scores such 
as the Framingham CV Risk Equation or Systematic Coronary Risk Evaluation 
were not specifically developed for patients with DM.3,4 There have been 
attempts to design risk engines for patients with DM such as the United 
Kingdom Prospective Diabetes Study and the Swedish National Diabetes 
Register, but the applicability of these scores for clinical practice needs further 
validation.5,6 Moreover, current risk engines do not incorporate (non-invasive) 
imaging tests, which have been shown to be of great value for risk stratification 
in patients with DM and without DM.7,8 Treatment with aspirin has been 
proved to reduce CV events in secondary prevention (in patients with coronary 
artery disease [CAD]).9 However, the efficacy and safety in primary preven-
tion are still unclear and need more research.10-12 Patients with DM often 
have (severe) CAD, but are frequently free of chest pain symptoms. However, 
not all patients with DM have CAD.13 Therefore, it is important to identify 
which patients at high-risk with DM are free of CAD and may not need aspirin. 
Assessment of CAD on coronary computed tomography angiography (CTA) 
could be of value over established traditional CV risk factors to identify 
patients without CAD who do not need aspirin. Therefore, aims of this study 
were: 1) to investigate the prevalence of CAD on coronary CTA and 2) to 
evaluate the association between the presence and number of traditional CV 
risk factors and the presence of CAD on coronary CTA in patients at high-
risk with DM without chest pain syndrome.
Methods
The population consisted of 448 patients with DM without chest pain syn-
drome who were clinically referred for coronary CTA for evaluation of CAD. 
The inclusion criteria were 1) a diagnosis of type 1 or 2 DM, 2) absence of 
chest pain syndrome defined as atypical or typical angina and 3) one or more 
traditional CV risk factors besides DM. The risk factors included hypercho-
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lesterolemia (defined as a self-reported history of hypercholesterolemia and/or 
therapeutic treatment with lipid lowering drugs), hypertension (defined as the 
self-reported history of hypertension and/or the use of antihypertensive medi-
cation, or systolic blood pressure ≥140 mmHg and/or diastolic blood pressure 
≥90 mmHg), family history of CV disease, current smoker and obesity (body 
mass index (BMI) ≥ 30 kg/m2). Patients with a history of CAD (history of 
myocardial infarction (MI), percutaneous coronary intervention or coronary 
artery bypass graft surgery), heart failure, valvular heart disease, arrhythmia 
or congenital heart disease were excluded.
 Demographic data were prospectively entered into the departmental 
Cardiology Information System (EPD-Vision©, Leiden University Medical 
Center, Leiden, the Netherlands) and retrospectively analyzed. For retrospec-
tive analysis of clinically acquired data, the institutional review board waived 
the need for patient written informed consent.
Coronary CTA was performed using a 64- or 320-detector row computed 
tomography scanner (64-slice: Aquillon 64, Toshiba Medical Systems, Otawara, 
Japan 320-slice: Aquillon ONE, Toshiba Medical System, Otawara, Japan). Data 
acquisition protocol has been previously described.14 In summary, a nonen-
hanced and contrastenhanced CT scans were performed. Postprocessing of 
scans was performed with dedicated software (Vitrea FX 1.0, Vital Images, Min-
netonka, Minnesota). Uninterpretable scans were excluded from the analysis.
 The coronary artery calcium (CAC) score was performed according to 
the algorithm of Agatston, which was categorized in four risk categories: 0, 1 
to 100, 101 to 400 and >400. All coronary CTAs were analyzed, according 
to the modified 17-segment American Heart Association classification. Only 
segments which were interpretable (no severe motion artifacts) with a diam-
eter of ≥ 1.5mm were analyzed. Structures > 1mm² within and/or adjacent to 
the vessel lumen that could be discriminated from surrounding pericardial 
tissue, epicardial fat and the vessel lumen itself were defined as plaque.15 
The severity of coronary stenosis in each segment was classified by visual 
estimation in 5 categories: no stenosis, stenosis 1 to 29%, stenosis 30 to 49%, 
stenosis 50 to 70% and stenosis ≥70%. Coronary plaques were stratified into 
3 groups: calcified (plaque containing ≥ 50% calcified tissue), mixed (plaque 
containing <50% calcified tissue) and non-calcified (plaque containing no 
calcified tissue). Importantly, 2 separate analyses were performed, based on 1) 
the presence of “any CAD” which was defined as at least one stenosis ≥30% in 
any vessel and 2) the presence of “obstructive CAD” which was defined as at 
least one stenosis ≥50% in any vessel. 
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Age (years) 56 ± 11
Height (meter) 1.72 ± 0.10
Weight (kg) 86 ± 18
Diabetes mellitus (type 2) 346 (81%)
BMI ≥ 30 (kg/m²) 156 (37%)
Family history of CV disease 173 (41%)
Hypercholesterolemia† 244 (57%)
Hypertension‡ 254 (60%)
Current smoker 98 (23%)




≥ 4 47 (11%)
Medication use







BMI = body mass index; CV = cardiovascular; DM = diabetes mellitus; OAC = oral 
 anticoagulation. Definitions: 
† Defined as self-reported history of hypercholesterolemia and/or therapeutic treatment with lipid 
lowering drugs; 
‡ Defined as self-reported history of hypertension, systolic blood pressure ≥140 mmHg and/or diastolic 
blood pressure ≥90 mmHg and/or the use of antihypertensive medication; 
* Additional CV risk factors consisted of family history of CV disease, hypercholesterolemia, 
 hypertension, obesity and current smoker. 
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Normally distributed variables were expressed as mean ± SD and nonnormally 
distributed variables as median and interquartile range. Categorical variables 
were expressed as frequencies. First, the distribution of any CAD (≥30% 
stenosis) in patients with a CAC score of 0 and above 0 was assessed. Second, 
the association between the number of CV risk factors and the presence of any 
CAD (≥30% stenosis) was evaluated. Patients were stratified into 1, 2, 3, and 
≥ 4 traditional CV risk factors. The prevalence of any CAD (≥30% stenosis) 
in each category was investigated with the Fisher’s exact Test. The effect of 
the number of traditional CV risk factors on the presence of any CAD (≥30% 
stenosis) was assessed with logistic regression analysis. Third, the association 
between the several traditional CV risk factors and the presence of any CAD 
(≥30% stenosis) was investigated. Patients were stratified according to the 
presence of several traditional CV risk factors: hypertension, hypercholester-
olemia, family history of CAD, current smoker and obesity. The prevalence 
of any CAD (≥30% stenosis) in each CV risk factor was assessed. The associ-
ation between the several traditional CV risk factors and the presence of any 
CAD (≥30% stenosis) was assessed with the Fisher’s exact Test. Similarly, the 
analyses were repeated for the presence of obstructive CAD (≥50% stenosis). 
A two-sided P-value <0.05 was considered statistically significant. All analyses 




The clinical characteristics of the patients are provided in Table 1; 23  
patients (5%) were excluded because of poor coronary CTA quality. The final 
population consisted of 425 patients at high-risk with DM without chest pain 
syndrome (mean age 56 ± 11 years, 57% men). Referral for coronary CTA 
included nonspecific chest pain/symptoms (16%), high-risk profile (81%), 
abnormal electrocardiogram (2%), and preoperative screening (1%).
A CAC score was performed in 388 patients (91%). The median CAC score 
was 29 (interquartile range 0-298). As depicted in Figure 1a, a CAC score of 
0 was observed in 124 patients(32%). Of these patients, 44 patients (35.5%) 
had any CAD (≥30% stenosis), of which 11 (9%) had obstructive CAD 
(≥50% stenosis). In the 264 patients (68%) with a CAC score >0, any CAD 
(≥30% stenosis) was observed in 237 patients (90%), of which 128 (48.5%) 
were obstructive CAD (≥50% stenosis; Figure 1b).
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Figure 1. Distribution of any CAD (≥30% stenosis)and obstructive CAD (≥50% 
stenosis; (1a.) within patients with a CAC score of 0 and (1b.) within patients with 
a CAC score above 0. 
CAD = coronary artery disease; CV = cardiovascular; no = number.
chapter 2
30
Coronary CTA results are presented in Table 2; the prevalence of any CAD 
(≥30% stenosis) was 73%. A coronary artery stenosis of 30 to 49% was 
observed in 160 (38%) patients and a coronary artery stenosis ≥ 50% in 149 
(35%) patients. Importantly, 116 patients (27%) presented with a normal 
coronary CTA. The mean number of calcified segments was 1 ± 2, the mean 
number of segments with mixed plaque was 2 ± 2 and on average 1 ± 2 seg-
ments had noncalcified plaque.
 
Table 2. Coronary artery calcium score and coronary CT angiography
Variable Patients 
CAC scoring (n=388)





> 400 83 (21%)
Coronary computed tomography angiography findings  (n=425)
Coronary stenosis
no stenosis 54 (13%)
stenosis <30% 62 (14.5%)
stenosis 30-49% 160 (37.5%)
stenosis 50%-69 119 (28%)
Stenosis ≥ 70% 30 (7%)
Coronary plaques composition
No. of calcified plaques 1 ± 2 
0 (IQr 0-1)
No. of mixed plaques 2 ± 2
0 (IQr 0-2)
No. of non-calcified plaques 1 ± 2
0 (IQr 0-1)
CAC = coronary artery calcium, CAD = coronary artery disease; coronary CTA = coronary computed 
tomography coronary angiography; IQR = interquartile range.
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In Figure 2, the distribution of any CAD (defined as ≥30% stenosis) accord-
ing to the number of traditional CV risk factors is shown. In patients with 
1 CV risk factor, the prevalence of any CAD (≥30% stenosis) was 66%. In 
patients with 2, 3 or ≥ 4 CV risk factors, the prevalence of any CAD (≥30% 
stenosis) was 73%, 76% and 81%, respectively. Overall, there was no signif-
icant association between the number of traditional CV risk factors and the 
presence of any CAD (≥30% stenosis) (P=0.18; Figure 3a). However, there 
was a significant trend for increasing numbers of traditional CV risk factors 
and the presence of any CAD (≥30% stenosis; P-value for trend 0.03).
 Within the various traditional CV risk factors the prevalence of any CAD 
(≥30% stenosis) was 73% in patients with hypercholesterolemia compared to 
79%, 71%, 80% and 71% for patients with hypertension, a family history of 
CAD, current smoker or obesity, respectively (Figure 4). Only hypertension 
was correlated with a higher frequency of any CAD (≥30% stenosis; OR 2.21 
[95% CI 1.43;3.41], P<0.001; Figure 3b).
Figure 2. Prevalence of any CAD (≥30% stenosis) and obstructive CAD (≥50% 
stenosis) according to the number of CV risk factors.
CI = confidence interval, CV = cardiovascular, CVD = cardiovascular disease;  
No = number; OR = odds ratio; Ref. Cat. = referential category.
Definitions: as in Table 1.
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In Figure 2, also the distribution of obstructive CAD (≥50% stenosis) accord-
ing to the number of traditional CV risk factors is shown. In patients with 1 
CV risk factor the prevalence of obstructive CAD (≥50% stenosis) was 27% 
compared to 36%, 42% and 36% for patients with 2, 3 or ≥ 4 CV risk fac-
tors. Overall, there was no significant association between the number of CV 
risk factors and the presence of obstructive CAD (≥50% stenosis) (P=0.13, 
P-value for trend 0.06). However, compared to 1 CV risk factor, patients 
with 3 CV risk factors presented significantly more often with obstructive 
Figure 3. Association between the number (3a.) and presence (3b.) of CV risk 
factors and the presence of any CAD (≥30% stenosis).
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CAD (≥50% stenosis) (OR 1.90 [95% CI 1.11;3.25], P=0.02) (Figure 5a). 
Within the different traditional CV risk factors the prevalence of obstructive 
CAD (≥50% stenosis) in patients with diabetes was 38% in patients with 
hyper cholesterolemia compared to 41%, 30%, 42% and 33% for patients 
with hypertension, a family history of CAD, current smoker and obesity, 
respectively (Figure 4). Comparable to patients with any CAD (≥30%), only 
hypertension was correlated with a higher frequency of obstructive CAD (≥50 
stenosis) (OR 2.03 [95% CI 1.33;3.11], P=0.001) (Figure 5b).
Figure 4. Prevalence of any CAD (≥30% stenosis) and obstructive CAD (≥50% 
stenosis) in diabetic patients with a different extra CV risk factor.
CVD = cardiovascular disease.
Definitions: as in Table 1. 
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Figure 5. Association between the number (5a.) and presence (5b.) of CV risk 
factors and the presence of obstructive CAD (≥50% stenosis).
CI = confidence interval; CV = cardiovascular; CVD = cardiovascular disease; No = number; 
OR = odds ratio; Ref. Cat. = referential category.
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Discussion
This present study assessed the prevalence of CAD on coronary CTA in a 
large prospective registry of patients at high-risk with DM without chest pain 
syndrome. On coronary CTA, 27% of these patients at high-risk had no CAD. 
Of the patients with any CAD (≥30% stenosis), nearly half had obstructive 
CAD (≥50% stenosis). Moreover, the present study demonstrated that the 
number and presence of traditional CV risk factors was not associated with a 
higher frequency of CAD, except for hypertension.
The cardioprotective benefit of aspirin results from its ability to inhibit plate-
let aggregation and prevent platelet plug formation in atherosclerotic arteries 
in case of plaque rupture.16 Inspite the fact that the exact mechanism of 
aspirin has yet to be fully elucidated, it is accepted that aspirin is only useful if 
coronary atherosclerosis is present and acts in case of a thrombotic event.16,17 
Contrary to lipid-lowering agents, aspirin has no influence on progression of 
atherosclerosis or plaque stability.18
 The increased prevalence of atherosclerosis and thrombosis in patients 
with DM justifies the need of primary prevention with aspirin therapy. 
However, the results of several trials aiming at establishing the beneficial 
effect of aspirin therapy in patients with DM have been controversial.11,19 
Particularly, 2 randomized trials have shown that aspirin was not associated 
with significant reductions in CV events in patients with DM.11,19 Conversely, 
a recent meta-analysis showed a modest-size reduction in MI and stroke in 
patients with DM treated with aspirin for primary prevention.12 These results 
are counterbalanced by a relatively increased risk of gastrointestinal bleeding 
(1 to 5/1,000 per year) with aspirin use. In a population-based cohort study of 
186,425 patients treated with aspirin (of which 29,030 had DM) compared 
with 186,425 matched controls (of which 27,066 had DM), patients with DM 
had an increased risk of major bleeding compared to patients without DM.20 
However, in patients with DM, there was no significant difference in risk of 
bleeding between patients with aspirin and without aspirin use.
 Despite the inconclusive results regarding the efficacy and safety of aspirin 
in patients with DM, current guidelines may recommend aspirin to protect 
patients with DM from CV events.1,21,22 The ESC guidelines state that 
aspirin should be considered in patients at high-risk with DM.1 However, the 
definition of patients at low-risk with DM is not entirely clear. The Endocrine 
Society Clinical Practice Guidelines recommend aspirin in patients with DM 
aged >40 years and whose 10-year CV disease risk is > 10%.22 The American 
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Diabetes Association, American Heart Association and American College of 
Cardiology Foundation recommend low-dose aspirin in patients with DM 
with an increased 10-year CV disease risk of 10%, who are not at increased 
risk for bleeding.21 In patients with DM with an intermediate CV risk (defined 
as a 10-year risk score between 5-10%) aspirin can be considered. 
 The differences between guidelines and conflicting evidence highlight 
the importance of identifying which patients can be expected to benefit most 
from primary prevention with aspirin. Importantly, in the aforementioned 
trials patients were treated with aspirin without previous demonstration of 
the presence or absence of CAD. It has previously been stated that DM is a 
CAD-equivalent, and the risk for CV mortality of patients with DM is as high 
as patients without DM with previous MI or known coronary heart disease 
(CHD),23 assuming that all patients with DM have CAD. However, more 
recent literature questioned this concept.24 Nevertheless, current guidelines 
and risk classifications do not include CAD status as assessed by non-invasive 
testing. As addressed in the present analysis, coronary CTA could be impor-
tant in identifying which patients will benefit most from primary prevention 
with aspirin.
The present study demonstrated that 27% of high-risk patients with DM 
without chest pain syndrome did not have any CAD (≥30% stenosis) on 
coronary CTA, and aspirin is not needed. Moreover, if obstructive CAD 
(≥50% stenosis) would have been selected as a cut-off for stratification of 
patients, in 65% of patients aspirin use could have been avoided. This percent-
age is consistent with previous studies where the absence of obstructive CAD 
(≥50% stenosis) in asymptomatic patients with DM varied between 63% and 
74%.13,25 Perhaps the greatest benefit of coronary CTA for tailoring prophy-
lactic aspirin will be reached by using the cut-off value of obstructive CAD 
(≥50% stenosis) instead of any CAD. Especially since recently a sub-analysis 
of the Coronary CT Angiography EvaluatioN For Clinical Outcomes (CON-
FIRM) registry demonstrated in 4,706 patients with nonobstructive CAD 
(defined as 1%-49%) stenosis that aspirin therapy was not associated with an 
improvement in all-cause mortality (1.04% versus 1.22%; P=0.473).26
 As an alternative of coronary CTA, screening patients at high-risk with 
DM by assessing the CAC score would result in lower radiation exposure and 
reduced costs. Silverman et al. demonstrated in 2,384 subjects with DM that 
CAC effectively stratifies across age, gender and risk factor burden: diabetic 
patients aged below 60 years with a CAC of 0 had a low near-term risk of 0.5 
deaths per 1,000 person-years. In contrast, subjects with CAC above 100 had 
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a mortality rate of more than 10 deaths per 1,000 person-years 27. However, 
in the present study 36% of the patients with a CAC of 0 in the present 
study population had any CAD(≥30% stenosis) and, of these a quarter of the 
patients had obstructive CAD (≥50% stenosis). This is in line with the results 
reported by Leem et al. who showed that in 157 asymptomatic patients with 
type 2 DM with a CAC score of 0, 28% had CAD (≥ 1% stenosis) on angiog-
raphy, of which 11% were obstructive CAD.28 Taking into account the results 
of present study, screening patients according to their CAC score instead of 
investigating CAD on coronary CTA would result in under-treatment of 9% 
(with obstructive CAD) to 36% (with any CAD) patients at high-risk with 
DM who may benefit from aspirin.
Some limitations need to be addressed. First, patients with DM were clinically 
referred for coronary CTA and may already constitute a higher risk group of 
patients. Second, the present study focused on the relation between CV risk 
factors and the presence of CAD, but the duration of DM was not taken into 
account. In addition, the effects of medical therapy (e.g. statins) on the pres-
ence of CAD might have reduced the impact of risk factors on the presence 
of CAD. Moreover, the age at which screening of patients with DM could be 
performed with coronary CTA to guide aspirin use remains to be established. 
Also, it is unclear whether coronary CTA should be repeated, because both 
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Long-term Prognosis of Patients 
with Intramural Course of 
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Objectives. The aim of the present study was to evaluated, in low-to-inter-
mediate pre-test probability patients who were referred for coronary computed 
tomography angiography (CTA) and did not show obstructive coronary 
artery disease (CAD), whether an intramural course of a coronary artery is 
associated with worse outcome compared with patients without an intramural 
course of the coronary arteries.
Background. The prognostic value of an intramural course of the coronary 
arteries on coronary CTA in patients without obstructive CAD is not well-
known.
Methods. The study population consisted of 947 patients with a low-to-inter-
mediate pre-test probability who were referred for coronary CTA and who 
did not have obstructive CAD. During follow-up, the occurrence of unstable 
angina pectoris that required hospitalization, nonfatal myocardial infarction 
and all-cause mortality was evaluated.
Results. On coronary CTA, 210 (22%) patients had an intramural course 
of a coronary artery. The median depth of the intramural course was 1.9 mm 
(IQR 1.4-2.6 mm). In 84 patients (40%) the depth of the intramural course 
was considered deep (>2 mm surrounding myocardium). During a median 
follow-up of 4.9 years (interquartile range (IQR) 3.2-6.9 years) a total of 43 
events occurred: hospitalization due to unstable angina pectoris in 13 patients 
(1.4%), 7 patients (0.7%) had a nonfatal myocardial infarction and 23 
patients died (2.4%). The 6-year cumulative event rate of unstable angina pec-
toris requiring hospitalization (0.0% vs. 1.1%), nonfatal myocardial infarction 
(0.5% vs. 0.4%), all-cause mortality (1.9% vs. 2.2%) as well as the combined 
endpoint of all 3 events (2.4% vs. 3.7%) was similar in patients with and 
without an intramural course of a coronary artery.
Conclusion. In patients without obstructive CAD on coronary CTA, the 
presence of an intramural course of a coronary artery was not associated with 
worse outcome.
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Introduction
Coronary computed tomography angiography (CTA) is increasingly used 
to assess or exclude coronary artery disease (CAD) in patients with low-to- 
intermediate pre-test probability.1,2 When analysing the coronary arteries 
for stenosis, variations in coronary anatomy are frequently observed. One of 
the most common findings on coronary CTA is an intramural course of the 
epicardial coronary arteries. The intramural course of a coronary artery is 
defined as any epicardial segment that runs intramurally through the myocar-
dium that completely surrounds the vessel.3 The reported prevalence of the 
intramural course of coronary arteries on coronary CTA ranges from 6% to 
58%.4 This large variation may be explained by the use of different imaging 
techniques and recent improvements in computed tomography (CT) technol-
ogy that provide high spatial resolution and permit more precise analyses. In 
addition, the definition of the intramural course of the coronary artery (depth 
and length) differs among studies.4
Although an intramural course of a coronary artery is considered a benign 
anomaly, small case series have linked the presence of an intramural course 
of the coronary artery to myocardial infarction5,6, arrhythmias7 and sudden 
cardiac death8. However, prognostic data in a large population with an intra-
mural course on coronary CTA are nonexistent. Accordingly, the present study 
evaluated, in patients with a low-to-intermediate pre-test probability who were 
referred for coronary CTA and without obstructive CAD, whether an intramu-
ral course of a coronary artery was associated with worse outcome compared 




A total of 1,000 patients (from the Leiden University Medical Centre, the 
Netherlands and the Turku University Hospital, Turku, Finland) with cardiac 
complaints and/or an increased cardiovascular risk profile and low-to-inter-
mediate pre-test probability2 who were clinically referred for coronary CTA 
were included in the present analysis. Patients with a history of CAD (previous 
myocardial infarction, percutaneous coronary intervention or coronary artery 
bypass graft surgery), heart failure, valvular heart disease, arrhythmia or 
congenital heart disease were excluded. In addition, patients with obstructive 
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CAD on coronary CTA (defined as any coronary artery stenosis ≥50%), a 
nondiagnostic coronary CTA study, and patients lost to follow-up were not 
included in this analysis.
 Clinical and coronary CTA data were prospectively entered into the 
database and analyzed retrospectively. For retrospective analysis of clinically 
acquired data, the Institutional Review Board of the Leiden University Medical 
Centre waived the need for written informed consent. Similarly, the Ethics 
Committee of the Hospital District of Southwest Finland approved the study 
protocol and waived the need for written informed consent. All clinically 
acquired data were handled anonymously.
Coronary computed tomography
All coronary CT scans were performed using a 64- or 320-detector row 
CT scanner (64-slice: Aquillon 64, Toshiba Medical Systems, Otawara, 
Japan; 320-slice: Aquillon ONE, Toshiba Medical System, Otawara, Japan) 
in the Netherlands and a 64-detector row scanner (GE Discovery VCT, 
General Electric Medical Systems, Waukesha, Wisconsin, USA) in Finland. 
A nonenhanced CT scan (for the assessment of the coronary artery calcium 
[CAC] score) and a contrast-enhanced CT scan (for noninvasive coronary 
angiography) were performed. Coronary CTA was performed as previously 
described.9,10 For the 64-slice scanner, a collimation of 64 x 0.5 mm, rotation 
time of 400 ms, and tube voltages and currents (adjusted to the body mass 
index) of 120 to 135 kV and 250 to 500 mA, respectively, were used. For the 
320-slice scanner, a collimation of 320 x 0.5 mm, rotation time of 350 ms, and 
tube voltages and currents of 100 to 135 kV and 200 to 580 mA, respectively, 
were used. Advanced iterative reconstruction algorithms were applied. The 
average contrast dose was 76 ± 14 ml. For the coronary CTA data acquired 
in Finland, a collimation of 64 x 0.625 mm, a gantry rotation time of 350 ms, 
tube current between 600 and 750 mA, and voltage between 100 to 120 kV, 
depending on patient size, were used. The average contrast volume used was 
60 to 80 ml.11 If not contraindicated, beta-blockers were administered orally 
(25 to 125 mg metoprolol) 1 hour or intravenously (5 to 30 mg metoprolol) 
a few minutes before the coronary CTA in patients with a heart rate of > 60 
beats/min. The mean heart rate at the time of image acquisition was 57 ± 8 
beats/min. Sublingual nitroglycerine (0.4 to 0.8 mg) was administered before 
the coronary CTA acquisition in the absence of contraindications.
 Post-processing of the scans was performed with dedicated software 
(Vitrea FX 1.0, Vital Images, Minnetonka, [in the Netherlands] and General 
Electric, GE ADW 4.5, Piscataway, New Jersey [in Finland]).
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As previously described,9 the CAC score was calculated according to the algo-
rithm of Agatston.12 All coronary CTAs were analyzed according to the modified 
17-segment American Heart Association classification.13 Coronary artery 
segments with a diameter of ≥ 1.5 mm were included for analysis. The severity  
of coronary stenosis in each segment was stratified into three categories: 1)  
normal if no plaques were present; 2) non-obstructive CAD if the plaque cov-
ered 1-49% of the lumen; and 3) obstructive CAD if the plaque covered ≥ 50%. 
Figure 1. Assessment of Intramural Course of Coronary Artery With Coronary 
Computed Tomography Angiography. 
Coronary computed tomography angiography images of a patient with an intramural course of the mid 
LAD coronary artery demonstrated on the axial image (A.), multiplanar reconstructed image (B.), and 
cross-section image (C.) at the side of the intramural course demonstrating the measurement of the depth 
(3.3mm).LAD: left anterior descending coronary artery; mm: millimeter; RCA: right coronary artery; 











Age (years) 47±13 53±12 0.001
Men (%) 46 44 0.78
Risk factors
BMI >30 (%) 23 19 0.52
Hypercholesterolemia* (%) 26 35 0.18
Hypertension† (%) 26 40 0.06
Current smoking (%) 17 15 0.70
Family history of CAD (%) 54 48 0.41
Diabetes mellitus (%) 28 27 0.88
Coronary CTA
Vessel dominance 0.22
right (%) 75 84
Left (%) 17 12
Balanced (%) 8 4
Intramural course of a 
 coronary artery
23 22 0.94
Coronary artery calcium score 
(IQr) n=811
0 (IQr 0-11) 0 (IQr 0-12) 0.44
Non-obstructive CAD (%) 64 58 0.41
Coronary plaques (composition)
No. of calcified lesions 0.2 ± 0.5 0.3 ± 1.0 0.51
No. of mixed lesions 0.8 ± 0.3 0.4 ± 1.1 0.52
No. of non-calcified lesions 0.8 ± 2.3 0.5 ± 1.4 0.37
Supplemental table 1. Comparison of baseline characteristics of the patients 
 excluded for analysis due to lost at follow-up in comparison with the patients 
 included for analysis.
Definitions and abbreviations as in tabel 1.
Prognosis of an intramural course of a coronary artery
49
Coronary plaques were stratified into 3 groups: calcified (plaque containing ≥ 
50% calcification); mixed (plaque containing <50% calcification) and non-
calcified (plaque containing no calcification). To evaluate the presence of an 
intramural course of the coronary artery, multiplanar reconstruction images 
and cross sectional views of the coronary arteries were created and interpreted 
(Figure 1). Intramural course was defined as any epicardial artery segment that 
ran intramurally, surrounded by at least 1 mm of myocardium.3 The intramu-
ral course was classified as superficial when the course was covered with 1 to 2 
mm myocardium or as deep when covered with >2 mm myocardium.14, 15
Follow-up data
Follow-up data for the Dutch group of patients were obtained from hospital’s 
files review, municipal civil registry and contacting the patients. For the Finn-
ish group of patients, follow-up data were obtained from the national health 
statistics and patients’ electronic medical records. The combined endpoint 
consisted of time to unstable angina pectoris that required hospitalization, 
nonfatal myocardial infarction or all-cause mortality. Both, unstable angina 
pectoris that required hospitalization13 and nonfatal myocardial infarction14 
were defined according to standard definitions. Coronary CTA data analysis 
was performed blinded to the clinical follow-up data. 
Statistical analysis
Normally distributed continuous variables were expressed as mean ± standard 
deviation and as median with 25-75 interquartile range (IQR) if not normally 
distributed. Categorical variables were presented as frequencies and percent-
ages. Continuous variables were compared between groups with the indepen-
dent samples t-test (if normally distributed) or with the Mann- Whitney U test 
(for non-Gaussian variables). Categorical variables were compared between 
groups using the Chi-Square test. Cumulative event rates for the endpoints 
of unstable angina pectoris that required hospitalization, nonfatal myocardial 
infarction and all-cause mortality and the combined endpoint comprising of 
the first time of all 3 events were estimated with the Kaplan-Meier method 
and compared among groups using the Log-Rank test. Cox proportional 
hazard models were used to assess the association between clinical charac-
teristics and coronary CTA results with the combined endpoint of unstable 
angina pectoris requiring hospitalization, nonfatal myocardial infarction and 
all-cause mortality. Hazard ratios (HR) and their respective 95% confidence 
intervals (CI) were reported. Statistical analysis was performed using the SPSS 
software Version 22.0 (IBM Corp., Armonk, New York, USA). A 2-sided 
P-value of <0.05 was considered statistically significant.
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Table 1. Baseline characteristics of the patients stratified according to 
















Age (years) 53±12 54±11 53±12 0.19
Men (%) 44 40 45 0.21
Risk factors
BMI >30 (%) 19 11 21 0.004
Hypercholesterolemia* (%) 35 36 35 0.74
Hypertension† (%) 40 40 39 0.82
Current smoking (%) 15 16 15 0.62
Family history of CAD (%) 48 52 47 0.21
Diabetes mellitus (%) 27 29 26 0.35
Chest pain 57 53 58 0.37
Typical angina pectoris (%) 11 9 11 0.36
Non-anginal chest pain or  atypical angina 
pectoris (%)
46 44 47 0.41
Early invasive diagnostic tests and  treatment 
Coronary angiography (< 6 months) (%) 6.5 5.2 6.9 0.39
revascularization (< 6 months) (%) 0.8 0.5 0.9 0.51
PCI (%) 0.7 0.5 0.8 0.61
CABG (%) 0.1 0 0.1 0.59
Coronary CTA
Vessel dominance 0.45
right (%) 84 87 83
Left (%) 12 9 12
Balanced (%) 4 4 5
Coronary artery calcium score (IQr) n=811 0 (0-12) 0 (0-27) 0 (0-8) 0.04
Non-obstructive CAD (%) 58 62 57 0.24
Coronary plaques (composition)
No. of calcified lesions 0.3±1.0 0.3±0.8 0.3±1.0 0.27
No. of mixed lesions 0.4±1.1 0.5±1.1 0.4±1.1 0.64
No. of non-calcified lesions 0.5±1.4 0.5±1.3 0.5±1.4 0.76
* Serum total cholesterol ≥230 mg/dl and/or serum triglycerides ≥200 mg/dl or treatment with lipid  
lowering drugs,
† Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or 
the use of antihypertensive medication. 
BMI: body mass index; CABG: coronary artery bypass grafting; CAD: coronary artery disease; IQR: 
interquartile range; No: number; PCI: percutaneous coronary intervention.
(<6 months)
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Table 2. Distribution of segments on CTA among 210 patients with  
an intramural course.
Distribution of segments with an 
intramural course
N=210




Diagonal branch 17 (8)
LCX coronary artery 109 (52)
Intermediate / anterolateral 98 (47)
Proximal or Distal 9 (4)
oM 2 (1)
Right coronary artery 2 (1)
Distal 1 (0.5)
rDP 1 (0.5)
Values are N (%). LAD: left anterior descending; OM: obtuse marginal branches; LCX: left circumflex; 
RDP: right descending posterior.











Follow-up period in years 4.9 (3.2;6.9) 4.6 (3.2;6.6) 5.0 (3.3;7.0) 0.15
unstable angina pectoris  requiring 
hospitalization
13 (1.4) 2 (1) 11 (1.5) 0.64
Nonfatal myocardial infarction 7 (0.7) 2 (1.0) 5 (0.7) 0.57
All-cause mortality 23 (2.4) 4 (1.9) 19 (2.6) 0.69
Combined endpoint* 43 (4.5) 8 (3.8) 35 (4.7) 0.73
Values are median (IQR) or N (%).
* Including unstable angina pectoris requiring hospitalization, nonfatal myocardial infarction or 





Of the 1,000 patients initially included, 53 patients (5%) were lost to follow- up 
and excluded from the analysis. All baseline characteristics of the patients 
excluded for analysis were similar to the patients included in the present 
analysis, except for age which was lower in the exclusion group (47±13 years 
versus 53±12 years, P=0.001) as demonstrated in supplemental Table 1. 
The clinical characteristics of the remaining 947 patients without obstructive 
CAD on coronary CTA (56% women, mean age 53±12 years) are presented 
in Table 1. 
Coronary computed tomography
CAC score analysis was feasible in 811 (86%) patients. The median CAC 
score was 0 (IQR: 0 to 12). Most of the patients (63%) had a CAC score of 
0, and 74 patients (9%) had a CAC score >100. The results of the coronary 
CTA are presented in Table 1. Non-obstructive CAD was observed in 553 
(58%) patients whereas the remaining patients (42%) had no coronary artery 
stenosis. The mean number of calcified segments and segments with mixed 
plaque were 0.3 ± 1.0 and 0.4 ± 1.1, respectively, and, on average, 0.5 ± 1.4 
segments had noncalcified plaque.
Presence of an intramural course
On coronary CTA, 210 (22%) patients had an intramural course of a coro-
nary artery. The median depth of the intramural course was 1.9 mm (IQR: 
1.4 to 2.6 mm). In 84 (40%) patients the depth of the intramural course was 
considered deep (>2 mm surrounding myocardium).
 Table 2 describes the segmental location of the intramural course. The 
most frequent segments that shows an intramural course were the mid / distal 
left anterior descending (LAD) coronary artery (37%) and the intermediate / 
anterolateral coronary artery (47%).
 Table 1 shows the differences in clinical characteristics between patients with 
versus without an intramural course of the coronary artery. Patients without an 
intramural course of the coronary artery were more frequently obese in com-
parison with patients with an intramural course of the coronary artery (21% 
versus 11%, respectively; P=0.004). On coronary CT scan, the median CAC 
score was significantly higher in patients with an intramural course compared 
with patients without an intramural course (0; IQR: 0 to 27 versus 0; IQR: 0 
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to 8, respectively; P=0.04). There were no differences in the presence of non- 
obstructive CAD or the number of calcified / mixed and non-calcified plaques 
between both groups.
Patient outcome
As shown in Table 3, the median follow-up was 4.9 years (IQR: 3.2 to 6.9 
years) and was similar in patients with and without an intramural course 
on coronary CTA (4.6; IQR: 3.2 to 6.6 versus 5.0; IQR: 3.3 to 7.0 years 
respectively, P=0.15). During follow-up, 43 events occurred; hospitalization 
due to unstable angina pectoris in 13 patients (1.4%), 7 patients (0.7%) had 
a nonfatal myocardial infarction and 23 patients died (2.4%). No patient 
experienced > 1 event. As shown in Figure 2A-2C, unstable angina pectoris 
that required hospitalization, nonfatal myocardial infarction and all-cause 
mortality occurred  similarly in patients with and patients without an intramu-
ral course of a coronary artery. At 6-year follow-up, the cumulative event rates 
for unstable angina pectoris that required hospitalization were 0.0% versus 
1.1%; for nonfatal myocardial infarction 0.5% versus 0.4%; and for all-cause 
mortality 1.9% versus 2.2%.
 The Kaplan-Meier event-free survival for the combined endpoint of 
unstable angina pectoris that required hospitalization, nonfatal myocardial 
infarction, and all-cause mortality stratified according to the presence of an 
intramural course of a coronary artery is shown in Figure 2D. Patients with 
an intramural course of the coronary artery had similar 6-year cumulative 
event rates of the combined endpoint compared with patients without an 
intramural course (the cumulative event rates were 2.4% vs. 3.7%, respec-
tively; Log Rank P=0.73). 
 Associates for the combined endpoint of unstable angina pectoris that 
required hospitalization, nonfatal myocardial infarction and all-cause 
mortality are presented in Table 4. The intramural course of coronary arteries 
was not significantly associated with the combined endpoint (HR 0.87; 
95%CI 0.40 to 1.88, P=0.73). In contrast, age, CAC score and the number 
of calcified and mixed plaques were associated with the combined endpoint 
of unstable angina pectoris requiring hospitalization, nonfatal myocardial 
infarction and all-cause mortality during long-term follow-up. 
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Figure 2. Kaplan-Meier Event-Free Survival Curves for Patients With and 
Without Intramural Course of the Coronary Artery.
Kaplan-Meier curves for the endpoint (A.) all-cause mortality, (B.) unstable angina pectoris requiring 
hospitalization, (C.) nonfatal myocardial  infarction and (D.) the combined endpoint. 
MI: myocardial infarction; No.: number; UAP: unstable angina pectoris. 
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Table 4. The association of clinical and coronary CTA characteristics with the 
combined endpoint: unstable angina pectoris requiring hospitalization, nonfatal  






HR 95% CI P-value
Clinical characteristics
Age (years) 60±12 53±12 1.06 1.03-1.09 <0.001
Women (%) 54 56 1.04 0.57-1.90 0.90
Risk factors
BMI >30 (%) 24 18 1.54 0.75-3.13 0.24
Hypercholesterolemia†(%) 24 36 0.61 0.3-1.24 0.17
Hypertension‡ (%) 44 39 1.07 0.58-1.98 0.83
Current smoking (%) 14 15 0.88 0.37-2.07 0.76
Family history of CAD (%) 37 49 0.61 0.33-1.13 0.11
Diabetes mellitus (%) 24 27 0.88 0.43-1.79 0.72
Coronary CTA
Calcium score (IQr) (n=811) 8 (0-247) 0 (0-11) 1.002 1.001-1.002 <0.001
Non-obstructive CAD (%) 70 58 1.57 0.82-3.00 0.18
Intramural course of the 
coronary arteries (%)
19 22 0.87 0.40-1.88 0.73
Coronary plaques  (composition)
No. of calcified lesions 0.98±1.68 0.26±0.90 1.34 1.16-1.56 <0.001
No. of mixed lesions 1.07±1.97 0.39±1.05 1.26 1.09-1.45 0.002
No of non-calcified lesions 0.42±0.76 0.49±1.40 0.95 0.72-1.24 0.69
* Including unstable angina pectoris requiring hospitalization, nonfatal myocardial infarction or 
 all-cause mortality. 
† Serum total cholesterol ≥230 mg/dl and/or serum triglycerides ≥200 mg/dl or treatment with lipid 
lowering drugs. 
‡ Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or 
the use of antihypertensive medication.




The present study evaluated, in a large cohort of patients without obstructive 
CAD, the prognostic implications of an intramural course of a coronary artery 
assessed on coronary CTA. An intramural course of a coronary artery was 
observed in 22% of patients. Patients with and without an intramural course 
of the coronary artery had similar low cumulative event rates for the combined 
endpoint of nonfatal myocardial infarction, unstable angina pectoris that 
required hospitalization or all-cause mortality during long-term follow-up. 
Presence of intramural course of a coronary artery 
Intramural course of the coronary artery was for the first time described 
on invasive coronary angiography by Porstmann et al. in 1960.18 Coronary 
CTA is a more sensitive imaging tool than invasive coronary angiography to 
characterizes the course of the coronary arteries, and, accordingly, studies have 
reported a prevalence of intramural course of coronary arteries on coronary 
CTA that is more than twice as high as observed on invasive angiography 
(0.5 to 11.8%).19, 20 Among 100 patients who underwent coronary CTA 
and invasive angiography, Leschka et al. observed an intramural course of 
the coronary artery in 26 patients on coronary CTA compared with only 12 
patients on invasive angiography.21 The lower prevalence of an intramural 
course on invasive angiography compared with coronary CTA can be partially 
explained by the fact that these 2 techniques detect different phenomena. 
Coronary CTA visualizes the anatomical relationship of the coronary artery 
to the surrounding myocardium. Conversely, invasive angiography can only 
detect systolic compression of the artery, which can be the consequence of an 
intramural course (also referred to as myocardial bridging22), but occurs only 
in a minority of patients with intramural course of the coronary artery. Uusitalo 
et al. demonstrated that only approximately one-third of the patients with 
an intramural course on coronary CTA showed systolic compression during 
invasive coronary angiography.11
  The prevalence of an intramural course of a coronary artery on coronary 
CTA in the current study was 22%. This is in accordance with studies using 
64-slice and 128-slice CT scanners, who have reported prevalences of 26% 
and 21%, respectively.23, 24 Similarly to the present study, the LAD coronary 
artery is the coronary artery more frequently showing an intramural course, 
regardless of the methodology used.15, 21 In addition, the present study also 
demonstrated that the intermediate / anterolateral coronary artery was fre-
quently involved.
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Intramural course of the coronary artery and long-term outcome
Some case reports have suggested that the presence of an intramural course of 
a coronary artery is associated with sudden cardiac death.7, 23 The present 
study revealed similar survival rates for both groups during long-term follow- 
up. In addition, the occurence of the combined endpoint of unstable angina 
pectoris that required hospitalization, nonfatal myocardial infarction, or 
all-cause mortality during long-term follow-up was similar in patients with 
and without an intramural course of a coronary artery. Rubinshtein et al. 
demonstrated in 334 patients that the presence of an intramural course of a 
coronary artery assessed with coronary CTA did not have a prognostic impact 
for the composite endpoint cardiovascular death or nonfatal myocardial 
infarction.26 In their study, during a mean follow-up duration of 6 years, there 
was no significant difference in cumulative event rates between both groups 
(5.1% in patients with versus 3.2% in patients without an intramural course 
of a coronary artery; P=0.40). The reason that the frequently present intra-
mural course of the coronary artery on coronary CTA was not associated with 
adverse events was probably because an intramural course only in the minor-
ity of the cases is associated with systolic compression (“bridging”).11
Study limitations
The present study visualized the anatomical relationship of the coronary 
artery to the surrounding myocardium, and therefore, cyclic changes in 
coronary artery flow nor dynamic compression could be evaluated. Because 
the study was retrospective, no assessment of the required sample size was 
performed.
Conclusion
In patients without obstructive CAD on coronary CTA, an intramural course 
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Objectives. The best strategy in patients with acute ST-segment elevation 
myocardial infarction (STEMI) with multivessel coronary artery disease 
(CAD) regarding completeness of revascularisation of the non-culprit 
lesion(s) is still unclear. To establish which strategy should be followed, 
 survival rates over a longer period should be evaluated. The aim of this study 
was to investigate whether complete revascularisation, compared with incom-
plete revascularisation, is associated with reduced short-term and long-term 
all-cause mortality in patients with first STEMI and multivessel CAD.
Methods. This retrospective study consisted of 518 patients with first STEMI 
with multivessel CAD. Complete revascularisation (45%) was defined as the 
treatment of any significant coronary artery stenosis (≥70% luminal narrow-
ing) during primary or staged percutaneous coronary intervention (PCI) prior 
to discharge. The primary end point was all-cause mortality. 
Results. Incomplete revascularisation was not independently associated with 
30-day all-cause mortality in patients with acute first STEMI and multivessel 
CAD (OR 1.98; 95% CI 0.62-6.37; P=0.25). During a median long-term 
follow-up of 6.7 years, patients with STEMI with multivessel CAD and 
incomplete revascularisation showed higher mortality rates compared 
with patients who received complete revascularisation (24% versus 12%, 
P<0.001), and these differences remained after excluding the first 30 days. 
However, in multivariate analysis, incomplete revascularisation was not 
independently associated with increased all-cause mortality during long-term 
follow-up in the group of patients with STEMI who survived the first 30 days 
post-STEMI (HR 1.53 95%CI 0.89-2.61, P=0.12). 
Conclusion. In patients with an acute first STEMI and multivessel CAD, 
incomplete revascularisation compared with complete revascularisation was 
not independently associated with increased short-term and long-term all-
cause mortality.
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Introduction
Primary percutaneous coronary intervention (PCI) of the culprit vessel in 
patients with ST-segment elevation myocardial infarction (STEMI) is a 
standard clinical practice.1 However, in patients with STEMI and multivessel 
coronary artery disease (CAD), the best revascularisation strategy (complete 
versus incomplete revascularisation) remains debated. While primary PCI of 
the infarct-related artery (IRA) should be performed systematically, immediate 
revascularisation of the non-culprit vessel(s) is/are only recommended in 
patients with cardiogenic shock or persisting large areas of ischemia.2 Recent 
landmark randomised trials such as the CvLPRIT (Complete versus Lesion-
only Primary PCI trial), DANAMI-3-PRIMULTI (The Third Danish Study 
of Optimal Acute treatment of Patients with STEMI: Primary PCI in Mul-
tivessel disease) and the PRAMI (Preventive Angioplasty in Acute Myocardial 
Infarction) trials demonstrated reduced risk of adverse cardiovascular events 
in patients undergoing immediate complete revascularisation compared with 
patients with incomplete revascularisation.3-5 In contrast, large observational 
studies did not show differences in adverse cardiovascular event rates between 
the two revascularisation strategies.6-8 Furthermore, the effect of complete 
versus incomplete revascularisation on clinical outcomes has not been evaluated 
at long-term follow-up (> 5 years).9, 10
 Therefore, the aim of the current retrospective, observational study was 
to investigate whether incomplete revascularisation, compared with complete 
revascularisation, is associated with increased short-term and long-term all-




The analysis concerns a retrospective analysis of patients who presented with 
a first acute STEMI and multivessel CAD at the Leiden University Medical 
Center (The Netherlands) between 2004 and 2008. The inclusion criteria 
were: 1) diagnosis of first acute STEMI that was defined as typical chest 
pain complaints <12 hours, elevated cardiac enzyme levels and significant 
ST-segment elevation or left bundle branch block on the ECG; 2) multives-
sel CAD on emergency coronary angiography (CAG); and 3) no history of 
CAD as defined by previous myocardial infarction, PCI or coronary artery 
bypass graft. All patients were treated according to the MISSION! protocol as 
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described earlier11, which was based on the most recent American College of 
Cardiology/American Heart Association and European Society of Cardiology 
guidelines for patients with acute myocardial infarction at that moment. The 
interventional cardiologist determined whether immediate or staged revas-
cularisation of the non-culprit vessel(s) occurred. Patients with 1) emergent 
or staged revascularisation with coronary artery bypass graft surgery before 
discharge and 2) incomplete or uninterpretable CAG images were excluded. 
The primary endpoint was all-cause mortality. Mortality data were obtained 
from hospital’s files review or municipal civil registries. Demographic, clinical 
and angiographic data were prospectively entered in the departmental Cardio-
logy Information System (EPD-Vision©, Leiden University Medical Center, 
the Netherlands) and analysed retrospectively. The Institutional Review Board 
of the Leiden University Medical Centre approved the retrospective, observa-
tional study and waived the need for written informed consent for retrospective 
analysis of clinically acquired data.
Primary percutaneous coronary intervention and  
angiographic data analysis
CAG data were acquired from standardized angiographic projections according 
to the guidelines of the American College of Cardiology/American Heart 
Association and were stored digitally.12 CAG data were reviewed retrospec-
tively by two experienced observers. During image analysis the following 
information was reported: (in)complete revascularisation, coronary vessel 
dominance, culprit vessel, severity of CAD and the results of primary PCI. 
IRA was determined by the evaluation of acute electrocardiographic changes 
on the ECG at admission.13 Complete revascularisation was defined as PCI 
of any significant coronary artery stenosis (≥70% luminal narrowing) of any 
vessel during the primary or staged PCI prior to discharge. 
Statistical analysis
Normally distributed variables were expressed as mean ± SD and non-normally 
distributed variables as median and IQR. Categorical variables were presented 
as frequencies and percentages. Differences in baseline characteristics between 
patients with complete revascularisation and patients with incomplete 
revascularisation were evaluated with the independent samples t-test, the 
Mann-Whitney U test or the Chi-Square test when appropriate. Survival 
analyses were performed using Kaplan-Meier analysis. Cumulative event rates 
for the end point of all-cause mortality were compared between patients with 
complete revascularisation and patients with incomplete revascularisation, 
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using the Log-Rank test. The influence of differences in baseline characteristics 
on 30-day mortality post-STEMI was assessed by performing univariate and 
multivariate logistic regression analysis. To avoid any overfitting of the model, 
only a selection of variables with significant P-values (<0.05) at univariate 
analysis were entered in the multivariate model: age, three-vessel CAD, culprit 
vessel left main, Killip class≥2 and incomplete revascularisation. The results of 
the multivariate analysis were reported as adjusted odds ratios (OR) with 95% 
confidence interval (CI). The independent associates of all-cause mortality at 
long-term follow-up were investigated using univariate and multivariate Cox 
regression analysis for those patients who survived the first 30 days. Only varia-
bles with significant P-values (<0.05) at univariate analysis were included in the 
multivariate model: age, diabetes mellitus, family history of CAD, three-vessel 
CAD, renal dysfunction (estimated glomerular filtration rate (eGFR) < 60 mL/
min/1.73m2), culprit vessel left main and incomplete revascularisation. The 
results of the multivariate Cox regression analysis were reported as hazard ratio 
(HR) and their respective 95% CI. Statistical analysis was performed using 
SPSS software (Version 22.0, SPSS IBM Corp., Armonk, New York, USA). A 
two-sided P-value of <0.05 was considered statistically significant. 
Results
Patients
Of 1,133 patients with acute first STEMI, 542 had multivessel CAD on CAG. 
Additionally, 24 patients (4%) were excluded because of revascularisation with 
coronary artery bypass graft surgery before discharge (n=8) or incomplete or 
uninterpretable CAG data (n=16). The clinical baseline characteristics of the 
remaining 518 patients are shown in Table 1. The majority of patients were 
male (76%), with a mean age of 63±12 years and in one third of the patients 
emergent CAG showed three-vessel CAD. At presentation, 36 patients (7%) 
were in Killip class≥2. Complete revascularisation was performed in 231 
patients (45%): in 197 patients (85%) during primary PCI and in 34 patients 
(15%) during staged revascularisation before discharge. Differences in baseline 
characteristics between patients with incomplete and complete revascularisation 
are presented in Table 1. Patients who received complete revascularisation 
before discharge were younger, presented less often with Killip class≥2, had 
the left anterior descending coronary artery less often as culprit vessel, had 
more often two-vessel CAD and had more often preserved renal function as 
compared with patients who received incomplete revascularisation.
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Gender (male) 76% 74% 78% 0.24
Age (years) 63 ± 12 64 ± 13 62 ± 12 0.02
Obesity (BMI ≥ 30kg/m2) 16% 17% 15% 0.41
Diabetes 12% 14% 10% 0.15
Hypercholesterolemia* 17% 19% 15% 0.30
Hypertension† 37% 40% 34% 0.17
Current smoker 44% 43% 45% 0.58
Family history of CAD 38% 38% 38% 0.90
Presenting in Killip class ≥ 2 7% 10% 4% 0.006
Culprit vessel
Left main 1% 1% 2% 0.50
rCA 42% 39% 45% 0.20
LAD 41% 46% 35% 0.02
LCx 16% 14% 18% 0.19
Three-vessel CAD 33% 42% 22% <0.001
eGFR ≤ 60 mL/min/1.73m² 13% 15% 9% 0.04







Peak cardiac troponin T level 
≥3.5 μg/L
59% 61% 56% 0.18
LV ejection fraction 47±10 46±10 47±10 0.07
LV ejection fraction ≤40% 28% 31% 25% 0.13
Blood pressure at discharge
Systolic 116 ± 17 115 ± 16 118 ± 18 0.10
Diastolic 70 ± 11 69 ± 10 71 ± 12 0.12
Medication at discharge
Beta-blocker 93% 92% 94% 0.36
Aspirin 96% 96% 97% 0.75
Clopidogrel 99% 99% 99% 0.80
ACE-inhibitor/ ARB 96% 96% 97% 0.55
Statin 98% 98% 98% 0.71
* Serum total cholesterol ≥230 mg/dl and/or serum triglycerides ≥200 mg/dl or treatment with lipid 
lowering drugs. 
†  Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or the 
use of antihypertensive medication. 
‡  Complete revascularisation was defined as treating all present significant coronary artery stenosis ≥ 
70% during primary PCI or before discharge. 
ACE-inhibitor: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blockers; BMI: body mass 
index; CAD: coronary artery disease; eGFR: glomerular filtration rate estimated using the Cockroft-Gault for-
mula; IQR: interquartile range; LAD: left anterior descending  coronary artery; LCx: left circumflex coronary 
artery; LV: left ventricle; RCA: right coronary artery; STEMI: ST segment elevation myocardial infarction.
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Table 2. Differences in baseline characteristics between patients who died within the 
first 30 days post-STEMI and those who survived. 
Deceased within  
the first 30 days 
post-STEMI
N=31




Gender (male) 55% 77% 0.005
Age (years) 74 ± 12 62 ± 12 <0.001
Obesity (BMI ≥ 30kg/m2) 29% 16% 0.13
Diabetes 10% 12% 0.8
Hypercholesterolemia* 14% 17% 0.63
Hypertension† 31% 37% 0.49
Current smoker 32% 45% 0.20
Family history of CAD 11% 40% 0.003
Presenting in Killip class ≥ 2 61% 4% <0.001
Culprit vessel
        Left main 16% 0.4% <0.001
        rCA 29% 43% 0.13
        LAD 42% 41% 0.91
        LCx 13% 16% 0.65
Three-vessel CAD 55% 32% 0.008
Incomplete revascularisation‡ 77% 54% 0.01
eGFR ≤ 60 mL/min/1.73m2 48% 11% <0.001
Peak cardiac troponin T level 
≥3.5 μg/L
83% 58% 0.01
LV ejection fraction ≤40% 70% 27% <0.001




In the first 30 days post-STEMI, 31 patients (6%) died (28 during index 
hospitalisation). The cause of death was cardiac in 27 patients (87%), terminal 
postanoxic encephalopathy in 1 patient (3%) and unknown reason in 3 patients 
(10%). The cardiac causes of death were cardiogenic shock (17 patients, 63%), 
ventricular fibrillation (1 patient, 4%), left ventricular free wall rupture (1 
patient, 4%), terminal heart failure (6 patients, 22%) and reinfarction due to 
intrastent thrombosis (2 patients, 7%). Table 2 shows the differences in baseline 
characteristics between the deceased patients and those who survived the first 
30 days post-STEMI. The variables (independently) associated with the end-
point 30-day mortality are shown in Table 3. In the multivariate analysis age, 
Killip class≥2 and left main coronary artery as the culprit vessel were inde-
pendently associated with increased 30-day mortality post-STEMI. However, 
incomplete revascularisation was not independently associated with increased 
30-day mortality post-STEMI (OR 1.98 [95%CI 0.62-6.37], P=0.25).
Long-term follow-up
Long-term follow-up was complete in all patients with a median follow-up of 
6.7 years (IQR 5.6-7.9 years). Ninety-eight patients died, 67 of them (68%) 
died after 30 days post-STEMI. The Kaplan-Meier survival curves stratified 
according to complete versus incomplete revascularisation are presented 
in Figure 1. Patients with STEMI with multivessel CAD and incomplete 
revascularisation showed higher mortality rates compared with patients who 
received complete revascularisation (24% versus 12%, P<0.001).
 The cumulative mortality rates at 1, 2 and 5 years of follow-up were 
significantly higher for patients who were treated with incomplete revascu-
larisation compared with patients who underwent complete revascularisation 
(9.8%,12.2% and 18.8% versus 4.3%, 5.2% and 6.9% respectively, P=0.02, 
P=0.006 and P<0.001 respectively). After excluding the patients who died 
within the first 30 days from the analysis, incomplete revascularisation was 
associated with worse long-term survival compared with complete revascu-
larisation (P=0.012; Figure 2). However, multivariate Cox regression analysis 
showed that incomplete revascularisation was not independently associated 
with increased all-cause mortality (Table 4). Age and left main coronary 
artery as the culprit vessel were independently associated with the endpoint of 
all-cause mortality. After excluding patients presenting in cardiogenic shock 
(Killip class 4) on the day of admission (n=7), incomplete revascularisation 
was not independently associated with increased all-cause mortality (HR 1.56 
[95%CI 0.91-2.69], P=0.11, supplemental Table 1).
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Table 3. Influence of baseline characteristics on 30-day mortality post-STEMI
Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
Gender (male) 0.36 0.17-0.75 0.006
Age (years) 1.09 1.05-1.13 <0.001 1.10 1.05-1.15 <0.001
Diabetes 0.85 0.25-2.91 0.80
Hypercholesterolemia* 0.77 0.26-2.26 0.63
Hypertension† 0.75 0.34-1.69 0.49
Current smoker 0.59 0.26-1.33 0.20
Family history of CAD 0.19 0.06-0.64 0.007
Presenting in Killip  
class ≥2 
38.42 16.32-90.43 <0.001 29.00 10.78-77.99 <0.001
Culprit vessel
Left main 46.64 8.63-251.88 <0.001 48.16 4.43-523.47 0.001
rCA 0.55 0.25-1.12 0.14
LAD 1.05 0.50-2.18 0.91
LCx 0.78 0.26-2.28 0.65
Three-vessel CAD 2.63 1.26-5.46 0.01 0.90 0.33-2.44 0.84
Incomplete  
revascularisation‡
2.92 1.24-6.91 0.02 1.98 0.62-6.37 0.25
eGFR ≤ 60 mL/
min/1.73m2
7.31 2.96-18.02 <0.001






For definitions: see Table 1.
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Figure 1. Kaplan-Meier curves for the endpoint all-cause mortality in the total 
patient population stratified according to complete / incomplete revascularisation.
Figure 2. Kaplan-Meier curve for all-cause mortality in the subgroup of  
survivors of the first 30 days after STEMI stratified according to complete /  
incomplete revascularisation
The survivors of the first 30 days post-STEMI with incomplete revascularisation compared with 
patients with complete revascularisation had a statistically significant higher cumulative incidence of 
all-cause mortality (P [Log Rank]=0.012) during long-term follow-up after STEMI. 
Patients with incomplete revascularisation had a statistically significant higher cumulative incidence of 
all-cause mortality (P [Log Rank] < 0.001) during long-term follow-up after STEMI in comparison 
with patients with complete revascularisation. 
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Table 4. Cox regression analysis for all-cause mortality during long-term follow-up 
in the group of STEMI patients who survived the first 30 days post-STEMI. 
 
Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Gender (male) 0.99 0.56-1.73 0.96
Age (years) 1.07 1.04-1.09 <0.001 1.05 1.03-1.08 <0.001
Diabetes 2.28 1.27-4.12 0.006 1.82 0.99-3.34 0.054
Hypercholesterolemia* 0.46 0.20-1.06 0.07
Hypertension† 1.20 0.74-1.96 0.46
Current smoker 0.91 0.56-1.48 0.71
Family history of CAD 0.57 0.33-0.97 0.04 0.75 0.43-1.32 0.32
Presenting in Killip class ≥ 2 1.47 0.53-4.05 0.46
Culprit vessel
Left main 9.49 2.31-38.94 0.002 8.40 1.89-37.39 0.005
rCA 0.86 0.52-1.40 0.54
LAD 1.24 0.77-2.00 0.39
LCx 0.71 0.34-1.48 0.35
Three-vessel CAD 1.95 1.21-3.16 0.006 1.34 0.80-2.23 0.26
eGFR ≤ 60 mL/min/1.73m2 2.50 1.40-4.44 0.002 0.93 0.48-1.80 0.83
Peak cardiac troponin T 
level ≥3.5 μg/L
1.31 0.79-2.17 0.30
LV ejection fraction ≤40% 1.43 0.85-2.41 0.18
Medication at discharge
Beta-blocker 0.75 0.30-1.87 0.54




ACE-inhibitor /  
ArB
0.76 0.24-2.42 0.64
Statin 0.81 0.11-5.86 0.84
Incomplete revascularisation‡ 1.91 1.14-3.20 0.01 1.53 0.89-2.61 0.12
For definitions and abbreviations: see Table 1.
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Supplemental table 1. Cox regression analysis for all-cause mortality during 
long-term follow-up in the subgroup of patients surviving the first 30 days and who 
were not in cardiogenic shock at admission.
Discussion
This study showed that patients with first acute STEMI and multivessel CAD 
who were treated with incomplete revascularisation had higher mortality rates 
at 30-day and long-term follow-up compared with patients who underwent 
complete revascularisation. However, after correcting for relevant clinical 
variables, incomplete revascularisation was not independently associated with 
increased all-cause mortality.
Prevalence of multivessel CAD and percutaneous  
revascularisation strategies
Multivessel CAD is present in 45%-55% of patients presenting with acute 
STEMI and is associated with 1.5-fold higher 30-day mortality rate com-
pared with patients with STEMI with single vessel CAD.8, 14-17 It has been 
hypothesised that complete revascularisation may improve the outcomes of 
STEMI patients with multivessel CAD. However, the results of various registries 
and randomised trials are conflicting.3, 4, 7, 9 The randomised CvLPRIT trial 
demonstrated in 296 patients with STEMI with multivessel CAD a significant 
reduction of the combined endpoint consisting of all-cause mortality, recur-
rent myocardial infarction or heart failure in the complete revascularisation 
group compared with the IRA-only PCI group (4.7% and 13%; P=0.025).4 
However, data of the large National CV Data Registry from the United States, 
that involved 28,936 STEMI patients with multivessel CAD, demonstrated a 
Multivariate
HR 95% CI P-value
Age (years) 1.07 1.04-1.09 <0.001
Presenting in Killip class ≥ 2 0.85 0.21-3.49 0.86
Culprit vessel left main 5.56 0.74-41.8 0.096
Three-vessel CAD 1.24 0.74-2.09 0.41
Incomplete revascularisation* 1.56 0.91-2.69 0.11
 
* Complete revascularisation was defined as treating all present significant coronary artery stenosis ≥ 
70% during primary PCI or before discharge.
CAD: coronary artery disease
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significantly higher mortality rate in patients with multivessel PCI (n=3,134) 
in comparison with IRA-only PCI (n=25,802) (7.9% and 5.1%, respectively; 
P<0.01).7 After adjusting for potential confounders, complete revascularisation 
was not independently associated with increased risk of all-cause mortality.
 Current guidelines recommend to consider complete revascularisation 
in selected patients with STEMI and multivessel CAD (class IIb, level of 
evidence B).2 In this study, 45% of the patients with STEMI and multivessel 
CAD underwent complete revascularisation (85% during primary PCI) before 
hospital discharge. In other registries, the rates of complete revascularisation 
varied between 11% and 30%.7, 18, 19 The disparities in complete revascu-
larisation rates across the several studies may be explained by differences 
in patient populations and operator decision making. In this study, patients 
with complete revascularisation before discharge were younger, presented less 
often with Killip class≥2, had the left anterior descending coronary artery less 
often as culprit vessel, had more often two-vessel CAD and had more often 
preserved renal function. This is in agreement with the National CV Data 
Registry where patients with complete revascularisation were more likely to be 
younger or presenting with cardiogenic shock.7
Incomplete revascularisation and 30-day mortality 
In the current study, independent associates for the endpoint of 30-day mortality 
in first patients with STEMI with multivessel CAD were higher age, Killip 
class≥2 and left main as culprit vessel. These observations are in line with the 
SHOCK trial, which demonstrated a high mortality rate in patients with acute 
myocardial infarction complicated by cardiogenic shock and lower prevalence 
of left main disease for in-hospital survivors.20 However, similar to other large 
registries, incomplete revascularisation was not independently associated with 
the endpoint of 30-day mortality in patients with first STEMI and multivessel 
CAD.7, 8, 18, 20  The EUROTRANSFER Registry (European Registry on STEMI 
Patients Transferred for PCI with Upstream Use of Abciximab), including 
777 patients with STEMI and multivessel CAD, showed that multivessel PCI 
(n=70) compared with IRA-only PCI (n=707) was associated with a higher risk 
of death at 30-day follow-up (5.9% vs 12.9%, respectively, P=0.04).8 However, 
this difference in mortality rate was no longer statistically significant after adjust-
ment for covariates (adjusted OR 2.42 [95%CI 0.96 to 6.06]). Similar findings 
were reported by the large National CV Data Registry from the United States.7 
 These findings contrast with the results of two recent randomised trials 
demonstrating short-term benefit of complete revascularisation in compar-
ison with incomplete revascularisation in patients with acute STEMI with 
chapter 4
76
multivessel CAD.3, 4 The PRAMI trial enrolled 465 patients with STEMI with 
multivessel CAD randomly assigned to multivessel PCI (n=234) or IRA-only 
PCI (n=231) and compared the groups for the occurrence of combined end-
point of cardiac death, nonfatal myocardial infarction, or refractory angina.3 
This study was prematurely terminated because of a highly statistically 
significant difference (P<0.001) in the primary outcome, favouring multives-
sel PCI. Complete revascularisation was associated with risk reduction within 
6 months after the procedure in comparison with the IRA-only PCI. These 
findings were similar to those reported by the CvLPRIT trial investigators.4 In 
this open-labelled randomised study, the impact of complete revascularisation 
at index admission (n=150) on short-term outcomes was compared with IRA-
only PCI (n=146). At 30-day follow-up, patients allocated to the complete 
revascularisation arm showed lower rates of all-cause mortality, recurrent 
myocardial infarction, heart failure, and ischemic driven revascularisation 
compared with patients treated with PCI of the IRA-only (HR 0.45 [95%CI 
0.19-1.04]; P=0.055). These conflicting results may be explained by patient 
characteristics and selection bias. Patients included in the registries showed 
higher risk (older age, associated co-morbidities and higher frequency of 
cardiogenic shock) compared with those included in the randomised trials. 
 A large meta-analysis by Moretti et al. demonstrated that the only benefit 
of complete revascularisation in patients with STEMI with multivessel CAD 
during short-term follow-up (1 year) related to less repeated revascularisation 
compared to patients with IRA-only revascularisation. 21
Incomplete revascularisation and long-term follow-up
Data on the impact of complete revascularisation in patients with STEMI 
with multivessel CAD on long-term outcome are limited. The PRAMI trial 
showed a non-significant risk reduction of cardiac death in the multivessel 
PCI group (n=234) in comparison with the IRA-only PCI (n=231) during a 
mean follow-up of 23 months (HR 0.34; 95%CI 0.11-1.08; P=0.07).3 Similar 
findings were reported by the DANAMI-3-PRIMULTI which showed no 
significant difference in all-cause mortality in 627 patients randomly allocated 
to no further invasive treatment or to complete FFR-guided revascularisation 
before discharge (HR 1.40; 95%CI 0.63-3.00, P=0.43).5 Furthermore, in a 
study including 214 patients with STEMI with multivessel CAD, there were 
no differences in mortality rates at 2.5 years follow-up between IRA-only 
PCI, staged complete revascularisation and complete revascularisation during 
primary PCI (15.5%, 6.2% and 9.2% respectively, P=0.17).10 In addition, 
Hannan et al. showed comparable 12-, 24- and 42-month mortality rates in 
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patients with IRA-only PCI (n=503) and multivessel PCI (n=503).9 After 
exclusion of patients with hemodynamic instability, left ventricular ejection 
fraction ≤20% and malignant ventricular arrhythmia, there were no differences 
in mortality rates between the two groups. 
 The results of the present study are in line with the above mentioned 
studies. Patients with STEMI with multivessel CAD who received incomplete 
revascularisation showed an increased long-term mortality rate compared 
with patients who underwent complete revascularisation (24% vs.12%, 
P<0.001). However, multivariate analysis showed that incomplete revascular-
isation was not independently associated with increased all-cause mortality.
 The results of the COMPLETE trial (ClinicalTrials.gov Identifier 
NCT01740479), including more than 3,900 patients who will be randomised 
and followed-up during a mean of 4 years, may shed light on this clinically 
relevant question.
Limitations
This study has some limitations that need to be addressed. First, this is a 
retrospective study. Second, patients with cardiogenic shock were not all 
completely revascularized. Following current guidelines, in this subgroup of 
patients, if there were truly critical (≥90%) stenoses or highly unstable lesions 
and if there was persistent ischemia after PCI of the culprit lesion, complete 
revascularisation was performed.2 However, non-culprit lesions without critical 
stenoses were not routinely stented.2 Additional analysis after excluding 
patients in cardiogenic shock at the time of admission demonstrated similar 
results: incomplete revascularisation was not independently associated with 
increased all-cause mortality during long-term follow-up. Third, the character-
istics of the stents used during PCI in the current study were not taken into 
account. Furthermore, the presence of chronic total occlusions of the coronary 
arteries was not recorded. In addition, to avoid misclassification of the cause 
of death, this study investigated only all-cause mortality.22 Moreover, although 
patients are advised to follow a cardiac rehabilitation program after hospital 
discharge, data on adherence to these programs were not available, and this 
could have influenced the survival rate. 
Conclusion
Incomplete revascularisation in patients with acute first STEMI and multi-
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The best revascularization strategy (complete versus incomplete revasculari-
zation) in patients with ST-elevation myocardial infarction (STEMI) is still 
debated. The interaction between gender and revascularization strategy in 
STEMI patients on all-cause mortality is uncertain. The aim of the present 
study was to evaluate gender-specific difference in all-cause mortality between 
incomplete versus complete revascularization in patients with ST-elevation 
myocardial infarction (STEMI) and multivessel coronary artery disease (CAD). 
The study population consisted of 375 men and 115 women with a first 
STEMI and multivessel CAD without cardiogenic shock at admission or left 
main (LM) stenosis. The 30-day and 5-year all-cause mortality was examined 
in patients categorized according to gender and revascularization strategy 
(incomplete and complete revascularization). Within the first 30 days men 
and women with incomplete revascularization were associated with higher 
mortality rates compared to men with complete revascularization. However, 
the gender-strategy interaction variable was not independently associated with 
30-day mortality after STEMI when corrected for baseline characteristics 
and angiographic features. Within the survivors of the first 30 days, men with 
incomplete revascularization (compared with men with complete revasculari-
zation) were independently associated with all-cause mortality during 5 years 
follow-up (HR 3.07 [95%CI 1.24;7.61], P=0.016). In contrast, women with 
incomplete revascularization were not independently associated with 5-year 
all-cause mortality (HR 0.60 [95%CI 0.14;2.51], P=0.48). In conclusion, 
no gender-strategy differences occurred in all-cause mortality within 30 days 
post-STEMI. However, in the survivors of the first 30 days, incomplete revas-
cularization in men was independently associated with all-cause mortality 
during 5-years follow-up, but this was not the case in women.
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Introduction
The long-term mortality risk in patients after ST-elevation myocardial 
infarction (STEMI) is between 5 and 15%.1 Women tend to have a higher 
mortality rate compared to men post-STEMI.2-4 It has been suggested that 
part of this difference can be explained by higher age and multi-morbidity in 
women presenting with STEMI.2 Furthermore, gender-related disparities in 
revascularization strategy (complete versus incomplete revascularization) may 
contribute to differences in mortality rate.5-7 Hence, evaluation of the inter-
action between gender and revascularization strategy in STEMI patients on 
all-cause mortality, independent of known confounders, is of interest, espe-
cially since the best revascularization strategy (complete versus incomplete 
revascularization) in STEMI patients is still debated.8, 9 Current guidelines 
of the European Society of Cardiology recommend to consider immediate 
revascularization of significant non-culprit lesions during the same procedure 
in selected patients.10 Therefore, the aim of the present study was to investigate 
gender-related differences between incomplete and complete revascularization 
on all-cause mortality in a large cohort of patients presenting with a first acute 
STEMI and multivessel coronary artery disease (CAD) without cardiogenic 
shock at admission or left main (LM) stenosis.
 
Methods
The study population consisted of 490 patients with a diagnosis of acute first 
STEMI and multivessel CAD on emergency coronary angiography (CAG) 
between 2004 and 2008. The diagnosis of first acute STEMI was defined as 
typical chest pain complaints <12 hours, elevated cardiac enzyme levels and 
significant ST-segment elevation or left bundle branch block on the electro-
cardiogram. Exclusion criteria were: (1) history of CAD, (2) cardiogenic 
shock at admission (defined as a Killip class of 4) and (3) LM stenosis. The 
study population consisted mostly of patients included in a previous study 
focusing on the all-cause mortality during short- and long-term follow-up.11 
The current evaluation will focus on differences between men and women in 
all-cause mortality during 30-days and 5-years follow-up, excluding patients 
with a cardiogenic shock at admission or LM stenosis. All patients were 
treated according to the MISSION! protocol as described earlier,12 which 
was based on the most recent American College of Cardiology/American 
Heart Association and European Society of Cardiology guidelines for patients 
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with AMI at that moment. The interventional cardiologist decided whether 
immediate or staged revascularization of the non-culprit vessel(s) occurred 
before discharge. 
 The endpoint was all-cause mortality. Mortality data were gained from 
the municipal civil registry or hospital files review. Demographic, clinical and 
angiographic data were prospectively entered in the departmental Cardiology 
Information System (EPD-Vision©, Leiden University Medical Center, 
the Netherlands) and analyzed retrospectively. According to the Dutch 
law, approval from The Medical Ethical Committee is not required for this 
retrospective analysis of clinically collected data. Likewise, no formal patient 
consent is required for this type of study. 
The protocol of the angiographic projections and analysis have been described 
in detail.11 In brief, the following information was reported during image analy-
sis: culprit vessel, (in)complete revascularization, coronary vessel dominance, 
severity of CAD and the results of the primary and/or staged PCI prior to 
discharge. Infarct-related artery was determined by the evaluation of acute 
electrocardiographic changes on the electrocardiogram at admission. The 
definition of complete revascularization was PCI of any significant coronary 
artery stenosis (≥70% luminal narrowing) of any vessel during the primary or 
staged PCI prior to discharge.
Normally distributed variables are presented as mean ± standard deviation and 
non-normally distributed variables as median and 25-75 interquartile range 
(IQR). Categorical variables are expressed as frequencies and percentages 
(%). Differences in baseline characteristics between men and women were 
evaluated using the independent samples t-test, the Mann-Whitney U test, or 
the Chi-Square test, when appropriate. Survival analyses were performed using 
Kaplan-Meier analysis. For men and women the cumulative event rates for the 
endpoint all-cause mortality were compared between patients with complete 
revascularization and incomplete revascularization, using the Log-Rank test. 
 A 4-modality variable was used to test the effect of the gender-strategy 
interaction on 30-day and 5-year mortality: men with complete revasculariza-
tion, men with incomplete revascularization, women with complete revascular-
ization, and women with incomplete revascularization. Odds ratios (OR) for 
30-day mortality and hazard ratios (HR) for 5-year mortality were calculated 
in reference to the group of men with complete revascularization.
 The influence of differences in baseline characteristics on 30-day mortality 
post-STEMI was assessed by performing univariate and multivariate logistic 
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regression analysis. To avoid over-fitting of the model, only five variables were 
entered in the multivariate model: age, Killip class ≥ 2, left ventricular (LV) 
ejection fraction ≤ 40%, renal dysfunction (eGFR ≤ 60 mL/min/1.73m2) and 
the 4-modality variable. The results of the univariate and multivariate analysis 
were reported as adjusted OR with 95% confidence interval (CI). The associ-
ates of all-cause mortality during 5-years follow-up were investigated using uni-
variate and multivariate Cox regression analysis for those patients who survived 
the first 30 days. Only variables with P-values <0.10 at univariate analysis were 
included in the multivariate model: age, three-vessel CAD, LV ejection fraction 
≤40%, a history of diabetes mellitus or hypertension and the 4-modality 
variable. The results of the univariate and multivariate Cox regression analysis 
were reported as HR with 95% CI. Statistical analysis was performed using 
SPSS software (Version 22.0, SPSS IBM Corp., Armonk, New York, USA). A 
two-sided P-value of <0.05 was considered statistically significant.
Results
The clinical baseline characteristics of the 490 patients with an acute first 
STEMI and multivessel CAD on CAG stratified according to gender (men 
[n=375] versus women [n=115]) are shown in Table 1. Women were older (69 
±12 vs. 61 ±12, P<0.001), had more often diabetes mellitus (DM), higher 
prevalence of hypertension and presented more often with Killip class ≥2, 
as compared to men. In addition, kidney function was worse in women. The 
medication at discharge between both groups were comparable. No difference 
existed in percentage of incomplete revascularization during admission, 53% 
in men versus 61% in women (P=0.16).
In the first 30 days post-STEMI, 21 patients (4%) died (18 during index hos-
pitalization). There was no difference between men and women in all-cause 
mortality rate within 30 days, 8/115 (7%) versus 13/375 (3.5%; P=0.11). The 
variables associated with the endpoint 30-day mortality are shown in Table 2. 
In the multivariate analysis, age and Killip class ≥ 2 were independently asso-
ciated with 30-day mortality post-STEMI. The gender-strategy interaction vari-
able demonstrated no independent associate with 30-day all-cause mortality 
post-STEMI with as reference category men with complete revascularization.
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Age (years) 61±12 69±12 <0.001
Obesity (body mass index ≥ 30kg/m2) 14% 20% 0.20
Diabetes mellitus 10% 18% 0.04
Hypercholesterolemia* 15% 23% 0.06
Hypertension† 32% 53% <0.001
Current smoker 47% 38% 0.09
Family history of cardiovascular disease 38% 42% 0.42
Presenting with Killip class ≥ 2 3.5% 8% 0.04
Culprit coronary artery
right 44% 38% 0.30
Left anterior descending 40% 49% 0.08
Left circumflex 17% 13% 0.37
Three-vessel coronary artery disease 31% 33% 0.63
Estimated glomerular filtration rate ≤ 60 
mL/min/1.73m²
7% 26% <0.001
Peak cardiac troponin T level ≥3.5 μg/L 58% 58% 0.97
Left ventricle ejection fraction ≤40% 28% 30% 0.70
Blood pressure at discharge
Systolic (mmHg) 115±17 119±19 0.07
Diastolic (mmHg) 70±11 69±12 0.19
Medication at discharge
Beta-blocker 93% 95% 0.36
Antiplatelet agent 100% 100% -
Angiotensin converting enzyme  
inhibitor / angiotensin receptor blockers
97% 96% 0.60
Statin 99% 96% 0.06
Incomplete revascularization‡ 53% 61% 0.16
Bold means significant P-values at <0.05 level.
* Serum total cholesterol ≥230 mg/dl and/or serum triglycerides ≥200 mg/dl or treatment with lipid 
lowering drugs. 
† Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or 
the use of antihypertensive medication. 
‡  Complete revascularization was defined as treating all present significant coronary artery stenosis ≥ 
70% during primary PCI or before discharge.
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Table 2. Influence of baseline variables on 30-day mortality post-STEMI.
Variable Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
Men 0.48 0.19-1.19 0.11






Men/incomplete 11.11 1.43-86.31 0.02 4.08 0.44-37.87 0.22
Women/complete 8.093 0.72-91.34 0.09 2.72 0.20-37.38 0.46
Women/incomplete 16.31 1.93-138.14 0.01 3.27 0.28-38.87 0.35
Age (years) 1.12 1.07-1.17 <0.001 1.11 1.03-1.19 0.009
Diabetes mellitus 0.37 0.05-2.84 0.34
Hypercholesterolemia* 0.53 0.12-2.34 0.40
Hypertension† 0.73 0.27-1.93 0.52
Current smoker 0.52 0.20-1.38 0.19
Family history of  
cardiovascular disease
0.078 0.01-0.59 0.01 0.27 0.03-2.38 0.24
Presenting with Killip class ≥ 2 34.17 12.19-95.76 <0.001 10.72 2.36-48.68 0.002
Culprit coronary artery
right 0.53 0.20-1.39 0.20
Left anterior descending 1.29 0.54-3.09 0.57
Left circumflex 1.28 0.42-3.90 0.67
Three-vessel coronary artery 
disease
2.07 0.86-4.99 0.10 0.70 0.18-2.73 0.60
Estimated glomerular filtration 
rate ≤ 60 mL/min/1.73m2
4.94 1.72-14.18 0.003 0.85 0.17-4.17 0.84
Peak cardiac troponin T level 
≥3.5 μg/L
3.81 1.09-13.33 0.04 1.95 0.44-8.52 0.38
Left ventricle ejection fraction 
≤40%
5.40 1.81-16.12 0.003 3.23 0.89-11.74 0.07
 
Bold means significant P-values at <0.05 level.
CI: confidence interval; OR: odds ratio. 
Definitions: see Table 1. 
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The 5-year follow-up was complete in all patients. In total 57 patients died, 
of which 43 (75%) were men. No significant difference occurred between 
5-year mortality rates between women 14/115 (12%) and men 43/375 (11%; 
P =0.84). After excluding the first 30 days post-STEMI, the 5-year mortality 
rate in women was 6/107 (6%) and in men 30/362 (8%; P=0.36).
 Table 3 summarizes the cumulative mortality rates at 1, 2 and 5 year 
follow-up in women and men stratified according to incomplete versus com-
plete revascularization. There was no significant difference in the cumulative 
mortality rates between incomplete and complete revascularization in women 
at 1-, 2- and 5-year follow-up (9%, 10% and 13% versus 7%, 7%, 11%). 
However, the cumulative mortality rates at 1-, 2- and 5-year were significantly 
higher in the group of men with incomplete versus men with complete revas-
cularization (8% versus 2% [P=0.017], 10% versus 3% [P=0.009] and 18% 
versus 4% [P<0.001], respectively). 
 Figure 1 displays the Kaplan-Meier curves of 5-year follow-up in men (a, c) 
versus women (b, d) stratified according to incomplete versus complete revas-
cularization. In men, the group with incomplete revascularization had worse 
long-term survival compared with the group of men with complete revascular-
ization (Log Rank 17.95, P<0.001). This difference remained after excluding 
the first 30 days post-STEMI (Log Rank 10.14, P=0.01). In women, there was 
no significant difference in 5-year survival between both groups (Log Rank 
0.10, P=0.75), even after excluding the first 30 days (Log Rank 0.26, P=0.61).
Table 3. Mortality rates during 1-, 2- and 5-year follow-up of women and men 
with complete versus incomplete revascularization.





Hazard ratio (95% CI) P-value
Women
one-year 3/45 (7%) 6/70 (9%) 1.33 (0.33-5.33) 0.68
Two-years 3/45 (7%) 7/70 (10%) 1.55 (0.40-6.01) 0.52
Five-years 5/45 (11%) 9/70 (13%) 1.20 (0.40-3.57) 0.75
Men
one-year 3/175 (2%) 15/200 (8%) 4.53 (1.31-15.66) 0.017
Two-years 5/175 (3%) 20/200 (10%) 3.66 (1.37-9.76) 0.009
Five-years 7/175 (4%) 36/200 (18%) 4.86 (2.16-10.91) <0.001
Bold means significant P values at <0.05 level.
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Figure 1. Five-year survival in men and women stratified according to complete 
versus incomplete revascularization. 
A. There was no difference in survival between complete and incomplete revascularization in women 
(P[Log Rank]=0.75). B. After excluding the first 30 days post-STEMI the outcome remained similar 
in women with incomplete revascularization compared with complete revascularization (P[Log Rank] 
=0.61). C. Men with incomplete revascularization in comparison with men with complete revascularization 
had a statistically higher cumulative incidence of all-cause mortality during 5-year follow-up after STEMI 
(P [Log Rank] < 0.001). D. After excluding the first 30 days post-STEMI, the outcome remained worse 
in men with incomplete revascularization compared with complete revascularization (P[Log Rank]=0.01).
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Table 4. Cox regression analysis for the survivors of the first 30 days post-
STEMI(N=469) for all-cause mortality during 5 years follow-up.
Univariate Multivariate
HR 95% CI P-Value HR 95% CI P-value
Men 1.50 0.63-3.61 0.36






Men/incomplete 3.86 1.58-9.44 0.003 3.07 1.24-7.61 0.016
Women/complete 2.05 0.51-8.21 0.31 0.77 0.15-3.91 0.75
Women/incomplete 1.36 0.34-5.44 0.66 0.60 0.14-2.51 0.48
Age (years) 1.05 1.02-1.08 0.001 1.06 1.02-1.09 0.001
Three-vessel coronary  
artery disease
2.41 1.26-4.64 0.008 1.39 0.69-2.81 0.35
Left ventricle ejection  
fraction ≤40%
2.21 1.12-4.35 0.02 2.32 1.16-4.61 0.017
Diabetes mellitus 2.43 1.14-5.17 0.02 1.91 0.86-4.21 0.11
Hypercholesterolemia* 0.43 0.13-1.40 0.16
Hypertension† 1.95 1.01-3.75 0.046 1.76 0.88-3.54 0.11
Current smoker 0.76 0.39-1.49 0.43
Family history of cardiovascular 
disease
0.64 0.31-1.30 0.21
Presenting with Killip class ≥ 2 2.49 0.60-10.38 0.21
Culprit coronary artery
right 0.73 0.37-1.45 0.37
Left anterior descending 1.63 0.85-3.14 0.14
Left circumflex 0.66 0.24-1.88 0.44  
Estimated glomerular filtration 
rate ≤ 60 mL/min/1.73m2
1.78 0.74-4.30 0.20




Beta-blocker 1.07 0.26-4.44 0.93
Angiotensin converting 
enzyme inhibitor / angio-
tensin receptor blockers
0.50 0.12-2.09 0.34
Statin 0.47 0.06-3.43 0.46
Bold means significant P-values at <0.05 level.
CI: confidence interval; HR: hazard ratio.
For definitions: see Table 1.
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The variables of the survivors of the first 30-days post-STEMI associated 
with all-cause mortality within 5 year follow-up are shown in Table 4. After 
correction for significant univariate associates, men with incomplete revascu-
larization remained independently associated with 5-year all-cause mortality 
(HR 3.07 [95%CI 1.24;7.61], P=0.016). In contrast, women with incomplete 
revascularization were not independently associated with 5-year all-cause 
mortality (HR 0.60 [95%CI 0.14;2.51], P=0.48). In addition, age and LV 
ejection fraction below 40% were independently associated with all-cause 
mortality during 5-year follow-up.
Discussion
The present study assessed gender-related differences on all-cause mortality 
between incomplete and complete revascularization in first STEMI patients 
with multivessel CAD during short- and long-term follow-up. Within the 
first 30-days post-STEMI, no differences in all-cause mortality rate between 
incomplete and complete revascularization occurred among men and women. 
However, during 5 years of follow-up, men with incomplete revascularization 
who survived the first 30 days were at 3.1-fold higher mortality risk compared 
with men with complete revascularization (after adjusting for confounders). 
In contrast, women stratified to incomplete and complete revascularization 
who survived the first 30 days had both similar mortality risk as men with 
complete revascularization. 
 
In STEMI patients there are disparities in clinical presentation and comor-
bidity between men and women.2 In the present study, women compared 
with men were older, presented with more comorbidity (higher percentage of 
DM and hypertension) and more frequently presented with Killip class ≥2. 
In addition, the kidney function was more often impaired in women. These 
findings are in line with large registries evaluating the clinical characteristics 
at presentation.2-4 The National Registry of Myocardial Infarction (NRMI) 
demonstrated that women were significantly older than men at the time of the 
first myocardial infarction: 73.9 versus 66.5 years, respectively (P<0.001).2 In 
addition, in this registry the proportion of patients presenting without chest 
pain / discomfort was significantly higher for women than men, which leads to 
longer ischemic time and worse outcomes.
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However, in the above mentioned registries the interaction of revasculariza-
tion strategy and gender on all-cause mortality was not taken into account. 
This is of importance since the best revascularization strategy (incomplete 
or complete revascularization) is still debated in STEMI patients with multi- 
 vessel CAD, as results of several studies are inconsistent.8, 9, 13-16 Furthermore, 
differences in revascularization benefit may exist between women and men. 
Ghauharali-Imami et al. analyzed gender differences in mortality in a prospec-
tive consecutive cohort of STEMI patients with multivessel CAD, with 
respect to complete versus incomplete revascularization with an intermediate 
follow up of 3.3 ±1.2 years.17 The results demonstrated that women under-
went less frequently complete revascularization compared with men, being 
30% vs 38%, respectively (P=0.04). However, the mortality rate in women 
was not significantly different between both revascularization strategies 
(complete and incomplete revascularization) during in-hospital, 1-year and 
intermediate follow-up. In contrast, men with complete revascularization 
had lower mortality rates than men with incomplete revascularization during 
in-hospital and 1-year follow-up (0% versus 3%; P<0.001 and 1% versus 5%; 
P=0.02). Conversely, no difference was observed for intermediate follow-up 
between men with complete revascularization and men with incomplete 
revascularization (6% versus 8%; P=0.30).
 The present study demonstrated no differences in all-cause mortality 
within 30-days post-STEMI between both revascularization strategies among 
women and men. However, when analysing the survivors of the first 30 days, 
men with incomplete revascularization showed a higher mortality rate during 
5-year follow-up compared with men with complete revascularization (18% 
versus 4%, P<0.001). In women, in both strategy groups (incomplete and 
complete revascularization) no significant difference were found in mortality 
rate during 5-year follow-up. Yet, the long-term benefit of complete revascu-
larization compared with incomplete revascularization in men was not noted 
in the previous mentioned study by Ghauharali-Imami et al.17 However, the 
current study differed in duration and completeness of follow-up. Addition-
ally, in the present study, the first 30 days were excluded from the long-term 
follow-up analysis. This is relevant since the mortality rate in the first 30 days 
is high and long-term results will be largely influenced by the outcome of the 
first 30 days.
 It is hypothesized that men have more benefit from complete revascular-
ization compared with women, since women tend to have fewer non-culprit 
lesions, with more often focal lesions with smaller minimal lumen area. In the 
present study stenosis characteristics were not taken into account. However, 
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the PROSPECT (Providing Regional Observations to Study Predictors of 
Events in the Coronary Tree) study validates that despites the fact that women 
have more comorbid risk factors than men, women have less extensive coronary 
artery disease both by angiographic and intravascular ultrasound (IVUS) 
measures.18 The lesions in women compared with men have less plaque 
rupture, similar plaque burden and smaller lumens. In addition, in comparison 
with men, angiographic lesions of similar severity by angiography are less likely 
to be ischemia-producing in women.19 Moreover, Kim et al. demonstrated in 
2-year data from the FAME (Fractional Flow Reserve versus Angiography for 
Multivessel Evaluation) study that the proportion of functionally significant 
lesions (FFR ≤ 0.80) was lower in women than in men for lesions with 70% to 
90% stenosis (71.9% vs. 82.0%, P = 0.019).19
The present study has some limitations that need to be addressed. First, this is 
a retrospective observational study with all its inherits. Furthermore, stenosis 
and stent-characteristics were not taken into account. In addition, to avoid 
misclassification of the cause of death, the present study investigated only 
all-cause mortality. 
Conclusion
The first 30-days post-STEMI, gender-strategy interaction variable was not 
independently associated with all-cause mortality. However, in the survivors 
of the first 30 days, incomplete revascularization in men with a first STEMI 
and multivessel CAD, in contrast to women, was independently associated 
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Two-dimensional echocardiographic left ventricular (LV) global longitudinal 
strain (GLS) after ST-segment elevation myocardial infarction (STEMI) is 
moderately correlated with infarct size and reflects the residual LV systolic 
function. This correlation may be influenced by the presence of myocardial 
ischemia. The present study investigated how myocardial ischemia modulates 
the correlation between LV GLS and infarct size determined with single-photon 
emission computed tomography (SPECT) myocardial perfusion imaging 
(MPI) in patients with first STEMI treated with primary coronary interven-
tion. A total of 1,128 patients (age 60±11 years) who underwent SPECT 
MPI for the evaluation of infarct size and residual ischemia were evaluated. 
LV GLS was measured on transthoracic echocardiography. The time interval 
between echocardiography and SPECT MPI was 1±1 month. A moderate 
correlation between echocardiographic LV GLS and infarct size on SPECT 
MPI was observed (r=0.58, P<0.001). This correlation was weakened by the 
presence or extent of ischemia; in the group of patients without ischemia, the 
correlation between LV GLS and infarct size on SPECT MPI was r=0.66 
(P<0.001), whereas in patients with mild or moderate to severe ischemia, 
the correlations were r=0.56 and r=0.38, respectively (both P<0.001). 
Moderate to severe myocardial ischemia was independently associated with 
more impaired LV GLS after adjusting for infarct size, age, diabetes mellitus 
and hypertension (ß 0.60, 95%CI 013-1.06). In conclusion, the presence of 
myocardial ischemia after STEMI impacts on the correlation between echo-
cardiographic LV GLS and infarct size measured on SPECT MPI. Residual 
ischemia is independently associated with more impaired LV GLS.
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Introduction
Left ventricular ejection fraction (LVEF) is the most widely used parame-
ter for risk stratification of patients with ST-segment elevation myocardial 
infarction (STEMI).1 However, left ventricular global longitudinal strain (LV 
GLS) measured with speckle tracking echocardiography may better reflect 
the extent of myocardial infarction and the residual LV systolic function.2-4 A 
strong correlation between LV GLS and infarct size assessed with late gado-
linium contrastenhanced magnetic resonance imaging (LGE-MRI) or single- 
photon emission computed tomography (SPECT) myocardial perfusion 
imaging (MPI) has been shown.5-10 However, this correlation is not straight-
forward because regional LV dysfunction may extend beyond the region of 
scar resulting in more impaired LV GLS. Factors that may negatively impact 
on LV GLS include burden of coronary artery disease, diabetes mellitus, age, 
hypertension and associated valvular heart disease among others.7, 11-14 
 In addition, the presence of myocardial ischemia may further impair LV 
GLS and weaken the correlation between LV GLS and infarct size. The present 
study evaluated the influence of myocardial ischemia on the correlation 
between LV GLS and infarct size in patients with STEMI who were clinically 
referred to SPECT MPI. Moreover, the independent association between 
myocardial ischemia and LV GLS was investigated.
 
Methods
A total of 1,224 patients with a previous first STEMI treated with primary 
coronary intervention at the Leiden University Medical Centre (The Nether-
lands) between 2004 and 2010 who were clinically referred for SPECT MPI 
were included (to evaluate infarct size and residual ischemia).15 The echocar-
diographic study closest to the date of SPECT MPI was selected to assess  
LV GLS. 
 Demographic, clinical, nuclear imaging, and echocardiographic data were 
prospectively entered in the departmental Cardiology Information System 
(EPD-Vision©, Leiden University Medical Center, the Netherlands) and 
retrospectively analyzed. The Institutional Review Board of the Leiden Uni-
versity Medical Center approved the study and waived the need for written 
informed consent for retrospective analysis of clinically acquired data.
 Echocardiographic images were obtained with the patient lying in the left 
lateral decubitus position. The data were acquired with commercially available 
chapter 6
102
ultrasound systems (Vivid 7 and E9; General Electric-Vingmed, Horten, Nor-
way) with 3.5-MHz or M5S transducers. Two-dimensional, color, continuous, 
and pulsed wave Doppler data were acquired from the parasternal (long- and 
short-axis) and apical (2-, 3-, and 4-chamber) views. Data were digitally 
stored for subsequent offline analysis with EchoPac 112.0.1 (GE Medical 
Systems, Horten, Norway). LVEF was calculated from the LV end-diastolic 
and end-systolic volumes measured from the apical 4- and 2-chamber views 
using the biplane Simpson method.1 In addition, LV diastolic dysfunction was 
assessed measuring the peak velocity of early (E) and late (A) peak diastolic 
velocities from the pulsed wave Doppler transmitral flow recordings and the 
deceleration time (DT) of the early filling wave. In addition, tissue Doppler 
imaging data were acquired to measure the mitral annulus E’ diastolic tissue 
velocity, and the E/E’ ratio was calculated as a measure of LV filling pressures. 
An experienced observer measured LV GLS from the apical 4-chamber, 
2-chamber, and long-axis views using 2-dimensional speckle-tracking analysis 
and blinded to the information from SPECT MPI.4 The software calculated 
the LV GLS as the average of the peak systolic longitudinal strain of the 3 
apical views and displayed in a 17-segment “bull’s eye” plot. 
 SPECT MPI was performed using a 2-day stress–rest protocol starting on 
day 1 with a stress acquisition. The patients underwent a symptom-limited 
bicycle test with continuously blood pressure and 12-lead electrocardio-
graphic recording or, when unable to exercise, a dobutamine stress test (5 
to 40 µg/kg/min for 15 minutes with handgrip-exercise starting at 6 minutes 
supplemented with atropine when necessary) or an adenosine stress test 
(140 µg/kg/min for 6 minutes with additional bicycle riding on individual 
level) according to current recommendations.16-18 At peak exercise, after 3.5 
minutes of the adenosine infusion or at peak heart rate during dobutamine, 
500 MBq of technetium-99m tetrofosmin was administrated intravenously. 
After 30 minutes, stress images were obtained with the patient lying on a 
supine position. On the second day, resting images were obtained 45 minutes 
after intravenously administration of 500 MBq technetium-99m tetrofosmin. 
The images were acquired with a triple-head SPECT camera (GCA 9300/
HG; Toshiba Corporation, Tokyo, Japan) or a double-head SPECT camera 
(7200pi; Toshiba Corporation, Tokyo, Japan). All cameras were equipped with 
low-energy, high-resolution collimators. A 20% window was used with a 140-
keV energy peak of technetium-99m, and data were stored in a 64x64 matrix. 
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Images were processed to obtain the short-axis, vertical long-axis and hori-
zontal long-axis tomographic sections, and polar map formats, normalized 
to maximal activity.16 The SPECT MPI data were scored semiquantitatively 
according to the 17-segment model.19 Each segment was scored on a 5-point 
scale: 0: normal, 1: slight reduction of tracer uptake (not definitely abnormal), 
2: moderate reduction of uptake (definitely abnormal), 3: severe reduction 
Table 1. Clinical characteristics
Variable Overall population
N=1128
Age (years)   60±11
Men   858 (76%)
BMI>30kg/m²   186 (17%)
Hypercholesterolemia†   203 (18%)
Hypertension‡   381 (34%)
Current smoker   556 (49%)
Family history of CAD   499 (44%)
Diabetes mellitus     97 (9%)
LAD culprit vessel   516 (46%)
Multivessel CAD   591 (52%)
TIMI flow 2-3 1112 (99%)
Peak CPK level (U/L) 1531 (IQr 751-3,129)
Peak cTnT level (µg/L)  4.05 (IQr 1.6-7.9)
eGFR level (mL/min/1.73m2)     97 (IQr 77;118)
Medications at discharge
ACE-inhibitors/ARBs 1105 (98%)
Antiplatelet therapy 1128 (100%)
Beta-blockers 1073 (95%)
Statins 1122 (99.5%)
ACE-I: ACE-inhibitor; AT-II: angiotensine-II receptor antagonist; BMI: body mass index; CAD: 
coronary artery disease; eGFR: glomerular filtration rate estimated with the Cockroft-Gault formula; 
IQR: interquartile range; LAD: left anterior descending; LCx: left circumflex; LM: left main; RCA: right 
coronary artery; STEMI: ST-segment elevation myocardial infarction.
† Serum total cholesterol ≥230 mg/dl and/or serum triglycerides ≥200 mg/dl or therapeutic treatment 
with lipid lowering drugs. 
‡ Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or 
the use of antihypertensive medication. 
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Table 2. Echocardiographic parameters.
Echocardiography parameters Overall population
N=1128
Left ventricle end-systolic volume (mL)     58±28
Left ventricle end-diastolic volume (mL)   116±40
Left ventricle ejection fraction (%)     51±10
Left ventricle global longitudinal strain (%) -17.4±3.9
E/A ratio  1.03±0.48
Deceleration time (ms)   244±83
E/E’ ratio      13±7
Mitral regurgitation ≥ grade 2 
(moderate to severe)
 107 (9%)
Figure 1. Pearson’s correlation between infarct size and LV GLS in the  
overall population.
In the overall population there is a moderate correlation between infarct size on SPECT MPI and LV 
GLS (r=0.58, P<0.001).
LV GLS: left ventricular global longitudinal strain; SRS: summed rest score. 
Influence of IschemIa on left ventrIcular global longItudInal straIn
105
Patients with no ischemia (SDS 0, Figure 2a) demonstrated a better correlation between infarct size 
and LV GLS (r=0.66, P<0.001) in comparison with patients with mild (SDS 1-3, Figure 2b: r=0.58, 
P<0.001) and moderate to severe ischemia on SPECT MPI (SDS ≥ 4, Figure 2c; r=0.38, P<0.001).
LV GLS: left ventricular global longitudinal strain; SRS: summed rest score. 
Figure 2. Pearson’s correlation between infarct size and LV GLS in patients 
 without ischemia (SDS 0, Figure 2a), mild ischemia (SDS 1-3,  Figure 2b) and 
moderate to severe ischemia on SPECT MPI (SDS ≥ 4, Figure 2c).
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of uptake and 4: absence of uptake.20 The summed stress score (SSS) and 
summed rest score (SRS) were calculated by the summation of the segmental 
scores at stress and rest, respectively. The summed difference score (SDS), 
reflecting the stress-inducible ischemia size, was calculated by subtracting the 
SRS of the SSS. Afterward, the SSS and the SRS were divided into tertiles. 
The SDS was categorized in three groups: SDS 0 (no ischemia), SDS 1-3 
(mild-moderate ischemia) and SDS ≥4 (severe ischemia).
 Normally distributed variables are expressed as mean ± standard deviation 
and non-normally distributed variables as median and interquartile range 
(IQR). Categorical variables are presented as frequencies and percentages. 
The correlation between LV GLS and infarct size on SPECT MPI was eval-
uated with Pearson’s correlation. Afterward, the total population was divided 
into 3 groups according to the presence of no (SDS =0), mild (SDS 1-3) or 
moderate to severe ischemia (SDS ≥4). Subsequently, the correlation between 
LV GLS and infarct size was assessed in each subgroup using Pearson corre-
lation. The association between (mild or moderate to severe) ischemia and LV 
GLS was corrected for factors known to affect LV GLS (age, hypertension, 
diabetes mellitus and infarct size) using a multivariate linear regression analy-
sis. The beta-coefficients and the 95% confidence interval (CI) were reported. 
A 2-sided P-value of <0.05 was considered statistically significant. Statistical 
analysis was performed using SPSS software (Version 22.0, SPSS IBM Corp., 
Armonk, New York, USA).
Results
Measurement of LV GLS was not feasible in 96 patients (8%), whereas 
SPECT MPI examination was incomplete or uninterpretable in 19 patients 
(2%), leaving 1,128 patients who were considered in the analysis (Table 1). 
Most patients were men (76%), and the mean age was 60±11 years. Left 
anterior descending coronary artery myocardial infarction was present in 46% 
of patients, and 52% had multivessel coronary artery disease.
 Table 2 summarizes the echocardiographic parameters. Mean LVEF was 
51±10%, and mean LV GLS was -17.4±3.9%. Table 3 presents the SPECT 
MPI results. The time elapsed between index STEMI and echocardiography 
was 3±0.9 months, between index STEMI and SPECT MPI 3±1.6 months 
and between the echocardiography and the SPECT MPI 33±43 days. In most 
patients, the stress test consisted of a symptom-limited bicycle test (75%). 
Fifty-one patients (4.5%) experienced cardiac symptoms during the stress test. 
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Table 3. Single-photon Emission Computed Tomography Myocardial Perfusion 
Imaging parameters. 






Maximal exercise (Watt) 155±43
Validity (%) 106±19





Heart rate rest (/min) 79±15
Maximum heart rate during exercise (/min) 138±29
Systolic blood pressure rest (mmHg) 145±24
Systolic blood pressure exercise (mmHg) 186±35
Diastolic blood pressure rest (mmHg) 84±13
Diastolic blood pressure exercise (mmHg) 91±17
Infarct size / summed rest score
    median 11 (IQr 4;22)
    1e tertile SRS ≤ 6 404 (36%)
    2e tertile SrS 7-18 371 (33%)
    3e tertile SRS ≥ 19 353 (31%)
Ischemia size / summed difference score
    median 0 (IQr 0;4)
    no ischemia / SDS 0 611 (54%)
    mild ischemia / SDS 1-3 219 (12%)
    moderate to severe ischemia / SDS ≥ 4 298 (26%)
Infarct + Ischemia size / summed stress score
    median 14 (IQr 7;24)
    1e tertile SSS ≤ 9 405 (36%)
    2e tertile SSS 10-20 354 (31%)
    3e tertile SSS ≥ 21 369 (33%)
 
 
IQR: interquartile range; LVEF: left ventricle ejection fraction; SDS: summed difference score; SRS: 
summed rest score; SSS: summed stress score.
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Based on electrocardiography, 154 patients (14%) were considered as having 
inducible ischemia. In addition, 46% of patients showed ischemia (SDS >0), of 
which 298 (26%) had moderate to severe ischemia (SDS ≥4). 
 In the overall population, there was a moderate correlation between 
LV GLS and infarct size (r=0.58, 95% CI 0.54;0.62, P<0.001) (Figure 1). 
After dichotomization of the patients according to the absence or presence 
of ischemia, the subgroup of patients without ischemia (r=0.66, 95% CI 
0.61;0.70, P<0.001; Figure 2a) showed stronger correlation between LV 
GLS and infarct size than in patients with mild ischemia (r=0.56, 95% CI 
0.45;0.66, P<0.001; Figure 2b) and patients with moderate to severe ischemia 
(r=0.38, 95% CI 0.27;0.47, P<0.001; Figure 2c). After correcting for age, 
diabetes mellitus, infarct size, and hypertension, moderate to severe ischemia 
was independently associated with worse (less negative) LV GLS after STEMI 
(Figure 3). Figure 4 illustrates the difference in LV GLS between 2 patients 
with similar infarct size, but 1 patient shows ischemia, whereas the other 
patient does not have ischemia.
Figure 3. Multivariate linear regression analysis
After correction for infarct size, diabetes mellitus, age and hypertension, moderate to severe ischemia 
(SDS ≥ 4) was independently associated with worse LV GLS (ß 0.60, 95%CI 0.13-1.06).
*Increasing values represents worsening of LV function (less negative LV GLS)
CI: confidence interval; LV GLS: left ventricular global longitudinal strain.
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Figure 4. Example of a difference between GLS measurements in two patients 
with similar infarct size, but different ischemia size.
In this example, both patients demonstrate on SPECT MPI similar infarct size (SRS=22). However, 
patient A has no ischemia on SPECT MPI with a LV GLS of -22 in contrast to patient B, which has 
severe ischemia (SDS=19) with a worse LV GLS of -15. HLA: horizontal-long axis, SA: short axis, 
vertical-long axis, LV GLS: left ventricular global  longitudinal strain.
Discussion
The present study demonstrated a modest correlation between LV GLS 
and infarct size determined on SPECT MPI in patients after STEMI. This 
correlation was influenced by ischemia extent: the group of patients without 
ischemia showed a stronger correlation between LV GLS and infarct size 
compared to patients with residual myocardial ischemia. The presence of 
myocardial ischemia was independently associated with more impaired LV 
GLS after adjusting for infarct size, age, diabetes mellitus, and hypertension.
Two-dimensional speckle tracking echocardiography has emerged as a quanti-
tative method to assess LV systolic function and has shown good correlations 
with infarct size using LGE-MRI and SPECT MPI as reference standard 
(Table 4).5-10 For example, Gjesdal et al. showed that LV GLS impaired in 
parallel with increasing infarct size assessed with LGE-MRI 8.5 months after 
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STEMI.6 The correlation between LV GLS and infarct size based on LGE-
MRI was 0.84 (p<0.001). The presence of ongoing edema may overestimate 
the infarct size and the presence of stunned myocardium may lead to more 
impaired LV GLS at early stages after STEMI, whereas at midterm follow-up, 
infarct size decreases and its correlation with LV GLS may change.21 The 
present study is the largest so far comparing LV GLS and infarct size based 
on SPECT MPI and provides further insight by evaluating the influence of 
resi dual ischemia on this correlation. The presence of residual myocardial 
ischemia or development of new coronary lesions that cause ischemia is an 
important question during follow-up of survivors after STEMI. In the present 
study the correlation between infarct size assessed with SPECT MPI and LV 
GLS was in line with previous studies (Table 4).5-10 Importantly, infarct size 
was assessed at 3 months after STEMI, and in addition, the presence of myo-
cardial ischemia was assessed, allowing to investigate whether this correlation 
may differ between patients with and without ischemia.
 In patients with an acute infarction, the follow-up may be complicated by the 
presence of stress-induced ischemia which is associated with a two- to fourfold 
increase in cardiac events compared to those without ischemia.22 In the present 
study, 46% of the population had ischemia on SPECT MPI of which 26% 
moderate to severe ischemia (SDS≥4). Repetitive episodes of ischemia might 
result in LV dysfunction (chronically stunned myocardium).23 Biering-Sørensen 
et al. demonstrated in 293 patients with clinically suspected coronary artery 
disease and preserved LVEF that patients with significant coronary artery 
disease (area stenosis ≥70% in ≥1 vessel on coronary angiography) had more 
impaired LV GLS compared with patients without significant coronary artery 
disease (-17.1±2.5% versus -18.8±2.6%, P<0.001).24 LV GLS remained an 
independent associate of coronary artery disease after multivariate adjustment 
for baseline characteristics, exercise test, and conventional echocardiography 
(OR 1.25; P=0.016 per 1% decrease). In post-STEMI patients, the assessment 
of myocardial ischemia may be challenged by the presence of preexistent wall 
motion abnormalities.25 LV segments with impaired longitudinal strain due to 
the presence of scar may influence the function of surrounding segments result-
ing in reduced function or hyperkinesia in the remote segments.26 Accordingly, 
the correlation between LV GLS and infarct size assessed with SPECT MPI 
may not be straight forward, particularly, if residual ischemia of the remote 
and peripheral areas of the myocardial infarction is present. Some limitations 
should be acknowledged. First, this was a single-center, retrospective, observa-
tional evaluation. Second, infarct size was assessed with SPECT MPI which 
has less spatial resolution than LGE-MRI.25
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Chapter 7
123I-MIBG SPECT for Evaluation of 
Patients with Heart Failure




Heart failure (HF) is characterized by activation of the sympathetic cardiac 
nerves. The condition of cardiac sympathetic nerves can be evaluated by
123I-metaiodobenzylguanidine (123I-MIBG) imaging. Most cardiac 123I-MIBG 
studies have relied on measurements from anterior planar images of the chest. 
However, it has become progressively more common to include single-photon 
emission computed tomography (SPECT) imaging in clinical and research 
protocols. This review examines recent trends in 123I-MIBG SPECT imaging 
and evidence that provides the basis for increased use of the procedure in clin-
ical management of patients with heart failure (HF). A particular area where 
123I-MIBG SPECT has been shown to be complementary to planar imaging 
in patients with HF in studies of coronary artery disease (CAD) after an acute 
myocardial infarction (MI). Moreover, 123I-MIBG SPECT has been used 
in numerous studies to document regional denervation for arrhythmic event 
risk assessment. For better quantification of the size and severity of innervation 
abnormalities in 123I-MIBG SPECT, programs and protocols specifically for 
123I have been developed. Also, the introduction of new solid-state cameras 
has created the potential for more rapid SPECT acquisitions or a reduction in 
radiopharmaceutical activity. Although positron-emission tomography (PET) 
imaging has superior quantitative capabilities, 123I-MIBG SPECT is, for the 
foreseeable future the only widely available nuclear imaging method for assess-
ing regional myocardial sympathetic innervation.
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Introduction
Heart failure (HF) is characterized by activation of the sympathetic cardiac 
nerves. The condition of cardiac sympathetic nerves can be evaluated with 
123I-metaiodobenzylguanidine (123I-MIBG), which is a norepinephrine analog 
and therefore a tracer for sympathetic neuron integrity and function.1 Most 
of the literature on the use of 123I-MIBG imaging for evaluating patients with 
HF is based on measurements from anterior planar images of the chest, with 
cardiac uptake quantified in terms of the heart-to-mediastinum ratio (HMR) 
and the washout rate (WR) between early and late images.2,3 However, given 
the conversion from planar to single-photon emission computed tomography 
(SPECT) techniques in clinical nuclear myocardial perfusion imaging (MPI) 
beginning in the 1980s, it is not surprising that 123I-MIBG SPECT was also 
performed by some early adopters of the radiopharmaceutical.4,5 Despite the 
challenges associated with performing 123I-MIBG SPECT and interpreting 
the images in patients with severely reduced cardiac 123I-MIBG uptake, it 
has become progressively more common for 123I-MIBG SPECT imaging to 
be included in clinical and research protocols; in such settings, it is usually 
performed as part of one or more of the imaging sessions when planar images 
are acquired.2
Both qualitative and quantitative image reviews of 123I-MIBG SPECT studies 
may be performed, to identify of focal areas of reduced uptake (similar to 
schemas used for the interpretation of MPI SPECT). Unfortunately, only 
small amounts of data from 123I-MIBG SPECT images in patients without 
heart disease are available; most often, segmental count density expressed as 
a percentage of total myocardial count density is used to compare affected 
areas with least affected areas in patients.6-8 Changes in relative uptake and 
absolute uptake between early and late SPECT images can be used to calcu-
late parameters comparable to the planar washout rate.9 In general, SPECT 
results have been used in the same way as planar data namely, to investigate 
the relationship between the quantitative value of 123I-MIBG uptake and a 
specific outcome event, such as worsening of chronic HF, the occurrence of 
an arrhythmic event or cardiac death, or another quantitative parameter, such 
as a change in the left ventricular ejection fraction or the MPI defect score. 
Consistent with findings on planar imaging, patients with larger or more 
severe regional 123I-MIBG SPECT defects usually have poorer outcomes.10
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This review examines recent trends in 123I-MIBG SPECT imaging and 
evidence that provides the basis for the increased use of the procedure in the 
clinical management of patients with HF. The focus of the article is primarily 
on work that has been done in the past 10-15 y, considering specifically how 
the technique can complement the established value of planar 123I-MIBG 
imaging and provide unique insight into the risk of arrhytmia and the need for 
advanced therapies. Recent advances in imaging technology and quantitation 
methods are also briefly reviewed, as these represent the future for the clinical 
use of cardiac 123I-MIBG SPECT.
123I-MIBG SPECT complements planar imaging
Several studies have examined the use of 123I-MIBG imaging as a diagnostic 
and prognostic tool in patients with HF.3,11 Although most of these studies 
relied primarily on planar imaging determinations of HMR and WR, some 
also included measurements from SPECT examinations because of the 
realization that SPECT may overcome the difficulties of planar imaging, 
including superposition of noncardiac structures and lack of segmental anal-
ysis (Figure 1). Many such 123I-MIBG SPECT studies were performed by 
Kasama et al., who investigated the effects of a variety of HF medications on 
123I-MIBG cardiac uptake and clinical outcome, usually performing imaging 
before the initiation of a new medication and again after 6 months.12-19 Early 
and late 123I-MIBG SPECT images (acquired at 15 min and at 4 hours) were 
scored visually using 20- and 17-segment regional polar or bull’s-eye maps. 
Additionally, segmental count data were used to calculate regional washout 
rates in some studies. The various randomized studies demonstrated statisti-
cally significant reductions in late 123I-MIBG total defect scores after treatment 
with angiotensin-converting enzyme inhibitor (perindopril), angiotensin 
receptor blockers (valsartan, candesartan), a loop diuretic (torasemide) and 
aldosterone inhibitors (spironolactone). Similar results were obtained by 
other investigators, such as Somsen et al.20 for enalapril, and Lotze et al.21 and 
de Milliano et al.22 for various beta blockers.
123I-MIBG SPECT has been shown to be complementary to planar imaging in 
studies of coronary artery disease (CAD) after an acute myocardial infarction 
(MI).23, 24 Viable but denervated myocardium has shown to be supersensitive 
to the effects of infused catecholamines,25 which may provide a substrate for 
the genesis of ventricular arrhythmias. For this reason, results of 123I-MIBG 
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SPECT and MPI SPECT are often compared to identifying segments with 
adrenergic/perfusion mismatch. As in MPI SPECT studies, the myocardium 
is usually subdivided into a number of segments (ranging from 5 to 20), and 
each location is scored for severity on scales from (0 to 3 or 0 to 4).
Three categories of 123I-MIBG SPECT and MPI SPECT findings are com-
monly reported: both normal; both equivalently abnormal (matched defects); 
or 123I-MIBG SPECT defect more severe than MPI defect (mismatched 
defect, as shown in Figure 2). A defect less severe on 123I-MIBG SPECT 
than on MPI SPECT is rarely, if ever, observed. Mismatched defects may be 
subcategorized in terms of whether the area in question demonstrates ischemia 
on stress MPI or remains unchanged.
Figure 1. 123I-MIBG SPECT complements planar imaging on segmental analysis. 
A 60 year old patient with planar and SPECT images in the short axis (SA), horizontal axis (HLA), 
vertical long axis (VLO) and bullseye of 123I-metaiodobenzylguanidine (MIBG). There is a reduced late 
heart/mediastinum ratio (HMR) of 1.45, whereby MIBG SPECT demonstrates a fixed apical defect.
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Most studies of 123I-MIBG imaging in the patients after MI have compared 
defects on 123I-MIBG SPECT with results on rest and stress MPI SPECT in 
order to assess the relationship between areas of infarction and denervation. 
Three small studies in which 58 patients were examined within 3 months 
after MI arrived at the joint conclusion that 123I-MIBG defects were generally 
larger than those on MPI, whether determined from quantitative count-based 
assessments or semi-quantitative scoring of SPECT myocardial segments.26-28 
Given that sympathetic nerve fibers in the heart travel in the subepicardium 
parallel to the vascular structures and penetrate the underlying myocar dium, 
it is conceivable that this difference in defect size, among others, is caused by 
the fact that neural tissue has a greater sensitivity to hypoxia than myocardial 
fibers and has longer recovery time.29,30 More recent studies, such as those by 
Simoes et al.,31 Marini et al.,32 and Hayashi et al.,33 confirmed the presence of 
denervated areas extending beyond the infarct borders and proposed associ-
ations with depolarization abnormalities, unappreciated myocardial necrosis, 
and long-term variability in induced ventricular tachyarrhythmias.
Interest has been shown in the potential for the global quantitation of 
123I-MIBG SPECT images to replace the planar HMR for diagnostic and 
prognostic purposes. An analysis of the 123I-MIBG SPECT studies from the
AdreView myocardial imaging for risk evaluation in heart failure (ADMIRE-
HF) trial, which is a prospective trial evaluating 123I-MIBG imaging for 
identi fying patients who have HF and are most likely to experience cardiac 
Figure 2. Innervation/perfusion mismatch between 123MIBG SPECT in comparison 
with rest myocardial perfusion imaging (MPI) with 99mTc-tetrofosmin. 
A 63 year old patient with ischemic cardiomyopathy with a large defect infero-postero-lateral expanding 
apical with on MIBG SPECT in comparison with rest MPI a more extended defect infero-lateral.
123I-MIBG SPECT In hEarT faIlurE PaTIEnTS
121
events, demonstrated that the SPECT HMR was equivalent to the planar 
HMR for discriminating between patients with HF and control subjects.6,34 
Additionally, the ability of 123I-MIBG SPECT to provide regional informa-
tion not available on planar images remains a driver for efforts to incorporate 
this procedure into assessments of patients with HF for arrhythmic risk.35
123I-MIBG SPECT for arrhythmic event 
risk assesment
Better arrhythmic event risk assessment is necessary given that in the MADIT 
II trial only 23.5% of the 720 patients with HF and a prophylactic implantable 
cardioverter defibrillator (ICD) received antiarrhythmia device therapy for 
ventricular tachyarrhythmia.36 Early research on experimentally denervated 
myocardium suggested that such regions were much more sensitive to norep-
inephrine infusion than normally innervated regions, a situation considered 
potentially proarrhythmic.37 Over the subsequent decades, 123I-MIBG SPECT 
was used in numerous studies to document such regional denervation and 
its association with naturally occurring or inducible ventricular arrhythmic 
events. The dominant observation was that the larger the extent of 123I-MIBG 
SPECT abnormality, the higher the likelihood of ventricular tachyarrhyth-
mia.38-41
Most investigators performing 123I-MIBG SPECT studies had expected to 
find that arrhythmic event risk would increase with the size of the denervated 
area as well as the amount of innervation-perfusion mismatch, as reflected by 
paired 123I-MIBG and MPI SPECT studies. Another expectation was that 
there would be a dividing point in 123I-MIBG defect size between patients with 
“low risk” and patients with “high-risk” for arrhythmic events. In the small 
study by Arora et al.,38 both mean 123I-MIBG defect scores and the number of 
late mismatches were higher in the 10 patients who had experienced appropri-
ate ICD discharges compared than in the 7 who had not. Patients who had 
ischemic heart disease and inducible ventricular tachycardia on electrophysi-
ology testing had higher total 123I-MIBG SPECT defect scores than patients 
who did not have inducible ventricular tachycardia, with a late total defect 
score threshold of 37, yielding a 77% sensitivity and a 75% specificity.39 In 
the prospective study by Boogers et al.,40 patients with an ICD and a late 
total defect score >26 were 10 times more likely to receive appropriate ICD 
therapy (cumulative 3-y event rate 52% vs. 5%, p<0.01). Interestingly, in the 
chapter 7
122
latter 2 studies, 123I-MIBG SPECT defect size was a significant predictor 
of arrhythmic events but not mismatch scores. In contrast, Marshall et al.42 
found differences in both the total 123I-MIBG SPECT defect score (37.0 ± 
9.4 versus 25.5 ± 7.7 (p=0.001)) and the mismatch score (18.5 ± 8.5 versus 
8.4 ± 5.0 (p<0.01)) between patients with ICD firing and those without ICD 
firing. As in the study of Bax et al., a total 123I-MIBG SPECT defect score 
≥31 had a sensitivity of 78% and a specificity of 77%.
Recent evidence suggests that quantitative characterization of myocardial 
transition zones (between normal and infarcted or denervated myocardium) 
may supplement the more simple definition of innervation-perfusion mis-
match. In a quantitative reanalysis of the MPI SPECT images that were 
interpreted visually in the study of Bax et al., 39 MPI scar extent, border 
zone extent, and 123I-MIBG uptake in the border zone were analyzed; the 
best prediction accuracy for ventricular tachycardia (VT) inducibility was 
achieved with the last (area under the ROC = 0.78).43 In a prospective study 
of 15 patients referred for ischemic VT ablation, 3D innervation models were 
derived from 123I-MIBG SPECT examinations and registered to high-density 
voltage maps.44 123I-MIBG innervation defects were ~2.5-fold larger than 
bipolar voltage-defined scars, all VT ablation sites were within areas of 
abnormal innervation, but 36% of successful ablation sites demonstrated 
normal voltages (>1.5mV). These studies strongly suggested that innovations 
in quantitative analysis techniques represent the future of 123I-MIBG SPECT 
for identifying arrhythmic event risk and guiding therapy.
Studies have also raised questions about the relationship between 123MIBG 
defect severity and arrhythmic event risk. Planar HMR data showed that the 
highest occurrence of arrhythmic events was seen in patients with HF and an 
intermediate reduction in uptake rather than the lowest values. In 2014, Ver-
berne et al. presented the results of an informed interpretation of 123I-MIBG 
and MPI SPECT studies from the ADMIRE-HF trial; the results showed that 
patients with HF and an intermediate severity of total defect scores (14-28 
of a possible maximum of 68) had higher arrhythmic event rates than those 
with more severe defects.45 As part of the same study, visual scoring of regions 
(anterior, inferior, septal, lateral, and apical) on 123I-MIBG SPECT and 
MPI SPECT studies as normal, matched, or mismatched resulted in similar 
findings; patients with HF and 1 or 2 mismatched regions had the highest 
arrhythmic event rate.46 In both of those analyses, the largest absolute number 
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of arrhythmic events was seen in patients with the most severe defects, but the 
highest proportion was seen in patients with intermediate-severity defects. 
The aforementioned results attest to the mechanistic complexity of arrhyth-
mia generation and support the conclusion that no single test can identify 
all at-risk patients with HF. Nevertheless, there is growing evidence that 
123I-MIBG SPECT imaging should be considered for the assessment of 
patients with HF for appropriate therapeutic interventions.
Advances in 123MIBG SPECT quantitation
123I-MIBG is internalized by neuroendocrine cells through the rapid energy- 
dependent uptake-1 mechanism,47 reaching a relative plateau within a few 
minutes after injection. It is stored, unmetabolized, in the neurosecretory 
granules, resulting in a specific concentration unlike in cells of other tissues. 
Because of flow-limited uptake of the 123I-MIBG tracer, retention measures 
are insensitive to low-to-moderate levels of regional denervation and decline 
only when nerve losses become fairly severe.48
Since the earliest investigations of 123I-MIBG SPECT in cardiology, quantita-
tion of the size and the severity of innervation abnormalities has been per-
formed.49 Initially, semiquantitative scoring from visual analysis, analogous 
to that used in MPI, was performed, as noted earlier for studies of patients 
after MI.27,28 When quantitative bull’s-eye mapping for MPI SPECT became 
readily available, it was also applied to 123I-MIBG SPECT analysis. 23,50-52 
However, because the quantitative programs were usually adapted from 
those developed for MPI SPECT, they did not take into account the unique 
physical properties of MIBG iodinated with 123I, which affects image quality. 
These include the presence of a significant number of high-energy photons 
(1.1% yield of 529 keV g rays);53 accumulation in the liver that overlaps the 
inferior wall (Figure 3); and scattering from the lung field to the lateral left 
ventricular wall,54 as a result of which the normal cardiac 123I-MIBG dis-
tribution includes relatively low uptake in the inferior wall,55 which is more 
pronounced in the elderly. Therefore, in contrast to what is observed in PET 
examinations with 11C-hydroxyephedrine and 18F-fluoro-dopamine, the 
regional 123I-MIBG uptake in the left ventricle is heterogeneous, in healthy 
subjects, as observed by Morozumi et al. and Yoshinaga et al.56,57 
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More recently, programs and protocols have been developed specifically for 
123I-labeled compounds such as 123I-MIBG. These have included the intro-
duction of iterative reconstruction techniques with compensation for scatter 
and septal penetration53,58,59 and use of volumetric analysis techniques.60 The 
development of 123I-MIBG databases of healthy subjects has also provided a 
more reliable means for quantifying the significance of reduced uptake in HF 
and other cardiology patients.6
The potential of improved 123I-MIBG quantitation techniques has been 
explored in recent reevaluations of the large 123I-MIBG SPECT imaging 
database from the ADMIRE-HF trial. Through the use of a variable ref-
erence threshold for pixel-based abnormalities based on the planar HMR, 
quantitative differences between 123I-MIBG SPECT patterns in patients with 
ischemic and patients with non-ischemic HF could be reliably demonstrated 
with satisfactory reproducibility by both voxel- and region-based methods.7,61 
In a separate analysis, global denervation (≥9 abnormal 123I-MIBG segments 
from the standard 17-segment map) was associated with the highest cardiac 
Figure 3. 123I-MIBG SPECT image with accumulation in the liver which 
 overlaps the inferior wall.
123MIBG SPECT images in the short axis (SA), horizontal axis (HLA), vertical long axis (VLO) 
and bull’s eye with accumulation in the liver which overlaps the inferior wall and affects image quality.
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mortality rates in both patients with ischemic and patients with non-ischemic 
HF patients, but further distinction was possible on the basis of MPI SPECT 
findings. In patients with ischemic HF, mortality risk was highest among those 
with 3-7 rest MPI segmental defects, whereas in patients with non-ischemic 
HF, the highest risk was associated with near normal rest MPI studies (0-3 
segmental defects).62
Pellegrino et al. demonstrated excellent observer reproducibility of visual 
evaluation of 123I-MIBG SPECT with a low-dose 123I-MIBG protocol.63 
Nevertheless, it can be challenging to evaluate 123I-MIBG SPECT studies 
visually, especially in patients with HF and a global reduction in uptake.35 
Automated quantitation of 123I-MIBG SPECT studies offers the potential to 
overcome some of the limitations of visual image interpretation and improves 
the clinical utility of such studies for diagnosis and prognosis.
123I-MIBG SPECT with solid-state cameras
The recent introduction of new solid-state cardiac nuclear cameras that 
provide 180-degree of imaging without the need for gantry rotation, improved 
collimator design, and optimized acquisition geometry with increased photon 
sensitivity and contrast resolution has created the potential for more rapid 
SPECT acquisitions or a reduction in radiopharmaceutical activity and thus a 
lower dose for patients.64-66
This technology also offers advantages for 123I-MIBG SPECT imaging, 
including better energy discrimination and temporal resolution.67 List-mode 
acquisition analogous to that used in PET presents an opportunity to obtain 
true dynamic SPECT data, which could provide new physiologic insights to 
enhance the information content of the examination.
 Initial experiences with 123I-MIBG SPECT imaging and solid-state 
cadmium-zinc-telluride (CZT) cameras have been promising. Patients with 
LV dysfunction were shown to have higher 123I-MIBG summed defect scores 
than those with normal function.68 Similar results were obtained when 
mechanical dyssynchrony on MPI SPECT was compared with 123I-MIBG 
SPECT findings.69
Data on the in vivo myocardial kinetics of 123I-MIBG are rare. Dynamic 
123I-MIBG SPECT has the potential for defining new quantitative parameters 
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as shown in early human experiments. Tinti et al. demonstrated the feasibility 
of dynamic 3-dimensional 123I-MIBG kinetic analysis for providing additional 
information on cardiac innervation, particularly though the analysis of time- 
activity curves for 123I-MIBG.70 Also, in an experimental pig model myocar-
dial peak uptake was observed earlier than had been previously described.71
Although the possibilities of dynamic 123I-MIBG SPECT were initially 
explored with conventional rotating gamma cameras,72 the clinical potential 
of this technique with CZT cameras likely will be established as the new 
solid-state camera technology matures and more users gain experience with it.
Comparison of SPECT and PET techniques
The superior quantitative capabilities of PET imaging make PET an attrac-
tive alternative to SPECT. However, unlike compounds such as 123I-MIBG, 
which can be centrally manufactured and widely distributed commercially, 
most PET agents are labeled with short half-life isotopes such as 11C and 
therefore are available only in facilities with an on-site cyclotron. Neverthe-
less, as a research tool, PET remains extremely valuable. The PET agent most 
analogous to 123I-MIBG is meta-hydroxephedrine (mHED), as the uptake of 
both by sympathetic neurons is mediated by the norepinephrine transporter. 
However, in only a few studies has the cardiac uptake of 123I-MIBG been 
directly compared with that of mHED.
 In a study of rabbits injected with both 123I-MIBG and mHED, similar 
reductions in uptake in denervated myocardium were observed.73 However, 
pretreatment with the norepinephrine-depleting compound reserpine had a 
greater effect on mHED uptake than on 123I-MIBG uptake, suggesting that 
the former might be more specific for intravesicular uptake than the latter. 
Luisi et al. showed that the relative retention of mHED was significantly 
greater than that of 123I-MIBG in pigs, reflecting improved specificity as 
a result of less nonspecific uptake of the former tracer.74 Rischpler et al. 
reported that the 131I-MIBG uptake defect in rats matched the area of an 
 earlier MI, whereas the mHED uptake defect was larger.75 However, in a 
direct comparison of 123I-MIBG SPECT and mHED PET in 21 patients 
with LV dysfunction, Matsunari et al. reported a high correlation between 
defect sizes in the 2 methods;76 however, late 123I-MIBG SPECT overesti-
mated defect sizes in the inferior and septal regions, presumably because of 
image quality issues caused by adjacent liver activity.
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Although the early development of an 18F-labeled compound for PET 
imaging of sympathetic neurons is continuing,77 for the foreseeable future 
123I-MIBG SPECT will remain the only widely available nuclear imaging 
method for assessing regional myocardial sympathetic innervation.
Conclusion
The shift from planar to SPECT techniques in 123I-MIBG imaging has been 
slow in comparison with what occurred in clinical MPI 25-30 y ago. Neverthe-
less, the accumulation of evidence regarding the value of 123I-MIBG SPECT 
results, along with improvements in imaging equipment and image processing 
techniques, should result in acceleration of the growth and clinical use of the 
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Chapter 8
Cardiac 123I-MIBG imaging 
beyond Heart Failure: Potential 
Clinical  Indications




123Iodine-metaiodobenzylguanidine (123I-MIBG) imaging can visualize 
cardiac sympathetic innervation by providing (semi-)quantitative information 
on the myocardial sympathetic activity. Although there are lots of prognostic 
studies in patients with heart failure, clinical application of cardiac 123I-MIBG 
outside Japan is still limited. However, the number of potential clinical indi-
cations for 123I-MIBG imaging is growing as autonomic dysfunction is also 
present in other cardiac diseases. 
 The present review gives an overview of the potential clinical cardiac 
indications beyond heart failure of 123I-MIBG imaging to evaluate the cardiac 
sympathetic activity. The focus of the manuscript is primarily based on studies 
that have been performed outside Japan.
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Introduction
123Iodine-metaiodobenzylguanidine (123I-MIBG) scintigraphy enables 
visualization of cardiac sympathetic innervation by providing (semi-)quan-
titative information of the myocardial sympathetic activity.1 From the early 
and late planar 123I-MIBG images the heart-to-mediastinum (H/M) ratio 
can be obtained. This parameter represents the relative distribution of cardiac 
sympathetic nerve terminals and offers information about the neuronal func-
tion. In addition, the washout rate of the tracer between the early and late 
planar image can be gained providing information about the sympathetic 
drive. Furthermore, focal innervation defects can be detected with 123I-MIBG 
single-photon emission computed tomography (SPECT).2
 Cardiac 123I-MIBG scintigraphy is a well-known technique for the deter-
mination of prognosis in patients with heart failure.3 The late H/M ratio and 
washout rate appeared to be powerful predictors of survival and ventricular 
arrhythmias.4 In addition, 123I-MIBG imaging can be used to monitor the 
effect of medical therapy.5 Therefore, the nuclear cardiology guidelines of the 
Japanese Circulation Society recommend cardiac 123I-MIBG in heart failure 
patients for assessment of heart failure severity and prognosis.6 Outside Japan 
the use of cardiac 123I-MIBG scintigraphy is low in clinical practice since 
it has not been implemented in clinical guidelines.7,8 In addition, there is a 
lack of standardization and validation of cardiac 123I-MIBG imaging and 
post-processing procedures.9 As well as the limited gains in cost-effectiveness 
and the long awaited FDA approval in the USA.10 However, clinical research 
with 123I-MIBG imaging is growing and the number of potential clinical 
indications is promising (as depicted in Table 1).11,12 An obvious case whereby 
cardiac denervation is present and 123I-MIBG imaging might give important 
information is after cardiac transplantation.13 Moreover, autonomic dysfunc-
tion can also be present beyond heart failure for instance in patients after 
myocardial infarction,14 with arrhythmias15 and amyloidosis.16 An area were 
123I-MIBG imaging provides additive information as well is for the evaluation 
of patients with cardiovascular risk factors such as diabetes mellitus (DM),17 
(resistant) hypertension,18 and obesity.19
 This review examines recent trends for potential clinical indications in the 
future for cardiac 123I-MIBG imaging. The focus of the article is primarily on 
clinical studies that have been performed outside Japan.
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Cardiac diseases beyond heart failure
Myocardial infarction
The autonomic function in patients after an acute myocardial infarction 
(AMI) can be disturbed since damaged myocardial tissue (scar) caused by 
prolonged ischemia and hypoxia results in denervated sympathetic fibers. 
Compared to normal innervated myocardium, denervated regions are more 
sensitive to norepinephrine and therefore of value in the risk assessment for 
arrhythmias.20 The size of the denervated myocardium represented by the 
total 123I-MIBG defect score correlates highly with the occurrence of ventricu-
lar arrhythmias resulting in appropriate ICD discharges.21 Similarly, inducible 
ventricular arrhythmias during electrophysiology testing are correlated with 
larger total 123I-MIBG defect scores.22 In addition, the areas of myocardial 
autonomic denervation determined with 123I-MIBG imaging often extent 
the infarct borders determined on myocardial perfusion imaging (MPI) 
SPECT.14,23 This so called innervation / perfusion mismatch is due to the fact 
that neural tissue is more sensitive to hypoxia compared to myocardial fibers 
and the recovery time in neural tissue is increased.24,25 The areas with inner-
vation / perfusion mismatch are at increased risk of ventricular arrhythmias.26 
However, there is an on-going debate whether the size of 123I-MIBG innerva-
Tabel 1. List op (potential) clincial application of cardiac 123I-MIBG imaging 
beyond heart failure.
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tion / perfusion mismatch on top of the size of innervation defect is associated 
with more ventricular arrhythmias since results are conflicting.26-28
 Another possible consequence of cardiac sympathetic denervation in post-
AMI patients is a disturbance in the nocturnal blood pressure drop.29 The 
exact underlying mechanism of this disturbance is not yet fully elucidated. 
However, acknowledged is the fact that the sympathetic activity is of impor-
tance as reports have demonstrated that the intrinsic catecholamine levels 
are strongly related to systemic blood pressure course.30 Therefore, cardiac 
dysinnervation reflected by lower H/M ratio is associated with dysregulation 
of blood pressure variation with significantly worse prognosis in patients 
post-AMI evidenced by higher rates of all-cause death, myocardial infarction, 
coronary revascularization, and stroke.31 
Takotsubo cardiomyopathy
The clinical presentation of patients with a Takotsubo cardiomyopathy 
resembles AMI. However, in contrast to an AMI, no significant coronary 
lesions or thrombi are found on invasive coronary angiography. There are 
different pathophysiological hypothesis explaining the exact mechanism of a 
Takotsubo cardiomyopathy.32,33 The two main hypothesis are that Takotsubo 
cardiomyopathy is caused by a stress-induced neurohormonal event affecting 
the coronary microcirculation or by undetected spasm, and / or thrombotic 
epicardial artery occlusion.32,33 To diagnose Takotsubo cardiomyopathy, 
123I-MIBG imaging might be helpful since regional myocardial uptake of the 
radiotracer is reduced in the hypokinetic / akinetic left ventricle segments 
(depicted in Figure 1).34 However, summarized data from 22 reviewed reports 
of 112 patients with Takotsubo cardiomyopathy who underwent 123I-MIBG 
scintigraphy demonstrated that the first 123I-MIBG scan was usually performed 
1 to 2 weeks after the admission suggesting that this technique did not contrib-
ute to the diagnostic process.34 Though, investigation with 123I-MIBG during 
the first day has to be performed to determine which abnormalities are already 
shown direct after admission and what the exact value of 123I-MIBG scintigraphy 
will be in the diagnostic process. 
 In addition, Cimarelli et al. demonstrated in a case report that patients 
with a Takotsubo cardiomyopathy revealed a similar pattern of 123I-MIBG and 
18F-FDG uptake underlying a relation between cardiac sympathetic function 




Activation of the autonomic nervous system plays an important role in the 
initiation and maintenance of atrial tachycardia as it induces various atrial 
electrophysiological changes with as result increased risk for atrial tachy-
arrhythmias, such as atrial fibrillation and atrial tachycardia.15
 In Japan, small studies have demonstrated the value of 123I-MIBG imaging 
in patients with atrial fibrillation.36-38 In patients with idiopathic paroxysmal 
atrial fibrillation a lower H/M ratio was associated with vascular events (36) 
and the occurrence of permanent atrial fibrillation.37 In addition, in patients 
with atrial fibrillation treated with a Maze procedure an increase in denerva-
tion occurred in the early stage after the procedure.38 However, after 1 year 
significant reinnervation of those areas occurred.
 Additionally, Wenning et al. demonstrated in 16 patients who underwent 
pulmonary vein isolation that new innervation deficits demonstrated on 
123I-MIBG SPECT images were associated with atrial fibrillation relapses.39
Figure 1. 123I-MIBG scintigraphy in a patient with Takotsubo cardiomyopathy.
A female patient presenting with typical chest pain without significant coronary artery disease on 
coronary agiography with on left ventriculogram (A.) a typical contraction pattern of the left ventricle 
suspected for Takotsubo cardiomyopathy. Additionally, on early and late planar 123I-MIBG image 
(B.) a decreased H/M ratio (1.68 and 1.46 respectively) and on SPECT 123I-MIBG (C.) reduced 
accumulation apical expanded to the inferior wall.
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Amyloidosis
In primary and familial amyloidosis, cardiac involvement is frequently man-
ifest.40 However, the diagnosis is often difficult.41 To ease the diagnosis of 
cardiac amyloidosis 123I-MIBG can be used, because it indirectly visualizes 
the effect of myocardial depositions of amyloid by evaluating the occurrence 
of sympathetic nerve destruction.16,42 In patients with biopsy-proven systemic 
amyloidosis echocardiographic signs of amyloidosis are associated with a 
lower H/M ratio and higher washout rate.43 Moreover, results suggest that 
123I-MIBG imaging detects cardiac amyloid earlier than echocardiography.44 
Therefore, it may play a pivotal role in the early detection of cardiac involve-
ment of amyloidosis. This is of importance since current therapies (including 
liver transplantation) limit disease progression but not amyloid depositions. 
Consequently, the H/M ratio does not improve after liver transplantation in 
patients with cardiac amyloidosis.45
 In addition, 123I-MIBG imaging can be useful as a prognostic marker. In 
patients with amyloidosis with a V30M transthyretin mutation, Coutinho et 
al. demonstrated that the late H/M ratio was independent associated with 
all-cause mortality.46 As a consequence, the five-year mortality risk in patients 
with a late H/M ratio <1.60 was 6-fold higher compared with patients with a 
late H/M ratio ≥1.60.
Cardiovascular risk factors
Diabetes Mellitus
The prevalence of DM is increasing in the western world, mainly consisting of 
type 2 DM.47 Several studies have examined the use of 123I-MIBG imaging as 
a diagnostic and prognostic tool in patients with type 1 and 2 DM.17,48,49 DM 
is often complicated by diabetic neuropathy affecting different parts of the 
peripheral nervous system including the autonomic nerve fibres innervating 
the heart.50 This so called cardiovascular autonomic neuropathy (CAN) is 
one of the most severe complications of DM; it causes abnormalities in heart 
rate regulation and impairs vascular dynamics resulting in an increased risk 
of silent ischemia, life-threatening arrhythmias and sudden cardiac death.50 
Hattori et al. demonstrated that in an early stage sympathetic impairment 
on 123I-MIBG SPECT was mainly localized in the inferior wall, while global 
uptake determined on planar images remained within the normal range.51 
However, gradually in a more advanced stage of CAN the adjacent segments 
were as well affected. Given that CAN is reversible if treated in an early stage, 
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early evaluation to detect regional denervation areas with 123I-MIBG SPECT 
might be of value to achieve a better prognosis.
 Non-insulin dependent DM appears to be more frequently related with 
123I-MIBG uptake impairment compared with insulin dependent DM. How-
ever, sympathetic myocardial dysinnervation is more common in patients with 
insulin-dependent DM than initially thought.49 Instead of measuring heart 
rate variability, 123I-MIBG imaging is a more precise method to investigate 
the presence of CAN. This was demonstrated in a cohort of asymptomatic 
patients with type 2 DM with normal myocardial perfusion the prevalence 
of CAN diagnosed with 123I-MIBG scintigraphy was much higher than by 
evaluation with heart rate variability, 58% versus 27%, respectively.17 
 In addition, in patients with heart failure and DM the H/M ratio is signifi-
cantly lower than in patients without DM.48,52 Furthermore, patients with heart 
failure and DM with a H/M ratio <1.6 are at 3-fold higher 2-years risk of heart 
failure progression compared with patients with a late H/M ratio ≥1.6.52
Resistant hypertension
If the blood pressure remains too high regardless of three antihypertensive 
medications of different classes or controlled with four or more agents, and 
secondary hypertension is excluded, resistant hypertension should be con-
sidered.53 It is important to treat resistant hypertension since it is a powerful 
predictor for cardiovascular morbidity and mortality. The sympathetic 
innervation of the kidney plays an important role in the pathophysiology 
of hypertension since efferent renal sympathetic outflow stimulates renin 
release, increases tubular sodium reabsorption and reduces renal blood flow.54 
In addition, increased afferent renal signals stimulate central sympathetic 
outflow resulting in neurogenic hypertension. Investigations have suggested 
that renal artery sympathetic denervation might reduce the sympathetic 
overdrive and thereby lower the blood pressure.55 The effect of renal artery 
sympathetic denervation on the cardiac sympathetic overdrive can be assessed 
with 123I-MIBG imaging. Studies demonstrated an increase in H/M ratio 
and decrease in washout rate, independently of blood pressure changes.18,56 
This improvement in cardiac innervation is of importance since studies have 
demonstrated controversial results of the effect of renal denervation on the 
blood pressure. Therefore, 123I-MIBG imaging has the potential to evaluate 
the effect of renal denervation on arrhythmias and heart failure.18,56 However, 
in contrast to above studies van Brussel et al. demonstrated no reduction in 
sympathetic activity on cardiac level in 16 patients with resistance hyper-
tension who underwent bilateral renal artery sympathetic denervation.57 
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Therefore, the precise role in renal denervation needs to be further evaluated 
in larger studies.
Obesity
Obese patients are at high risk for cardiovascular events. To fight obesity, acti-
vation of brown adipose tissue (BAT) is a new treatment target as it increases 
energy consumption and thereby inducement of weight loss. 18F-FDG PET/
CT is a common imaging tool to evaluate therapies targeting BAT activity.58 
However, 123I-MIBG imaging might also be indicated since BAT is activated 
mainly by adrenergic receptors. The increased number of adrenergic receptors 
on BAT visualized by 123I-MIBG allows discrimination between brown and 
white adipose tissue since white tissue has only a limited number of adren-
ergic receptors. Okuyama et al. demonstrated in rats that 123I-MIBG and 
125I-MIBG accumulates in BAT and not in white adipose tissue.19 In line with 
previous study, Admiraal et al. demonstrated in 10 healthy Caucasian men 
that 123I-MIBG SPECT/CT compared with 18F-FDG PET/CT classified the 
same anatomic regions as active BAT.59 Therefore, 123I-MIBG SPECT/CT is 
indicated to visualize and quantify sympathetic stimulation of BAT.
 However, the activity of sympathetic drive and BAT visualized by 
123I-MIBG SPECT/CT is age-dependent.60 In contrast, between lean and 
obese patients the visualized BAT volume did not differ in volume suggesting 
that 123I-MIBG SPECT/CT is capable of detecting the sympathetic nervous 
system BAT activity in both patient groups.
Evaluation of chemotherapy related 
cardiotoxicity 
The survival rates in patients with cancer have increased tremendously 
over the last years because of improved therapeutic options. However, by 
prolonging life cardiologic side effects from treatments have become more 
clear.61 One of the best known cardiotoxic agent is anthracycline which causes 
dose-dependent permanent damage at cellular level with as the most frequent 
and serious side effect the onset of heart failure by reducing left ventricular 
ejection fraction (LVEF). Although dose reduction limits the cardiotoxicity, 
cardiologic evaluation around cancer treatment is necessary since decline in 
LVEF still occurs. Experts state that evaluation of the LVEF is the cornerstone 
in the cardiac imaging assessment.62 However, 123I-MIBG imaging might be 
a novel approach in the early evaluation of cardiotoxicity.63 Early investiga-
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tion by Wagasugi et al. suggest that in the early phase after chemotherapy the 
evaluation of cardio toxic effects with 123I-MIBG is more sensitive than LVEF 
since 123I-MIBG accumulation in the heart shows a greater and more linear 
dose-dependent decrease than LVEF after doxorubicin therapy.64
 However, not only patients treated with anthracyclines should be evaluated 
with 123I-MIBG since the novel agent monoclonal antibody trastuzumab 
affects the heart as well by inducing transient reversible myocyte dysfunction 
independent of dose (as demonstrated in Figure 2).65 
 123I-MIBG parameters might indicate in patients treated with trastuzumab 
with an affected LVEF whether recovery of the LVEF occurs during follow- 
up.66 Stokkel et al. suggested in a pilot study that 123I-MIBG scintigraphy 
might indicate whether recovery of LVEF will occur.66
Figure 2. Effects of trastuzumab on sympathic activity.
A 69-year old-patient treated with trastuzumab (Herceptin®) due to breast carcinoma with on 
123I-MIBG SPECT a innervation defect in the anterior and apical region.
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Heart transplantation and left ventricular assist
device implantation
Complete denervation of the allograft occurs after heart transplantation. In 
some patients the catecholamine storage capacity is regained which is asso-
ciated with improved response of the heart rate and contractile function to 
exercise.67 However, this is a slow process that takes often more than 1 year 
up to even 12 years and can be demonstrated by 123I-MIBG imaging.13,68 In 
addition, patients with idiopathic cardiomyopathy are less likely to re-gain 
innervation compared to other aetiologies of congestive heart failure, as well 
as in patients with DM.69
 Patients pending on or non-eligible for a heart transplantation can nowadays 
be treated with a left ventricular assist device (LVAD) to reduce mortality and 
improve quality of life. To evaluate the effects of LVAD on cardiac sympathetic 
innervation 123I-MIBG imaging has demonstrated that after LVAD implantation 
the early and late H/M ratio increases and the washout rate decreases.70,71
Conclusion
This review provides an overview of the potential increasing number of 
clinical indications of cardiac 123I-MIBG imaging besides heart failure in the 
last few years. 
 However, first cardiac 123I-MIBG has to be implemented in heart failure 
guidelines outside Japan, before other potential indications will. Until then 
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Chapter 9
The Impact of Acquisition Time 
of Planar Cardiac 123I-MIBG 
Imaging on the Late Heart- To-
Mediastinum Ratio




Purpose. The aim of this study was to investigate whether performing the 
late cardiac 123Iodine-metaiodobenzylguanidine (123I-MIBG) scan earlier 
than 4 hours post-injection (pi) has relevant impact on the late heart-to- 
mediastinum ratio (H/M ratio) in patients with heart failure (HF).
Methods. Forty-nine patients with HF (median left ventricular ejection 
fraction of 31%, 51% ischemic HF) referred for cardiac 123I-MIBG scintig-
raphy were scanned at 15 minutes (early) pi and at 1, 2, 3 and 4 hours (late) 
pi of 123I-MIBG. Late H/M ratios were calculated and evaluated using a linear 
mixed model with the mean late H/M ratio at 4 hours pi as a reference. A 
difference in late H/M ratios of more than 0.10 between the different acquisi-
tion times in comparison with the late H/M ratio at 4 hours pi was considered 
as clinically relevant. 
Results. Statistically significant mean differences were observed between 
the late H/M ratios at 1, 2 and 3 hours pi compared with the late H/M ratio 
at 4 hours pi (0.09, 0.05 and 0.02, respectively). However, the mean differ-
ences did not exceed the cut-off value of 0.10. On an individual patient level, 
compared to the late H/M ratio at 4 hours pi, the late H/M ratios at 1, 2 and 3 
hours pi differed more than 0.10 in 24 (50%), 9 (19%) and 2 (4%) patients, 
respectively.
Conclusions. Variation in acquisition time of 123I-MIBG between 2 and 4 
hours pi does not lead to a clinically significant change in the late H/M ratio. 
An earlier acquisition time seems to be justified and may warrant a more 
time-efficient cardiac 123I-MIBG imaging protocol. 
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Introduction
Heart failure (HF) is an increasing healthcare problem in the Western world.1 
Among other features, the pathophysiology of HF is characterized by a 
deregulated sympathetic nervous system.2 123Iodinemetaiodobenzylgua nidine 
(123I-MIBG) imaging is able to visualize cardiac sympathetic innervation by 
providing (semi-)quantitative information on the myocardial sympathetic 
activity.3 Several studies have reported that cardiac 123I-MIBG uptake provides 
unique information for predicting prognosis and evaluating therapeutic effects 
in patients with HF.4-7 The semi-quantitative parameter that is most used to 
analyse cardiac 123I-MIBG uptake is the heart-to-mediastinum ratio (H/M 
ratio) of the late planar image. The reported acquisition time for this so-called 
“late” scan varies considerably, but it is recommended 4 hours after injection 
of 123I-MIBG.8 A shorter time interval between the injection of 123I-MIBG and 
the late scan reduces waiting time and may facilitate clinical use. However, 
only a few studies have investigated the impact of variation in acquisition time 
after 123I-MIBG administration on the late H/M ratio.9, 10 Therefore, the aim 
of this study was to investigate whether performing the late scan earlier than 4 




Fifty patients with HF from 2 centres (Leiden, the Netherlands and Pisa, 
Italy), clinically referred for cardiac 123I-MIBG scintigraphy between 2012 
and 2015 were included. The inclusion criteria were symptoms of HF New 
York Heart Association functional class II-IV and age between 18 and 74 
years. Patients with severe shortness of breath who were unable to lie flat 
for several times under a gamma camera were excluded from this study. All 
patients were treated according to the European Society of Cardiology guide-
lines for the diagnosis and management of HF and therefore received optimal 
pharmacological therapy, revascularization and implantable defibrillator with 
or without cardiac resynchronization therapy (CRT) device when appropriate.11
The study complied with the Declaration of Helsinki and was approved by the 
Medical Ethics Committee of the Leiden University Medical Center. Written 




After thyroid blockade according to the local protocol and a resting period of 
30 minutes, 185 MBq of 123I-MIBG (AdreView; GE Healthcare, Princeton 
NJ, USA) was administrated as an intravenous bolus. Afterwards, 123I-MIBG 
planar imaging was performed in the supine position five times pi; the early 
acquisition was performed 15 minutes pi and the late acquisitions were per-
formed at 1, 2, 3 and 4 hours pi. Planar images were acquired in the anterior 
view for 10 minutes with dual head gamma cameras, a Siemens ECAM (Pisa, 
Italy) or a Toshiba GCA 7200/PI (Leiden, the Netherlands), and stored in a 
256x256 matrix. All camera heads were provided with low-energy high-reso-
lution collimators and the images were obtained with a 15% energy window 
centred at the 159 keV photopeak of 123I.
Planar 123I-MIBG image analysis
All planar 123I-MIBG images were transferred to the Leiden University Medical 
Center for a centralized analysis. The images were semi-quantitatively analysed 
by calculating the H/M ratio using dedicated post-processing software on a 
Syngo-MI workstation (Siemens Medical Solutions, Malvern, PA). Manually 
a polygonal region-of-interest (ROI) was drawn over the myocardium including 
the left cavity and a rectangular ROI was placed upon the upper half of the 
mediastinum using the following anatomical landmarks: the lung apex as 
upper border, the upper cardiac border and the medial contours of the lungs. 
The H/M ratio was calculated by dividing the mean count density (i.e. counts/
pixel) within the cardiac ROI by the mean count density in the mediastinal 
ROI. The washout rate was expressed as a percentage of decrease in myocardial 
counts between early and late planar images with correction for background 
and physical decay of 123I. For this calculation the following formula was used: 
WRBKG corrected = [(He-Me)-(Hl-Ml x
123I decay correction)]/(He-Me) x 100.
8 
In this formula H represents the mean count density in the cardiac ROI and 
M represents the mean count density in the mediastinal ROI in the early (e) 
and (l) late images. 
Statistical analysis
Normally distributed variables were expressed as mean ± standard deviation, 
and non-normally distributed variables as median and interquartile range 
(IQR). Categorical variables were given as absolute values and percentages. 
Patient characteristics and 123I-MIBG scintigraphy results of subgroup 
analyses were compared with the independent sample t-test, the Mann-Whit-
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ney U test or the chi square test when appropriate. The late H/M ratios at 1, 
2 and 3 hours pi were compared with the late H/M ratio at 4 hours pi with 
a linear mixed model with a given fixed factor time. A mean difference in 
late H/M ratio of more than 0.10 between the (mean) different H/M ratios 
at 1, 2 and 3 hours pi and the (mean) late H/M at 4 hours pi was considered 
clinically relevant. This was assessed by evaluating whether the 95%-confi-
dence intervals (95% CI) for the real differences in means of the late H/M 
ratios at 1, 2 and 3 hours pi respectively compared with the late H/M ratio at 4 
hours pi included the value 0.1. In the subgroup analysis, the influence of left 
ventricular ejection fraction on the differences in late H/M ratios between the 
ischemic and non-ischemic HF groups at 1, 2, 3 and 4 hours pi was assessed by 
performing multivariate logistic regression analyses including H/M ratio and 
left ventricular ejection fraction. The washout rates between 15 minutes and 
1, 2 and 3 hours pi were compared with the washout rate between 15 minutes 
and 4 hours pi with a linear mixed model with a given fixed factor time. A 
paired t-test power analysis demonstrated that a sample size of 49 patients 
achieved 90% power to reject the null hypothesis that the test and standard 
are equivalent, thereby assuming an absolute difference of more than 0.10 
with an estimated standard deviation of 0.20 with a significance level (alpha) 
of 0.01670. A two-sided P value <0.05 was considered statistically significant. 
All analyses were performed with SPSS software (Version 22.0, SPSS IBM 
Corp., Armonk, NY, USA).
Results
Patients
The study population comprised 49 patients with HF, because 1 patient with-
drew his informed consent after the examination. The patient characteristics 
of the study population are depicted in Table 1. Seventy-six percent (37/49) 
of the total study population was male with a mean age of 64±9 years. The 
aetiology of HF was ischemic in 51% (25/49) of the patients. Patients with 
ischemic HF had a statistically significantly lower left ventricular ejection 
fraction compared with patients with non-ischemic HF, 28% (IQR 23-35) 
versus 33% (IQR 29-40) (P=0.04), respectively and antiplatelet or oral 




Table 1. Baseline characteristics of the study population (n=49) 








Age (years) 64±9 66±9 62±8 0.08
Sex (male) 37 (76%) 21 (84%) 16 (67%) 0.16
Height (cm) 176±9 175±8 176±10 0.73
Weight (kg) 85±14 84±13 87±14 0.36
Cardiovascular risk factors
Diabetes Mellitus* 8 (16%) 4 (16%) 4 (17%) 0.95
Obesity, BMI ≥ 30 (kg/m²) 7 (14%) 2 (8%) 5 (21%) 0.20
Family history of CVD† 19 (39%) 9 (36%) 10 (42%) 0.68
Hypercholesterolemia‡ 27 (55%) 16 (64%) 11 (46%) 0.20
Hypertension§ 30 (61%) 13 (52%) 17 (71%) 0.18
Current smoker 8 (16%) 4 (16%) 4 (17%) 0.95







CRT-D / ICD therapy 31 (63%) 17 (68%) 14 (58%) 0.48
Medication
ACE-/AT II-inhibitor 45 (92%) 23 (92%) 22 (92%) 0.97
Beta blocker 39 (80%) 20 (80%) 19 (79%) 0.94
Calcium antagonist 3 (6%) 2 (8%) 1 (4%) 0.58
Lipid-lowering agent 35 (71%) 20 (80%) 15 (63%) 0.18
Antiplatelet/OAC therapy 42 (86%) 24 (96%) 18 (75%) 0.04
Diuretics 38 (78%) 22 (88%) 16 (67%)
oral antidiabetics 8 (16%) 4 (16%) 4 (17%) 0.95
Insulin 3 (6%) 1 (4%) 2 (8%) 0.53
Nitrates 3 (6%) 3 (12%) 0 (0%) 0.08
NYHA class 0.28
I 11 (22.45%) 7 (28.0%) 4 (16.7%)
II 27 (55.1%) 11 (44.0%) 16 (66.6%)








ACE: angiotensin converting enzyme inhibitor; AT-II: angiotensin-II; BMI: Body Mass Index, CRT-D: 
cardiac resynchronization therapy defibrillator; CVD: cardiovascular disease; HF: heart failure; ICD: 
implantable cardioverter defibrillator; IQR: interquartile range; NT-proBNP: N-terminal pro-brain 
natriuretic peptide; NYHA: New York Heart Association; OAC: oral anticoagulant.
* Self-reported history of Diabetes Mellitus and/or treatment with antidiabetics, 
† presence of coronary artery disease in first-degree family members at age <55 years in men and <65 
years in women,
‡ Self-reported history of hypercholesterolemia and/or treatment with lipid-lowering drugs, 
§ Self-reported history of hypertension and/or use of antihypertensive medication, or a systolic blood 
pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg.
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Planar 123I-MIBG image analysis
The results of the planar 123I-MIBG image analysis are shown in Table 2. Of 
the 49 patients, 1 patient did not have an acquisition 4 hours pi. In the total 
study population the late H/M ratio was 1.60±0.18 at 1 hour, 1.56±0.19 at 
2 hours pi and 1.53±0.19 at 3 hours pi and differed all significantly from the 
late H/M ratio of 1.52±0.20 at 4 hours pi (P <0.001, P<0.001 and P=0.02, 
respectively). However, none of the mean differences between the late H/M 
ratios at 1, 2 and 3 hours pi exceeded the predefined clinically relevant 0.10 
difference with the late H/M ratio at 4 hours pi (Figure 1a). An example of a 
patient with only small differences between the late H/M ratios at 1, 2 and 3 
hours pi compared with the late H/M ratio at 4 hours pi is depicted in Figure 
2. On an individual patient level, compared to the late H/M ratio at 4 hours pi, 
the late H/M ratios at 1, 2 and 3 hours pi differed more than 0.10 in 24 (50%), 
9 (19%) and 2 (4%) patients, respectively (Figure 1b). 
Figure 1. Mean differences (1a.) and absolute differences of each individual patient 
in the H/M ratios at 1, 2 and 3 hours pi in comparison with H/M ratio at 4 hours pi.
1. The mean difference with 95% CI of H/M ratios of late 123I-MIBG images with acquisition at 1, 2 
and 3 hours pi in comparison with the H/M ratio of the late 123I-MIBG image at 4 hours pi analysed 
with a linear mixed model (1a.). Each dot represents an absolute difference of each individual patient 
in the late H/M ratios at 1, 2 and 3 hours pi compared with H/M ratio at 4 hours pi (1b.). A mean 
difference in H/M ratio of more than 0.10 between the different acquisition times in comparison with the 
late H/M ratio at 4 hours pi was considered clinically relevant.
CI: confidence interval; hrs: hours; H/M ratio: heart-to-mediastinum ratio; pi: post-injection.
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Table 2. 123I-MIBG scintigraphy results









Actual acquisition time 





































Early scan 1.60±0.15 1.55±0.15 1.64±0.14 0.03
Late scan 1H 1.60±0.18 1.54±0.16 1.66±0.18 0.02
Late scan 2H 1.56±0.19 1.51±0.17 1.61±0.21 0.09
Late scan 3H 1.53±0.19 1.47±0.16 1.59±0.20 0.03
Late scan 4H 1.52±0.20 1.46±0.17 1.58±0.21 0.03
Washout rate (%)
Late scan 1H 11±12 13±12 9±11 0.23
Late scan 2H 21±16 21±16 21±16 0.96
Late scan 3H 29±17 32±17 26±17 0.29
Late scan 4H 34±17 36±17 33±17 0.50
  
H: hour(s); HF: heart failure; IQR: interquartile range.
The H/M ratios of the early scan and the late scan performed at 1, 3 and 4 
hours pi were significantly higher in the non-ischemic HF group in comparison 
with the ischemic HF group (P=0.03, P=0.02, P=0.03 and P=0.03, respec-
tively). When corrected for the left ventricular ejection fraction there was no 
independent association between the late H/M ratio at 1, 3 and 4 hours pi 
and type of HF (OR 0.09 [95%CI 0.006-0.18], P=0.07; OR 0.07 [95% CI 
-0.027;0.17], P=0.16 and OR 0.06 [95%CI-0.03-0.16], P=0.16, respec-
tively). Figure 3 shows the mean differences in late H/M ratios at 1, 2 and 3 
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Figure 2. Example of a patient with ischemic HF and planar acquisitions 1, 2, 3 and 
4 hours pi, respectively.
HF: heart failure; H/M ratio: heart-to-mediastinum ratio, pi: post-injection.
Figure 3. Mean differences of H/M ratios at 1, 2 and 3 hours pi in comparison 
with H/M ratio at 4 hours pi in the ischemic HF and non-ischemic HF subgroups.
Mean difference with 95% CI of H/M ratio of late 123I-MIBG images at 1, 2 and 3 hours pi in compar-
ison with H/M ratio of late 123I-MIBG image at 4 hours pi analyzed with a linear mixed model in the 
ischemic HF (in blue) and non-ischemic HF (in red) subgroups. A difference in H/M ratio of more than 
0.10 between the different acquisition times in comparison with the H/M ratio at 4 hours was considered 
clinically relevant.
CI confidence interval; hrs: hours; HF: heart failure; H/M ratio: heart-to-mediastinum ratio. 
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hours pi compared with the late H/M ratio at 4 hours pi in both subgroups. 
Compared to the late H/M ratio at 4 hours pi, the mean late H/M ratios at 1 
and 2 hours pi were statistically significant different in the ischemic 
HF group (both P<0.001) as well as in the non-ischemic HF group (P<0.001 
and P=0.005, respectively). In the ischemic HF group only the mean late 
H/M ratio at 1 hour pi exceeded the predefined clinical relevant 0.10 differ-
ence with the late H/M ratio 4 hours pi.
 The mean washout rate between the early scan and the late scans at 1, 2, 3 
and 4 hours pi increased from 11±12% to 21±16%, 29±17%, and 34±17%. 
The mean washout rates between the early scan and the late scans at 1, 2 
and 3 hours pi differed all statistically significantly from the washout rate 
between the early and 4 hours pi scan (all P <0.001). There was no statistically 
significant difference between the washout rates in the ischemic HF and the 
non-ischemic HF subgroups.
Discussion
The present study evaluated the impact of variations in acquisition time of pla-
nar 123I-MIBG scintigraphy on the late H/M ratio in patients with HF. There 
were statistically significant differences between the late H/M ratios at 1, 2 and 
3 hours pi compared with the late H/M ratio at 4 hours pi. However, compared 
with the late H/M ratio at 4 hours pi, the late H/M ratios at 1, 2 and 3 hours pi 
did not exceed the predefined clinically relevant cut-off difference of 0.10. 
The late H/M ratio is the most frequently used parameter to semi-quanti-
tatively analyse the cardiac 123I-MIBG uptake in patients with HF.12 The 
Cardiovascular Committee of the European Association of Nuclear Medicine 
and the European Council of Nuclear Cardiology recommend calculating 
the late H/M ratio from planar images at 4 hours after receiving 123I-MIBG.8 
This recommendation is based on several studies.13-17 First, Nakajo et al., 
investigated the appropriate time for cardiac radioiodine labelled MIBG 
imaging.14 This study demonstrated in rats that the accumulation of cardiac 
131I-MIBG in adrenergic nerves reached a maximum plateau at 4 hours pi, 
while the accumulation of the tracer in other compartments rapidly decreased 
in a period of 6 hours pi. Second, the mechanism of myocardial uptake of 
123I-MIBG in the presynaptic sympathetic nerve endings was elucidated by 
DeGrado et al.15 This group demonstrated that 123I-MIBG-uptake was mainly 
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between 1 and 7 minutes pi and depended primarily on both uptake-1 (the 
neuronal pathway via the norepinephrine transporter) as well as on uptake-2 
(the extraneuronal pathway) activity. The clearance half-time of neuronal 
123I-MIBG uptake (via uptake-1) was 112 minutes, in contrast to the much 
lower clearance half-time of extraneuronal 123I-MIBG uptake (uptake-2) of 
22 minutes. Finally, Sisson et al. demonstrated that 123I-MIBG patterns in 
the heart were consistent with the concept that 123I-MIBG resides mostly in 
adrenergic neurons, mainly via the uptake-1 mechanism.16, 17 This supports the 
hypothesis that the late H/M ratio at 4 hours pi mainly represents the uptake, 
storage and release of 123I-MIBG in the myocardial vesicles at the nerve termi-
nals, while accumulation in extraneuronal compartments is relatively low. 
In the present study only small differences (≤ 0.10) were observed between 
the late H/M ratios at 1, 2 and 3 hours pi compared with the commonly 
used late H/M ratio at 4 hours pi. Subgroup analysis between patients with 
ischemic and non-ischemic HF showed similar results. At patient level, a 
high percentage of patients (50%) exceeded a difference of 0.10 between the 
late H/M ratio at 1 hour pi compared to the late H/M ratio at 4 hours pi. In 
contrast, between the late H/M ratio at 2 hours pi and the late H/M ratio at 
4 hours pi the percentage of patients who exceeded a difference of 0.10 was 
much lower (19%). In comparison with the late H/M ratios at 3 and 4 hours 
pi only 4% of the patients had a difference of more than 0.10. These results 
are in line with a previous investigation by Kline et al., who demonstrated 
a small difference in late heart-to-lung ratio in 4 healthy subjects between 
1 and 2 hours after administration of 74 MBq 123I-MIBG of approximately 
1.3 versus 1.44.3 More recently, Giorgetti et al. reported the mean H/M 
ratios at different acquisition times in 6 pigs after administration of 54±14 
MBq 123I-MIBG using a cadmium zinc telluride camera. The mean H/M 
values ± SD, at 125 minutes, extrapolated to 176 and 240 minutes, were 
4.33%±1.23%, 3.95%±1.46% and 3.63%±1.64%, respectively. In addition, 
Okuda et al. demonstrated in 96 patients that the mean count density in the 
cardiac ROI and the mediastinum ROI at 3 hours were highly correlated with 
the mean count density in the cardiac ROI and the mediastinum ROI at 4 
hours (r=0.98, P<0.0001 and r=0.89, P<0.0001). As well as, the fact that 
there was only a small mean difference of 0.02 between the late H/M ratios 
at 3 and 4 hours pi (1.88±0.56 and 1.86±0.57, respectively).9 Slow efflux of 
123I-MIBG from the neuronal compartments can probably explain the small 
differences between late H/M ratios in the latter and the present study. 13, 18 
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The present results show that, at group as well as at an individual patient 
level, the change in the late H/M ratios between 2 and 4 hours pi is limited 
and probably not clinically relevant. Since the late H/M ratio has been proven 
to provide important information in predicting prognosis in HF patients,4 
our results may have clinical implications by allowing a more flexible and/
or shorter interval between the injection of 123I-MIBG and the acquisition 
time of the late scan for the determination of the late H/M ratio, especially in 
patients with HF. 
With a shorter interval between the injection of 123I-MIBG and the “late” scan 
the washout rate will change. Previous studies have shown that the instant 
myocardial uptake of 123I-MIBG uptake normalized for blood pool activity 
is close to zero after 3 hours.10 Evaluating the washout rate at least 3 hours 
after radiotracer injection is therefore recommended. However, Arimoto et al. 
demonstrated in 42 patients with HF a good correlation of the early washout 
rate between 5 and 15 minutes and the washout rate between 15 minutes and 
3 hours (r=0.606, P<0.0001).19 Moreover, the early washout rate provided 
prognostic information as well. In addition, Henderson et al. demonstrated 
that a washout rate recorded between 15 and 85 minutes showed a significant 
difference in 16 patients with non-ischemic cardiomyopathy compared with 
14 healthy volunteers; 28±12% and 6±8% respectively (P<0.001).20 Addi-
tional imaging was performed in a subset of patients (n=8) at 4 hours pi and 
123I-MIBG retention appeared to be lower and showed greater disparity in the 
washout rate. In the present study, myocardial 123I-MIBG washout increased 
over time from 11±12% at 1 hour pi to 34±17% at 4 hours pi. The mean 
washout rates between the early scan and the late scans at 1, 2 and 3 hours pi 
differed all statistically significantly from the washout rate between the early 
and 4 hours pi scan (all P <0.001).
Limitations
It should be addressed that although myocardial washout rates were corrected 
for 123I-decay and mediastinal background the myocardial washout rate can 
still be influenced by 123I-MIBG washout in surrounding lung and liver tissues.21 
Moreover, more research is needed before implementing the acquisition time 
at 2 hours to avoid misclassification since the difference between the late H/M 
ratio at 2 hours pi in comparison with 4 hours pi at the patient level was not 
non-negligible.
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Conclusion
Variation in acquisition time of 123I-MIBG between 2 and 4 hours pi does not 
lead to a clinically significant change in the late H/M ratio. With the knowledge 
that the late H/M ratio is the best validated and most used prognostic parameter 
for cardiac sympathetic innervation in patients with HF, an earlier acquisition 
time seems to be justified and may warrant a more time-efficient cardiac 
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Chapter 10
Cardiac 123I-MIBG Parameters 
at 4 Hours Derived from Earlier 
 Acquisitions Times




Background. The clinical implementation of cardiac 123Iodine-metaiodo-
benzylguanidine (123I-MIBG) scintigraphy for the evaluation of prognosis in 
patients with heart failure (HF) is still limited. This may partially be related to 
the long examination time with an almost 4 hour delay between the early and 
late acquisition. Additionally, outcome derived at different late acquisition 
times cannot be compared with each other. To assess whether earlier acquisi-
tion time of the late image is justified, the aim of present study was to evaluate 
in a HF patient cohort whether a developed direct comparison method for 
cardiac 123I-MIBG imaging enables comparison of washout rates and late 
heart mediastinum (H/M) ratios from 1 to 3 hours post injection (pi) with 
measurements at 4 hours pi. 
Methods. Forty-eight patients with HF were clinically referred for cardiac 
123I-MIBG scintigraphy. The washout rate and late H/M ratio at 4 hours 
pi were estimated with a previous published linear model from heart and 
mediastinal counts at 1, 2 and 3 hour pi and compared with the actual values 
at 4 hour pi. 
Results. The estimated washout rate and late H/M ratio at 4 hours pi from 
counts at 1 hour pi demonstrated large differences. However, the average esti-
mated late H/M ratio at 4 hours pi derived from 2 and 3 hours pi did not differ 
with the actual late H/M ratio at 4 hours pi (P=0.84 and P=0.06). As well as, 
the actual and estimated washout rate at 4 hours pi derived from 3 hours pi 
did not differ significantly (P=0.22). Yet, the mean estimated washout rate at 
4 hours pi derived from the acquisition at 2 hours pi showed a difference com-
pared with the actual washout rate at 4 hours pi (25±19 vs. 34±17, P<0.001).
Conclusions. The direct comparison method for cardiac 123I-MIBG imaging 
enables accurate estimation of the actual late H/M ratio and washout rate at 4 
hours pi derived from the acquisitions at 3 hours pi. The acquisition at 2 hours 
pi should only be performed in exceptional cases when clinically necessary 
because of the existing difference between the actual and estimated washout 
rate at 4 hours pi derived from 2 hours pi.
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Introduction
The increasing prevalence of heart failure (HF) worldwide is a major health-
care problem.1 In patients with HF the cardiac sympathetic nervous system 
is activated, which can be visualized with 123Iodine-metaiodobenzylguanidine 
(123I-MIBG) imaging;2 the procedure of 123I-MIBG imaging consists of 
an early acquisition (15 minutes post-injection [pi]) and a late acquisition 
(varying between 3 and 4 hours after tracer injection). Different parameters 
can be extracted from these images. First, the late heart-to-mediastinum ratio 
(H/M ratio), which is calculated by dividing the cardiac 123I-MIBG uptake by 
the mediastinal 123I-MIBG-uptake.3 It represents the relative distribution of 
cardiac sympathetic nerve terminals, offering information about neuronal 
function from uptake to release. The other 123I-MIBG parameter is the myo-
cardial washout rate representing the tracer washout between the early and 
late planar 123I-MIBG acquisition and therefore the washout rate provides an 
index of the sympathetic drive.
 Several studies have shown that patients with HF and a low late H/M ratio 
and/or an increased washout rate, are at increased risk for cardiac death and 
arrhythmic events.4-6 However, the clinical implementation of this technique 
is still limited. This may partially be related to the long examination time with 
an almost 4 hour delay between the early and late acquisition. Additionally, 
outcome derived at different late acquisition times cannot be compared with 
each other. This is of importance since most Japanese studies in contrast to 
Western studies perform the late acquisition at 3 hours pi.7,8
 Recently a more time-efficient cardiac 123I-MIBG protocol demonstrated 
only small differences between the late H/M ratio 2 and 3 hours pi compared 
with the late H/M ratio at 4 hours pi, suggesting that the late imaging can be 
performed at an earlier stage.9 This will shorten the acquisition time and may 
increase patient comfort. However, the differences between the washout rates 
were larger and increased over time, which makes comparison of the washout 
rate measured at different acquisition times difficult. Okuda et al. recently 
developed a linear model to ease comparison of the washout rate at 3 hours pi 
with 4 hours pi.10 Yet, no external validation has taken place in a HF cohort 
and it is unknown whether this model can be applied to estimate the washout 
rate and the late H/M ratio at 4 hours pi from even earlier acquisitions times 
than 3 hours pi. 
 To assess whether earlier acquisition time of the late image is justified, 
the present study evaluated whether the linear model based formula enables 
comparison of washout rates and late H/M ratios determined from acquisi-
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tion times from 1 to 3 hours pi with the actual measurements at 4 hours pi in 
a cohort of HF patients.
Methods
Patients
The study population consisted of patients included in a previous study focus-
ing on the change in late H/M ratio between 1, 2 and 3 hours pi in comparison 
with the late H/M ratio at 4 hours pi.9 The inclusion criteria for the study 
population were age between 18 and 74 years and symptoms of HF New York 
Heart Association class (NYHA) II-IV. Excluded for that study were patients 
with severe shortness of breath who were unable to lie flat for several times 
under a gamma camera. Previous study concentrated on the determination of 
the late H/M ratio at 1, 2, 3 and 4 hours pi. The current evaluation will focus on 
a recently developed direct comparison method for cardiac 123I-MIBG imaging 
to evaluate whether this method provides an accurate estimation of the late 
H/M ratio and washout rate at 4 hours pi derived from earlier (1, 2 and 3 hours 
pi) acquisitions to overcome differences in late H/M ratios and washout rates 
between different acquisitions. The population consisted of 50 patients with 
HF and NYHA II-IV from two centers (Leiden, Netherlands and Pisa, Italy) 
clinically referred for cardiac 123I-MIBG scintigraphy between 2012-2015. The 
study was approved by the Medical Ethical Committee from the Leiden Uni-
versity Medical Centre (the Netherlands) and the Medical Ethical Committee 
from the Fondazione Toscana/CNR Gabriele Monasterio (Italy) and complied 
with the Declaration of Helsinki. All patients signed the informed consent form.
123I-MIBG data acquisition and analysis 
The protocol of the 123I-MIBG data acquisition and analysis have been 
described in detail.9 In brief, after an intravenous bolus injection of 185 MBq 
123I-MIBG (AdreView; GE Healthcare, Princeton NJ) 5 frontal planar images 
of the chest were obtained 15 minutes pi (early scan) and 1, 2, 3 and 4 hours 
pi (late scans). All examinations were performed with a Siemens ECAM (Pisa, 
Italy) or a Toshiba GCA 7200/PI (Leiden, The Netherlands) scanner with 
dual head gamma cameras in combination with low-energy high-resolution 
collimators with a matrix 256 x 256. The Siemens ECAM scanner has a 1.23 
zoom factor and 1.9 mm pixel size and the Toshiba scanner a 1.5 zoom factor 
and 1.4 mm pixel size 1.4 mm.
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Post-processing enhanced a manually drawn polygonal region-of-interest 
(ROI) over the myocardium including the left cavity and a rectangular ROI 
upon the upper half of the mediastinum. The H/M ratio was calculated by 
dividing the mean counts per pixel within the cardiac ROI by the mean counts 
per pixel in the mediastinal ROI. The washout rate with correction for back-
ground and physical decay of 123I was calculated with the following formula: 
WRBKG and decay corrected = [({H}e-{M}e)-({H}l-{M}l x123I decay correction)]/ 
({H}e-{M}e) x 100. 
 In this formula {H} represents the mean counts per pixel in the cardiac 
ROI and {M} represents the mean counts per pixel in the mediastinal ROI in 
the early (e) and late (l) images.11
Estimation of 123I-MIBG parameters
To estimate the mean cardiac counts per pixel of 123I-MIBG at 4 hours 
derived from acquisitions at 1, 2 and 3 hours pi, the following formula was 
extracted from the linear regression model between 3 and 4 hours pi, pro-
vided by Okuda et al.10: {H}ih-estimated =(1.039i-j x {H}jh-actual) – ((1.039i-j-1 
+1.039i-j-2+…+1) x 0.067 x {H}e ). {H}ih-estimated represents the estimated 
mean count density in the cardiac ROI at i hours pi and {H}jh-actual, the actual 
mean count density in the cardiac ROI at j hours. {H}e represents the mean 
count density in the cardiac ROI of the early image at 15 minutes. Thus, the 
formulas for the estimated mean cardiac counts per pixel of 123I-MIBG at 4 
hours from acquisitions at 1, 2 and 3 hours pi were: 
Cardiac counts at 1 hour pi: {H}4h-estimated = (1.122 x {H}1h-actual ) – (0.209 x {H}e ), 
Cardiac counts at 2 hours pi: {H}4h-estimated = (1.080 x {H}2h-actual ) – (0.137 x {H}e ), 
Cardiac counts at 3 hours pi: {H}4h-estimated = (1.039 x {H}3h-actual ) – (0.067 x {H}e ).
In addition, to estimate the mean mediastinal counts per pixel of 123I-MIBG at 
4 hours derived from acquisitions at 1, 2 and 3 hours pi the following formula 
was extracted from the linear regression model between 3 and 4 hours pi, 
provided by Okuda et al.10: {M}ih-estimated=0.967i-j·{M}jh – ((0.967i i-j-1+0.967i 
i-j-2+…+1) x 0.003 x {M}e ). {M}ih-estimated represents the estimated mean count 
density in the mediastinal ROI at i hours pi and {M}ih-actual, the actual mean 
count density in the cardiac ROI at j hours. {M}e represents the mean count 
density in the mediastinal ROI of the early image at 15 minutes. Consequently, 
the formulas to calculate the estimated mean mediastinal counts per pixel of 
123I-MIBG at 4 hours from acquisitions at 1, 2 and 3 hours pi were: 
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Mediastinal counts at 1 hour pi: {M}4h-estimated = (0.904 x {M}1h-actual ) – (0.009 x {M}e ),
Mediastinal counts at 2 hour pi: {M}4h-estimated = (0.935 x {M}2h-actual ) – (0.006 x {M}e ),
Mediastinal counts at 3 hour pi: {M}4h-estimated = (0.967 x {M}3h-actual ) – (0.003 x {M}e ).
Afterwards, the late H/M ratio and myocardial washout rate with background 
and decay correction at 4 hours pi were calculated from the estimated mean 
cardiac and mediastinal counts per pixel at 4 hours pi.
Statistical analysis
Normally distributed variables were expressed as mean ± standard deviation 
and non-normally distributed variables as median with interquartile range 
(IQR). Categorical variables were presented as frequencies and percentages. 
 To evaluate the differences in estimated and actual measured cardiac and 
mediastinal counts at 4 hours pi, the following analyses were performed. First, 
the estimated cardiac and mediastinal counts derived from 1, 2 and 3 hours 
pi were compared with the actual cardiac and mediastinal counts at 4 hours 
pi using a paired samples t-test. In addition, the agreement of the estimated 
and the actual cardiac and mediastinal counts at 4 hours was evaluated with 
the Pearson’s correlation and Bland Altman analysis. Similarly, these analyses 
were repeated for the comparison of the estimated and actual late H/M ratios 
and washout rates.
 Furthermore, the sensitivity and specificity for the threshold of < 1.6 of 
the actual late H/M ratio were calculated for the estimated late H/M ratio at 4 
hours pi derived from the 1-, 2- and 3-hour scan (4). As well as, the sensitivity 
and specificity for the threshold of ≥ 27% of the actual washout rate at 4 hours 
pi were computed for the estimated washout rate at 4 hours pi derived from 
the 1-, 2- and 3-hour scan (12). 
 Statistical analysis was performed using SPSS software (Version 22.0, 
SPSS IBM Corp., Armonk, New York, USA). A two-sided P-value of <0.05 
was considered statistically significant.
Results
Patients
The clinical characteristics of the patients are depicted in Table 1. Of the study 
population 2 patients (4%) were excluded since 1 patient withdrew his informed 
consent after the examination and 1 patient did not have an acquisition 4 hours 
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pi due to logistic reasons. The final population comprised 48 patients with HF of 
which 77% (37/48) were male with a mean age of 64±9 years. 
Planar 123I-MIBG image analysis
Results of the planar 123I-MIBG images of the early and late scans at 1, 2, 3 and 
4 hours pi and the actual acquisition time-intervals after 123I-MIBG injection 
are shown in Table 2. In the total study population the late H/M ratio decreased 
over time and was 1.60±0.18 at 1 hour, 1.56±0.19 at 2 hours pi and 1.54±0.19 
at 3 hours pi and differed all significantly from the late H/M ratio of 1.52±0.20 
at 4 hours pi (P <0.001, P<0.001 and P=0.02, respectively). The washout rate 
increased over time from 11±11 at 1 hour pi, 21±16 at 2 hours pi, 28±17 at 3 
hours pi to 34±17 at 4 hours pi. The washout rate at 1, 2 and 3 hours were all 
significantly different from the washout rate at 4 hours pi (all P<0.001).
Estimated and actual 123I-MIBG parameters
The estimated mean cardiac and mediastinal counts per pixel for 4 hours pi 
determined from the cardiac and mediastinal counts at 1, 2 and 3 hours pi are 
depicted in Table 3.
 The Pearson’s correlation was excellent between the estimated cardiac 
counts at 4 hours pi determined from the late acquisitions at 1, 2 and 3 hours 
pi and the actual cardiac counts at 4 hours pi (r=0.995, r=0.996 and r=0.996; 
all P<0.001, Figure 1). In the Bland-Altman analysis there was a bias of -11.4 
(95%CI-30.4;7.6), -5.8 (95%CI-15.8;4.2) and -2.5 (95%CI -9.0;4.0) between 
the actual and estimated cardiac counts at 4 hours pi calculated from the late 
scan at 1, 2 and 3 hours pi, respectively.
 Depicted in Figure 2, the estimated mediastinal counts at 4 hours pi 
determined from the late acquisitions at 1, 2 and 3 hours pi and the actual 
mediastinal counts at 4 hours pi demonstrated excellent Pearson’s correlations 
(r=0.994, r=0.994, r=0.995, respectively, all P<0.001). In the Bland-Altman 
analysis there was a bias of -6.1 (95%CI-16.2;4.1), -3.7 (95%CI-10.1;2.7) and 
-1.9 (95%CI -6.5;2.7) between the actual and estimated mediastinal counts at 
4 hours pi calculated from the late scan at 1, 2 and 3 hours pi, respectively.
Estimated and actual late H/M ratio
The mean estimated late H/M ratio at 4 hours pi derived from the counts at 1, 
2 and 3 hour pi were 1.58±0.19, 1.52±0.20 and 1.50±0.20, respectively. Com-
pared with the actual late H/M ratio at 4 hours pi (1.52±0.20) the differences with 
the estimated late H/M ratio at 4 hours pi from 1, 2 and 3 hours pi were 0.06, 
0.002 and -0.015, respectively (P<0.001, P=0.84 and P=0.06, respectively).
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Table 1. Characteristics of the study population
Patient characteristic Total group
(N=48)
Age (years) 64±9
Sex (male) 37 (77%)
Height (cm) 176 ± 9
Weight (kg) 85 ± 14
Cardiovascular risk factors
Diabetes mellitus* 7 (15%)
Obesity, BMI ≥ 30 (kg/m²) 7 (15%)
Family history of CVD† 19 (40%)
Hypercholesterolemia‡ 26 (54%)
Hypertension§ 29 (60%)
Current smoker 8 (17%)
Ejection fraction (%) 31 (IQr 25-37)
CRT-D / ICD therapy 31 (65%)
Medication
ACE-/AT II-inhibitor 44 (92%)
Beta blocker 39 (81%)
Calcium antagonist 3 (6%)
Lipid-lowering agent 34 (71%)
Antiplatelet/OAC therapy 41 (85%)
Diuretics 37 (77%)
oral antidiabetics 8 (17%)
Insulin 3 (6%)
Nitrates 3 (6%)





NT-proBNP (pg/L) 811 (IQr 419-1265)
 
ACE: angiotensin converting enzyme inhibitor; AT-II: angiotensin-II; BMI: Body Mass Index, CRT-D: 
cardiac resynchronization therapy defibrillator; CVD: cardiovascular disease; HF: heart failure; ICD: 
implantable cardioverter defibrillator; IQR: interquartile range; NT-proBNP: N-terminal pro-brain 
natriuretic peptide; NYHA: New York Heart Association; OAC: oral anticoagulant.
* Self-reported history of Diabetes Mellitus and/or treatment with antidiabetics, 
† presence of coronary artery disease in first-degree family members at age <55 years in men and <65 
years in women, 
‡ Self-reported history of hypercholesterolemia and/or treatment with lipid-lowering drugs, 
§ Self-reported history of hypertension and/or use of antihypertensive medication, or a systolic blood 
pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg.
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Table 2. 123I-MIBG scintigraphy results
MIBG scintigraphy Total group
(N=48)
Actual acquisition time after injection (in minutes)
Early scan 15 (IQr 13-19)
Late scan 1H 66 (IQr 62-71)
Late scan 2H 118 (IQr 115-122)
Late scan 3H 177 (IQr 176-182)
Late scan 4H 239 (IQr 236-245)
Heart/mediastinum ratio
Early scan 1.60±0.15
Late scan 1H 1.60±0.18
Late scan 2H 1.56±0.19
Late scan 3H 1.54±0.19
Late scan 4H 1.52±0.20
Washout ratea (%)
Late scan 1H 11±11
Late scan 2H 21±16
Late scan 3H 28±17
Late scan 4H 34±17
H: hour(s); HF: heart failure; IQR: interquartile range. 
a Washout rate with 123I-decay and background correction
Estimated 
counts
at 4 hours pi
Actual counts
at 4 hours pi
Difference between 
estimated and actual 
counts at 4 hours pi
P-value
Cardiac counts  
per pixel
H1 55±39 44±30 11(95%CI 9;14) <0.001
H2 50±34 44±30 6 (95%CI 4;7) <0.001
H3 47±32 44±30 2 (95%CI 1;3) <0.001
Mediastinum  
counts per pixel
M1 35±23 29±19 6 (95%CI 5;8) <0.001
M2 33±21 29±19 4 (95%CI 3;5) <0.001
M3 31±20 29±19 2 (95%CI 1;3) <0.001
H1: mean heart counts per pixel from 1 hour pi, H2: mean heart counts per pixel from 2 hour pi, H3: mean 
heart counts per pixel from 3 hour pi, M1 mean mediastinal counts per pixel from 1 hour pi, M2 mean 
mediastinal counts per pixel from 2 hour pi, M3 mean mediastinal counts per pixel from 3 hour pi.
Table 3. Actual and estimated cardiac and mediastinal counts per pixel at 4 hours 
calculated from 1, 2 and 3 hours pi.
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Figure 1. Pearson’s correlation and Bland-Altman analysis of the relationship 
between the actual and estimated cardiac counts at 4 hours pi from the cardiac counts 
at 1, 2 and 3 hours pi. 
Figure 2. Pearson’s correlation and Bland-Altman analysis of the relation-
ship between the actual and estimated mediastinal counts at 4 hours pi from the 
 mediastinal counts at 1, 2 and 3 hours pi. 
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Figure 3. Pearson’s correlation and Bland-Altman analysis of the relationship 
between the actual and estimated heart-to-mediastinum ratio at 4 hours pi from the 
cardiac and mediastinal counts at 1, 2 and 3 hours pi. 
Figure 4. Pearson’s correlation and Bland-Altman analysis of the relationship 
between the actual washout rate at 4 hours and estimated washout rate at 4 hours 
from the late acquisitions at 1, 2 and 3 hours pi.
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There was a positive correlation between the actual late H/M ratio at 4 hours 
pi and estimated late H/M ratio at 4 hours pi derived from the scans at 1, 2 
and 3 hours pi (Figure 3). The Pearson’s Correlation was excellent between 
the estimated late H/M ratio at 4 hours pi derived from 1, 2 and 3 hours pi 
and the actual late H/M ratio at 4 hours pi, r= 0.914, r=0.950 and r=0.965, 
respectively (all P<0.001). In the Bland-Altman analysis there was a bias 
of -0.059 (95%CI-0.216;0.098), -0.0018 (95%CI-0.124;0.121) and 0.015 
(95%CI-0.087;0.117) between the actual and estimated late H/M ratio at 4 
hours pi calculated from the late scan at 1, 2 and 3 hours pi, respectively. No 
correlation existed between the difference and the mean of the actual and 
estimated late H/M ratios obtained from 1, 2 and 3 hours pi.
 Of the 34 patients with an actual late H/M ratio < 1.6, 25 (74%), 29 (85%) 
and 31 (91%) patients had an estimated late H/M ratio at 4 hours pi < 1.6 
derived from 1, 2 and 3 hours pi, respectively. The sensitivity and specific-
ity for the actual late H/M ratio < 1.6 for the estimated late H/M ratio at 4 
hours pi derived from the 1-hour scan were 74% and 93%, respectively. For 
the estimated late H/M ratio at 4 hours pi derived from 2 and 3 hours pi the 
sensitivity and specificity were 85% and 93%, 91% and 86%, respectively.
Estimated and actual washout rate
The mean estimated washout rate (with background and 123I-decay correc-
tion) at 4 hours pi calculated from the acquisitions at 1 and 2 hours pi differed 
significantly from the actual washout rate at 4 hours pi, 12±15 and 25±19 
in comparison with 34±17 (both P<0.001). The mean estimated washout 
rate at 4 hours pi derived from 3 hours pi did not differ significantly with the 
actual washout rate at 4 hours pi, 32±19 and 34±17, respectively (P=0.22). 
There was a positive correlation between the actual washout rate at 4 hours 
pi and the estimated washout rate at 4 hours pi derived from 1, 2 and 3 hours 
pi (Figure 4). The Pearson’s Correlation of the actual washout rate at 4 hours 
and the estimated washout rate at 4 hours obtained from the scan at 1 hour 
pi was strong (r=0.736) and excellent for the estimated washout rate at 4 
hours from the 2- and 3-hour pi scan (r=0.896 and r=0.846, respectively). 
In the Bland-Altman analysis for the actual and estimated washout rate there 
was a bias of 22.7 (95%CI 0;45), 9.2 (95%CI -7.5;25.9) and 1.8 (95%CI 
-18.2;21.8) between the actual and estimated washout rate at 4 hours pi 
calculated from cardiac and mediastinum counts at 1, 2 and 3 hours pi. No 
correlation existed between the difference and the mean of the actual washout 
rate at 4 hours pi and the estimated washout rate at 4 hours pi derived from 
1,2 and 3 hours pi.
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Of the 34 patients with an actual late H/M ratio < 1.6, 25 (74%), 29 (85%) 
and 31 (91%) patients had an estimated late H/M ratio at 4 hours pi < 1.6 
derived from 1, 2 and 3 hours pi, respectively. The sensitivity and specificity 
for the actual late H/M ratio < 1.6 for the estimated late H/M ratio at 4 hours 
pi derived from the 1-hour scan were 74% and 93%, respectively. For the 
estimated late H/M ratio at 4 hours pi derived from 2 and 3 hours pi the sensi-
tivity and specificity were 85% and 93%, 91% and 86%, respectively.
Discussion
The present study demonstrated that by using the direct comparison method 
for cardiac 123I-MIBG imaging, it is possible to provide an accurate estima-
tion of the actual late H/M ratio and washout rate at 4 hours pi, derived from 
acquisitions at 2 and 3 hours pi.
The timing to acquire late planar myocardial 123I-MIBG images is still 4 
hours pi.11 However, several studies calculated the late H/M ratio and / or 
washout rate from acquisitions at 3 hours pi.7 Recently, we demonstrated in 
patients with HF only small differences (≤ 0.05) between the late H/M ratio 
determined at 2 and 3 hours pi compared with the late H/M ratio at 4 hours 
pi.9 In addition, in the present study the late H/M ratio at 4 hours pi could 
be accurately estimated from the ratio at 2- and 3-hour scan pi by means of 
a linear model, in contrast to the 1-hour scan pi. In addition, the sensitivity 
and specificity of the estimated late H/M ratio derived from 2 and 3 hours 
pi to determine the actual late H/M ratio at 4 hours pi <1.6 were high. These 
findings may allow a more time-efficient cardiac 123I-MIBG-imaging protocol. 
The washout rate between the early and several late acquisition times increased 
from 11±11 between 15 minutes and 1 hour pi to 34±17 between 15 minutes 
and 4 hours pi. This increase in washout rate over time was also observed 
by Henderson et al. This study demonstrated in patients with severe dilated 
cardiomyopathy that the global myocardial 123I-MIBG concentration reduced 
from 117±41 at 15 minutes to 85±35 and 52±14 at 85 and 240 minutes, 
respectively.13
 To correct for the increasing washout rate over time Okuda et al. developed 
a linear model using the early and 3-hour planar image which makes compar-
ison of the washout rate determined at 3 hours pi with 4 hours pi possible.10 
In that study, total population (n=96) was randomly divided into two groups: 
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one group for the creation of a linear regression model between the heart and 
mediastinal counts at 3 and 4 hours pi and group 2 for the clinical validation. 
The results demonstrated that the estimated washout rate at 4 hours pi by the 
linear regression model determined from the early and 3-hour pi scan did not 
differ from the actual washout rate at 4 hours pi.
 Similar results were detected in present HF cohort between the actual and 
estimated washout rate at 4 hours pi from the 3-hour scan pi. In addition, the 
sensitivity and specificity for the threshold of ≥ 27% of the actual washout rate 
at 4 hours pi were high for the estimated washout rate at 4 hours pi derived 
from 3 hours pi. Only small differences were found between the actual and 
estimated washout rate at 4 hours pi from the 2-hour scan pi. Although the 
specificity for the threshold of ≥ 27% of the actual washout rate at 4 hours pi 
was high (100%) for the estimated washout rate at 4 hours pi derived from 
2 hours pi, the sensitivity was relatively low (63%). This means that patients 
with an estimated washout rate ≥27% at 4 hours derived from the 2-hour scan 
do not need a second scan at 4 hours pi. Within present study population, 
22/48 (42%) patients could be excluded for a second scan at 4 hours pi.
 A large difference was observed between the actual and estimated washout 
rate at 4 hours pi derived from the 1-hour pi scan. Therefore, the formula seems 
not useful for the estimation of the washout rate from the 1-hour pi scan.
In the created formula for the cardiac and mediastinal counts at the acquisi-
tion at 1, 2 and 3 hours pi to estimate the counts at 4 hours pi, it is assumed 
that the clearance of 123I-MIBG is linear over time and that extra-neuronal 
123I-MIBG uptake plays no pivotal role. This is in line with data showing that 
123I-MIBG clearance has a clear distinction between an early more acceler-
ated phase and a slower linear phase.14 These findings are corroborated by an 
earlier study by Morozumi et al., which demonstrated in 15 healthy subjects 
that the mean counts per pixel in the cardiac and upper mediastinal ROI was 
linear over time.15 In addition, Dae et al. concluded that non-neuronal uptake 
does not seem to be operational in humans since there was no 123I-MIBG 
uptake on early and late planar images present in post-cardiac transplant 
patients.16 However, in the present study there was an overestimation of the 
estimated cardiac and mediastinal counts at 4 hours from the 1-hour scan 
pi which resulted in a lower estimated washout rate and a significant higher 
mean late H/M ratio compared to the actual numbers. Possibly, the cardiac 
123I-MIBG uptake at 1 hour pi and in some extent at 2 hour pi is affected by 
attenuation of the liver, which is more present at the early hours pi since the 
clearance time of 123I-MIBG in the liver is shorter.15,17
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Limitations
Since there were differences between the actual and the estimated washout 
rate at 4 hours pi calculated from the scan 2 hours pi, implementation of the 
late scan at 2 hours pi to estimate the washout rate at 4 hours pi needs to be 
evaluated in larger cohorts.
Conclusion
By using the direct comparison method for cardiac 123I-MIBG imaging it is 
possible to accurately estimate the actual late H/M ratio and washout rate 
at 4 hours pi, derived from acquisitions at 3 hours pi. This will allow a more 
time efficient protocol, increase the clinical implementation in patients with 
HF and ease comparison of 123I-MIBG parameters from acquisitions from 
3 with 4 hours pi. The acquisition at 2 hours pi should only be performed in 
exceptional cases when clinically necessary because of the existing difference 
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The aim of the studies presented in this thesis was to evaluate the clinical 
value of different imaging techniques and invasive strategies in the prevention, 
management and prognosis of ischemic heart disease. In more detail, Part I 
explored the role of coronary computed tomography angiography (CTA) in 
the early detection of coronary artery disease (CAD), while Part II explored 
the most effective revascularization strategy in patients with ST-elevation 
myocardial infarction (STEMI) and multi-vessel CAD. Part III evaluated the 
clinical relevance of 2-dimensional strain echocardiography and 123Iodine-
metaiodobenzylguanidine (123I-MIBG) scintigraphy in patients with ischemic 
heart disease and ways to optimize the use of these non-invasive imaging 
techniques.
PArT I: DETECTIoN oF ATHEroSCLEroSIS AND  
VArIATIoNS IN CoroNAry ANAToMy 
Chapter 2 of the thesis used coronary CTA in patients at high-risk with 
diabetes mellitus (DM) to detect or exclude CAD. The coronary CTAs of 425 
clinically referred patients at high-risk with DM without chest-pain syndrome 
or a history of cardiac disease were evaluated, revealing that 73% had some 
degree of CAD defined as any stenosis ≥ 30%, of whom 48% had obstructive 
CAD, defined as any stenosis ≥ 50%. But, 27% had no CAD, and 52% of the 
patients with any CAD had non-obstructive CAD. Moreover, the present 
study demonstrated that the number and presence of other traditional cardio-
vascular (CV) risk factors (i.e. hypercholesterolemia, hypertension, obesity, 
family history of CV disease and current smoker) were not associated with 
a higher frequency of CAD, except for hypertension. Accordingly, coronary 
CTA may be used in patients at high-risk with DM to determine who needs 
aspirin as primary prevention of CAD events.
 Coronary CTAs performed to determine the presence of CAD frequently 
show an intramural course of a coronary artery, defined as any epicardial 
segment that runs intramurally through the myocardium which completely 
surrounds the vessel. Chapter 3 examined whether the presence of an 
intramural course of a coronary artery in patients without obstructive CAD 
was associated with worse outcomes. Evaluating the data of 947 patients with 
a low-to-intermediate pre-test probability and who did not have obstructive 
CAD on coronary CTA results demonstrated that in 22% of the patients their 
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coronary CTA showed an intramural course of a coronary artery. During a 
median follow-up of 4.9 years (IQR 3.2 to 6.9 years) there was a low event-
rate of 43 events (4.5%); with 13 (1.4%) patients being hospitalized due to 
unstable angina, 7 (0.7%) patients suffering a non-fatal myocardial infarction, 
while 23 (2.4%) patients died. No differences occurred in the event rates 
between patients with and those without an intramural course of the coro-
nary artery. This suggests that no therapeutic adjustments are warranted for 
patients with an intramural course of a coronary artery on coronary CTA. 
PArT II: MANAGEMENT oF ACuTE MyoCArDIAL 
INFArCTIoN 
There is ongoing debate about the most effective invasive treatment for patients 
presenting with STEMI and multi-vessel CAD. The purpose of chapter 4 
was to assess whether there are any differences in the short- and the long-term 
all-cause mortality rates in patients with complete or incomplete revasculariza-
tion. Evaluating the endpoint all-cause mortality in 518 patients with a first 
STEMI and multi-vessel CAD, 31 mortalities (6%; of which 28 during index 
hospitalisation) were recorded in the first 30 days and 98 mortalities (19%) 
during long-term follow-up (with a median of 6.7 years). The group of pa-
tients with incomplete revascularisation showed a higher mortality rate during 
both periods than those with complete revascularization. However, after 
correcting for relevant clinical variables, incomplete revascularisation was no 
longer independently associated with all-cause mortality during either period. 
This observational study supports findings of previous reports (with shorter 
follow-up), suggesting that complete revascularization has no benefits over 
incomplete revascularization in patients with first STEMI and multi-vessel 
CAD in terms of all-cause mortality.
To find out whether any subgroups with STEMI and multi-vessel CAD benefit 
(more) from complete rather than incomplete revascularization Chapter 5 
investigated gender-specific differences in all-cause mortality. The study 
popu lation consisted of 375 men and 115 women with a first STEMI and 
multi-vessel CAD without cardiogenic shock at admission or left main (LM) 
stenosis. Within the first 30 days, the mortality rates for men and women 
having received an incomplete revascularization were higher than the rates 
recorded for men and women having received a complete revascularization. 
However, this association disappeared after correction for baseline character-
192
chaPter 11
istics and angiographic features. Of the 30-day survivors, men with incomplete 
revascularization had a 3.1-fold higher mortality risk during the 5-year follow-
up than men with complete revascularization. In contrast, women who survived 
the first 30 days had similar mortality risk as men with complete revasculari-
zation independently of (incomplete or complete) revascularization strategy.
PArT II I :  ProGNoSIS IN ISCHEMIC HEArT DISEASE
Since the introduction of primary percutaneous coronary intervention (PCI), 
survival of acute myocardial infarction has risen greatly, thereby inevitably 
increasing the number of patients with chronic ischemic heart disease. One 
of the main predictors of a poor prognosis after STEMI is the infarct size. 
Although the echocardiographic parameter of left ventricular global longitudi-
nal strain (LV GLS) correlates well with infarct size, this relationship is influ-
enced by various factors. Chapter 6 investigated how myocardial ischemia 
modulates the correlation between LV GLS and infarct size as determined 
with single-photon emission computed tomography (SPECT) myocardial 
perfusion imaging (MPI) in 1,128 patients with a first STEMI treated with 
primary PCI. Similar to other studies, a moderate correlation between the 
LV GLS and infarct size on SPECT MPI was observed in the total popula-
tion (r=0.58, P<0.001). This correlation was weakened by the presence of 
ischaemia; the correlation between LV GLS and infarct size on SPECT MPI 
was r=0.66 (P<0.001) in the group of patients without ischaemia, whereas 
in patients with mild or moderate to severe ischemia, the correlations were 
reduced to r=0.56 and r=0.38, respectively (both P<0.001). Even after adjust-
ment for known confounders, residual ischemia remained independently 
associated with more impaired LV GLS. Accordingly, this study demonstrated 
that the correlation between LV GLS and infarct size as assessed with SPECT 
MPI is not straight forward, particularly in the presence of residual ischemia.
 Another main predictor of worse prognosis is denervated myocardium, 
which can be visualized by 123I-MIBG scintigraphy. Chapter 7 explored 
recent trends in 123I-MIBG SPECT imaging in patients with heart failure. 
This review provides evidence of an increased use of 123I-MIBG SPECT 
imaging in the clinical management of this patient population. In addition to 
planar imaging, one of the main advantages of 123I-MIBG SPECT imaging is 
that it also provides information about regional myocardial sympathetic inner-
vation, which is of particular interest in patients with ischemic heart disease.
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Since cardiac denervation not only occurs in patients with heart failure, 
123I-MIBG imaging could also be of relevance in the evaluation of other 
cardiac diseases. Chapter 8 provides an overview of the potential clinical 
indications for 123I-MIBG imaging to evaluate the cardiac sympathetic 
activity beyond heart failure. The technique appears potentially relevant in 
the following clinical indications: 1) after heart transplantation since complete 
denervation of the allograft occurs after heart transplantation, 2) in case of 
arrhythmias, and 3) in amyloidosis. In addition, 123I-MIBG SPECT imaging 
provides additive information for the evaluation of patients with cardiovascu-
lar risk factors such as DM, (resistant) hypertension, and obesity.
 However, before above-mentioned indications should be included in car-
diac guidelines, 123I-MIBG imaging first needs to be included in the current 
heart failure guidelines. Given that in this group the success of the imaging 
technique has been proven, with results demonstrating in the past that heart- 
failure patients with a low late heart-to-mediastinum (H/M) ratio and/or an 
increased washout rate are at increased risk of arrhythmic events and cardiac 
death. One of the great disadvantages of 123I-MIBG imaging is the long waiting 
period (up to 4 hours) between the two necessary scans. Focusing on ways 
to optimize the clinical usefulness of the technique, Chapter 9 investigated 
whether performing the late cardiac 123I-MIBG scan earlier than 4 hours 
post-injection has a relevant impact on the late H/M ratio. To this end, 49 
patients with heart failure were scanned at 15 minutes (early scan) and at 1, 2, 
3 and 4 hours (late scans) after an 123I-MIBG injection. The results demon-
strated that in the scans performed between 2 and 4 hours post-injection 
variations did not lead to clinically significant changes in the late H/M ratios. 
Earlier acquisition times therefore seem to be justified, clearing the way for 
more patient-friendly and time-efficient cardiac 123I-MIBG imaging protocols. 
 The implementation of 123I-MIBG imaging in clinical and study settings 
is also limited due to the lack of standardization, with large differences in 
the acquisition times of the late scans complicating the comparison of out-
comes. To overcome this problem, Chapter 10 evaluated a method in which 
the washout rates and late H/M ratios obtained 1 to 3 hours post-injection 
were compared with the measurements conducted 4 hours post-injection. 
The actual and estimated 4-hour washout rates and late H/M ratios derived 
from the counts made 1 hour post-injection demonstrated large differences. 
Whereas the estimated late 4-hour H/M ratios derived from the 2- and 
3-hour post-injection counts did not differ from the actual ratios after 4 
hours (P=0.84 and P=0.06). The actual and estimated 4-hour post-injection 
washout rates derived from the 3-hour counts also did not differ significantly 
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from each other (P=0.22). However, the mean estimated 4-hour washout 
rates derived from the 2-hour acquisitions did show a significant difference 
compared to the actual 4-hour washout rates (25±19 vs. 34±17, P<0.001). 
Therefore, the direct comparison method enables accurate estimation of the 
actual late H/M ratio and washout rate at 4 hours post-injection derived from 
the acquisitions at 3 hours post-injection. Because of the marked difference 
between the actual and estimated washout rates, estimations based on acqui-
sitions made 2 hours post-injection should only be performed in exceptional 
cases, where the clinical relevance is high. 
Conclusions and future perspectives
The diversity in medicine and the scope of both non-invasive and invasive 
diagnostic instruments and treatments for ischemic heart disease have grown 
exponentially the last few decades. The objective of this thesis was to establish 
the value of different imaging techniques and treatments targeting different 
stages of ischemic heart disease. The results reported have demonstrated that 
multimodality imaging is of high relevance in patients with ischemic heart 
disease, facilitating the decision-making process in different groups of patients 
and allowing medical and (non-)invasive treatments to be better tailored to 
individual cases from prevention to treatment while potentially improving 
prognoses. 
Part I
If coronary CTA shows evidence of atherosclerosis in patients at high-risk with 
DM this may support the decision to start preventive treatment with aspirin. 
Whereas starting diabetic patients without atherosclerosis on aspirin seems 
unnecessary, especially since its use is not without hazards. However, further 
work is needed to evaluate whether not prescribing aspirin to this latter group 
is indeed justified. Additionally, more information is needed to establish at 
which age a first coronary CTA scan is opportune and whether or not, and if 
so, at which intervals scans should be repeated given that atherosclerosis is an 
ongoing process.
 A common finding on coronary CTA is the presence of an intramural 
course of a coronary artery. However, since in patients with this anomaly 
event rates are low and similar to those found in patients without the anomaly, 
management and treatment do not appear to warrant adaptation. To date, the 
importance of this coronary anomaly appears to be overestimated, with even 
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chirurgical correction being performed as a therapeutic solution. Still, future 
research is needed. Perhaps that only patients with an intramural course of a 
coronary artery on coronary CTA with systolic compression on invasive coro-
nary angiography need (additional) treatment (which is only in the minority 
of the patients the case). 
Part II
Patients with first STEMI and multi-vessel CAD as evidenced by the initial 
angiogram did not benefit from complete revascularization in comparison 
with incomplete revascularization in terms of all-cause mortality. This is of 
importance, since more invasive interventions are not without hazards (e.g. 
procedure complications or stent thrombosis), while costs are relatively high. 
On the other hand, landmark trials did show that the risk of adverse cardiovas-
cular events in patients having received immediate complete revascularisation 
was reduced relative to that reported for peers having undergone incomplete 
revascularisation. It should be noted that the largest differences in these trials 
between patients with and without complete revascularization occurred in 
PCI frequency. 
 Sub-analyses in this thesis demonstrated that men who survived the first 
30 days on the long run benefit from complete revascularization in comparison 
with incomplete revascularization independent of baseline characteristics.  
In contrast, women did not demonstrate any difference between incomplete 
and complete revascularization in comparison with men with complete revascu-
larization. It would be of interest to conduct a larger-scale investigation into 
the need of a gender-tailored revascularization strategy for STEMI survivors 
with multi-vessel CAD. 
Part III
The correlation between LV GLS and myocardial infarct size assessed with 
SPECT MPI is not straight forward. Results demonstrated that the extent of 
ischemia influenced the correlation of LV GLS and infarct size on SPECT 
MPI: the group of patients with residual myocardial ischemia showed a weaker 
correlation between LV GLS and infarct size compared to patients without 
ischemia. This finding is of importance for a correct interpretation of LV GLS 
values. To increase the clinical usefulness and reliability of LV GLS it is of 
importance to fully elucidate which factors influence this parameter. 
 The results reported on in this thesis not only underline the value of eva-
luating the presence of denervation of the heart with 123I-MIBG scintigraphy 
in patients with ischemic heart disease, they also underscore the technique’s 
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relevance for other clinical indications. Therefore, it is of importance that 
implementation and standardization of 123I-MIBG imaging in current 
guidelines will occur. Hopefully this process is eased with present evidence 
that shorter waiting periods are justified and comparison of results between 
different acquisition times is possible with a direct comparison method.










Onze kennis over ischemische hartziekten is de laatste decennia exponentieel 
gegroeid mede door de ontwikkeling en uitbreiding van verschillende diag-
nostische technieken en behandelmogelijkheden. Helaas blijft ondanks deze 
ontwikkelingen ischemisch hartlijden de nummer 1 doodsoorzaak, verant-
woordelijk voor 1 op de 3 sterfgevallen wereldwijd. 
 In dit proefschrift worden diverse aspecten van een aantal beeldvormings-
technieken en invasieve-strategieën besproken ter preventie, behandeling 
en prognose van ischemische hartziekten. Deel I evalueert de rol van een 
computertomografie (CT) coronairangiografie voor de vroege detectie van 
coronairatherosclerose. Deel II onderzoekt wat de beste invasieve-strategie 
is bij patiënten met een ST-segment elevatie acuut myocardinfarct (STEMI) 
met meervatslijden. En Deel III onderzoekt de klinische waarden van 
2-dimensionale strain echocardiografie en 123Iodine-metaiodobenzylguani-
dine (123I-MIBG) scintigrafie in patiënten met ischemische hartziekten en 
onderzoekt manieren om het gebruik van deze non-invasieve beeldvormings-
technieken te optimaliseren.
DEEL I: DETECTIE VAN ATHEroSCLEroSE EN 
 VArIATIES IN CoroNAIr ANAToMIE
Hoofdstuk 2 van dit proefschrift onderzoekt de prevalentie van coronairlijden 
op een CT-scan van de coronairen in patiënten met diabetes mellitus (DM) 
en een sterk verhoogd cardiovasculair risicoprofiel. Hiertoe zijn 425 diabetes 
patiënten geïncludeerd met een sterk verhoogd cardiovasculair risicoprofiel. 
Deze patiënten waren verwezen voor een CT-scan van de coronairen zonder 
dat ze klachten hadden van pijn op de borst of een voorgeschiedenis van coro-
nairlijden. Van de totale onderzoeksgroep had 73% enige vorm van coronair-
lijden dat was gedefinieerd als een stenose in een van de coronairen van ≥30%, 
hiervan had 48% obstructief coronairlijden (≥50% stenose). Verder bleek dat 
het type of aantal traditionele cardiovasculaire risicofactoren (bestaande uit 
hypertensie, hypercholesterolemie, roken, overgewicht en een positieve fami-
lieanamnese voor hart- en vaatziekten ) niet van invloed was op de prevalentie 
van coronairlijden, behoudens de aanwezigheid van hypertensie. Hierbij was 
de prevalentie hoger bij patienten met hypertensie in vergelijking tot de andere 
risicofactoren. Bovenstaande resultaten laten zien dat het uitvoeren van een 
CT-scan van de coronairen van toegevoegde waarde kan zijn naast de aanwe-
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zigheid van traditionele risicofactoren in de besluitvorming voor het wel of 
niet starten van acetylsalicylzuur voor de primaire preventie van hartziekten in 
patiënten met DM. Het starten van een bloedverdunner bij patiënten zonder 
coronairlijden lijkt niet zinvol.
 Frequent wordt er op een CT-scan van de coronairen een intramyocardiaal 
beloop (van een gedeelte) van de coronair gezien. Onduidelijk is of de aanwezig -
heid van een intramyocardiaal beloop van de coronair therapeutische conse-
quenties zou moeten hebben. Hoofdstuk 3 onderzoekt of de aanwezig heid 
van een intramyocardiaal beloop van een van de coronairen geassocieerd is 
met een slechtere prognose. In de onderzoekspopulatie bestaande uit patiënten 
zonder obstructief coronairlijden op de CT-scan had 22% een intramyocardiaal 
beloop van de coronair op CT-scan. Gedurende een langdurige follow-up 
(mediaan 4.9 jaren) was het aantal cardiovasculaire events bestaande uit 
ziekenhuisopname in verband met instabiele angina pectoris, een niet fataal 
myocardinfarct en overlijden laag (43 events; 4.5%). Hierbij werd er geen 
significant verschil gezien tussen de patiënten met en zonder een intramyo-
cardiaal beloop van de coronairen. Deze resultaten suggereren dat er geen 
therapeutische consequenties noodzakelijk zijn bij patiënten met een intra-
myocardiaal beloop van de coronair op een CT scan. 
DEEL II: BEHANDELING VAN EEN ACuuT  
MyoCArD INFArCT
In patiënten met een STEMI is het verkrijgen van een spoed coronairangio-
gram en aansluitend revascularisatie van het aangedane vat de gouden stan-
daard. Het initiële angiogram toont in meer dan de helft van deze patiënten 
meervats coronairlijden. Momenteel zijn er veel discussies over de beste 
invasieve-strategie (incomplete dan wel complete revascularisatie) met 
betrek king tot de vernauwing in het vat dat niet gerelateerd is aan het acute 
myocardinfarct. In hoofdstuk 4 wordt een betere overleving gezien in de 
patiëntengroep met complete revascularisatie in vergelijking met de patiënten 
met een incomplete revascularisatie op zowel korte en lange termijn. Echter, 
na correctie voor klinische relevantie variabelen, werd er geen verschil meer 
gezien in overleving op zowel korte- als lange termijn. Deze resultaten komen 
overheen met eerdere observationele studies. Dit suggereert dat er geen voor-
deel in overleving wordt bereikt door complete revascularisatie in patiënten 
met een STEMI en meervatslijden. 
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 Vrouwen met een STEMI hebben in vergelijking tot mannen een hogere 
kans op overlijden. Dit wordt onder andere veroorzaakt doordat zij vaak ouder 
zijn bij presentatie en meer co-morbiditeit hebben. Onbekend is echter of 
er man-vrouw verschillen zijn in overleving tussen verschillende invasieve-
strate gieën. Hoofdstuk 5 kijkt of er mogelijk man-vrouw verschillen zijn 
in overleving tussen patiënten met complete revascularisatie en incomplete 
revascularisatie op korte en lange termijn. In de onderzoeksgroep van 490 
patiënten, van wie 115 vrouwen, werd er na correctie voor patiëntkarakteris-
tieken en angiografische kenmerken binnen 30 dagen geen verschil gevonden 
tussen mannen en vrouwen in overleving tussen incomplete en complete 
revasculairsatie. Gedurende een follow-up van 5 jaar hadden mannen, die de 
eerste 30 dagen hadden overleefd, met incomplete revascularisatie een 3 maal 
hoger risico op overlijden dan mannen met complete revascularisatie. Daaren-
tegen hadden vrouwen, die de eerste 30 dagen hadden overleefd, een zelfde 
kans op overleving onafhankelijk van de revascularisatie-strategie. 
DEEL II I :  ProGNoSE VAN ISCHEMISCHE  
HArTzIEKTEN
Sinds de introductie van percutane coronaire interventies is de prognose van 
patiënten met een hartinfarct aanzienlijk verbeterd. Dit heeft geleid tot een 
toename van het aantal patiënten met chronisch ischemisch hartlijden. Een 
van de belangrijkste voorspellers voor een slechte prognose is de grootte van 
het hartinfarct. De globale longitudinale strain van de linker ventrikel (LV 
GLS) is een goede echocardiografische parameter voor de infarct grootte.
Deze waarde wordt echter door verschillende factoren beïnvloed. Hoofdstuk 6 
onderzoekt of en hoe de aanwezigheid van ischemie de correlatie beïnvloed 
van LV GLS en infarctgrootte vastgesteld met een myocard perfusie scinti-
grafie in patiënten met een eerste STEMI behandeld met primaire percutane 
coronaire interventie (PCI). Evenals in eerdere studies werd er in de totale 
studiepopulatie bestaande uit 1.128 patiënten een redelijke correlatie tussen 
LV GLS en infarctgrootte gezien. Deze correlatie werd verzwakt door de 
aanwezigheid van ischemie: in de groep van patiënten met een groot gebied 
van ischemie was de correlatie een stuk zwakker (r=0.38, P<0.001) dan in de 
groep van patiënten zonder ischemie (r= 0.66; P<0.001). Dit verschil bleef 
bestaan na correctie voor reeds bekende factoren die de LV GLS meting 




en infarctgrootte niet eenvoudig is en mede wordt beïnvloed door de aan- dan 
wel afwezigheid van ischemie. 
 Een andere belangrijke voorspeller voor een slechte prognose in patiënten 
met een hartinfarct is de verminderde sympathisch neuronale opname in het 
myocard. Dit kan worden gevisualiseerd met een 123Iodine gelabeld norepi-
nephrine analoog 123I-MIBG. Gebruikelijk is om de verminderde neuronale 
opname zichtbaar te maken met planaire opnames en weer te geven als hart- 
mediastinale ratio (H/M ratio). Ook kan de cardiale uitwas tussen de vroege en 
late planaire opname worden berekend, de zogenaamde ‘washout ratio’.
 Hoofdstuk 7 demonstreert in een review de trends in het gebruik van 
beeldvorming met 123I-MIBG in patiënten met hartfalen. De review toont aan 
dat er een toename is in het gebruik van 123I-MIBG SPECT hierbij wordt in 
tegenstelling tot planaire opnames ook informatie verkregen over regionale 
verschillen in innervatie. Cardiale denervatie wordt niet alleen gezien in 
patiënten met hartfalen. Hierdoor wordt deze beeldvormingstechniek ook 
steeds meer ingezet bij andere hartziekten. Hoofstuk 8 geeft een overzicht 
van mogelijk toekomstige indicaties voor het gebruik van beeldvorming met 
123I-MIBG. Met name in patiënten na harttransplantatie, hartritmestoornis-
sen en amyloïdosis kan beeldvorming met 123I-MIBG van meerwaarde zijn. 
Het geeft tevens extra informatie in patiënten met DM, (resistente) hyperten-
sie en obesitas. 
 Echter, voordat beeldvorming met 123I-MIBG bij bovenstaande patiënten-
groepen moet worden toegevoegd aan de richtlijn, is het van belang dat de 
meerwaarde van deze beeldvormingstechniek bij patiënten met hartfalen 
wordt erkend. Het bewijs in deze patiëntengroep is namelijk reeds ruimschoots 
aanwezig: studies hebben in het verleden laten zien dat patiënten met hart-
falen met een lage H/M ratio dan wel een hoge washout ratio een verhoogd 
risico hebben op het krijgen van ritmestoornissen en overlijden. Een van de 
grote nadelen van deze beeldvormingstechniek in de prakijk is echter de lange 
wachttijd van 4 uur tussen de eerste en tweede scan. Om het gebruik te doen 
stijgen onderzoekt hoofdstuk 9 of het mogelijk is om de late opname na 4 uur 
te vervroegen. Voor dit onderzoek is er behalve na 15 minuten en 4 uur ook een 
opname gemaakt na 1 uur, 2 uur en 3 uur. Hierbij zijn van alle scans de H/M 
ratios berekend. Onderzoek laat zien dat er kleine verschillen in H/M ratio zijn 
tussen de scans van 2, 3 en 4 uur. Hierdoor lijkt het verkrijgen van de late opna-
mes eerder dan na 4 uur na injectie van 123I-MIBG gerechtvaardigd, waardoor 
een patiëntvriendelijker en tijdefficiënter protocol kan worden opgesteld. 
 
206
 De implementatie wordt ook bemoeilijkt door de afwezigheid van stan-
daardisatie van beeldvorming met 123I-MIBG. Hierdoor bestaan er grote ver-
schillen in tijdstip na injectie voor de late opname. Hoofdstuk 10 onderzoekt 
een methode om het vergelijken van H/M ratio maar ook de washout ratio 
van verschillende afnametijdstippen met de late opname na 4 uur te kunnen 
vergelijken. Hierbij wordt een formule gebruikt die de daadwerkelijke opname 
exploreert naar 4 uur. 
Conclusie en toekomstperspectieven
Over de afgelopen jaren zijn zowel het aantal non-invasieve als invasieve 
diagnostische technieken en behandelingen in patiënten met ischemisch 
hartlijden exponentieel gegroeid. Het doel van dit proefschrift is om tijdens 
verschillende stadia van ischemische hartziekten de waarden van verschil-
lende beeldvormingstechnieken en invasieve strategieën in kaart te brengen. 
De genoemde resultaten tonen aan dat non-invasieve beeldvorming van 
meerwaarde kan zijn bij de totstandkoming van keuzes in medicamenteuze 
therapieën en invasieve strategieën in de individuele patiënt in het kader van 
preventie tot behandeling met als doel de prognose te verbeteren. 
Deel I 
In het kader van primaire preventie wordt op dit moment bij diabeten met 
een verhoogd cardiovasculair risicoprofiel geadviseerd te overwegen acetylsali-
cylzuur te starten. De aanwezigheid of afwezigheid van atherosclerose op een 
CT coronairangiografie kan deze keuze wellicht vergemakkelijken, aangezien 
het starten van acetylsalicylzuur in patiënten met DM zonder atherosclerose 
op de CT coronairangiografie niet zinvol lijkt, rekening houdend met de 
bijwerkingen die niet gering zijn. Hierdoor kan bij minimaal een kwart van de 
patiënten bloedverdunning worden onthouden. De vraag is echter op welke 
leeftijd men diabeten op de aanwezigheid van atherosclerose op CT coronair-
angiografie zou moeten screenen en of men de CT zou moeten herhalen in de 
wetenschap dat atherosclerose een dynamisch en progressief proces is.
 Een intramuraal beloop van de coronairarterie is een frequent voorko-
mende toevalsbevinding. Aangezien er geen verschil in uitkomst is tussen 
patiënten met en zonder een intramuraal beloop van de coronairarterie lijkt 
verdere diagnostiek of behandeling niet noodzakelijk. Dit is een belangrijke 
bevinding aangezien tot op heden chirurgische interventies ter correctie van 




onderzoek is echter noodzakelijk. Wellicht dat bij de kleine groep van patiënten 
met een intramuraal beloop van de coronairarterie met systolische compressie 
op een invasieve coronairangiogram een behandeling wel van aanvullende 
waarde kan zijn. 
Deel II
Patiënten met een STEMI en meervatslijden hadden geen voordeel in het kader 
van overleving met complete revascularisatie in vergelijking met patiënten bij 
wie alleen het aangedane vat dat verantwoordelijk was voor het hartinfarct werd 
gerevasculariseerd. Aan de andere kant laten grote gerandomiseerde studies wel 
voordelen zien van direct complete revascularisatie in vergelijking tot incomplete 
revascularisatie. Echter, de grootste verschillen werden in deze studies gezien in 
de frequentie van revascularisatie en niet in mortaliteit.
 Resultaten in dit proefschrift laten zien dat mannen mogelijk meer baat 
hebben bij complete revascularisatie in vergelijking tot incomplete revascula-
risatie dan vrouwen. Toekomstig grootschaliger onderzoek is noodzakelijk om 
nader te onderzoeken waar dit verschil in zit en of er een geslacht toegesneden 
revascularisatie-strategie noodzakelijk is bij patiënten met een STEMI met 
meervatslijden.
Deel III
De correlatie tussen LV GLS en infarctgrootte is niet eenvoudig. Resulta-
ten laten zien dat de aanwezigheid van ischemie deze correlatie verzwakt: 
patiënten met ischemie hebben een zwakkere correlatie tussen LV GLS en 
infarctgrootte dan de groep van patiënten zonder ischemie. Deze bevinding 
is van belang bij het interpreteren van LV GLS metingen. Om de klinische 
bruikbaarheid en betrouwbaarheid van deze echocardiografische parameter 
te vergroten is het van belang dat door middel van toekomstig onderzoek 
gekeken wordt of er nog meer parameters zijn die deze correlatie beïnvloeden.
 Huidige resultaten benadrukken dat de prognostische waarde van vermin-
derd sympathische neuronale opname van het myocard bij patiënten met 
ischemisch hartlijden groot is en dat er in de toekomst ook andere belangrijke 
potentiële indicaties zijn voor het gebruik van 123I-MIBG scintigrafie.
 Door de wachttijd tussen de vroege en late scan te vervroegen en het ver-
gelijken van resultaten van verschillende opname tijdstippen door de directe 
vergelijkingsmethode te vergemakkelijken zal 123I-MIBG scintigrafie hopelijk 
eindelijk kunnen worden geïmplementeerd in de huidige richtlijnen voor 
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